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Liver cirrhosis is the end stage of chronic liver diseases and causes more than 1 million 
deaths per year worldwide (1). In liver cirrhosis, the lobular architecture and vasculature are 
disrupted by excessive deposition of scar tissue. Variceal hemorrhage, hepatic 
encephalopathy and hepatic failure are the main lethal complications of decompensated 
liver cirrhosis. Additionally, cirrhosis is a risk factor for the development of hepatocellular 
carcinoma (2). To date, no medication is available to prevent or reverse liver cirrhosis. 
Patients with liver cirrhosis can only be cured by liver transplantation. 
Chronic liver diseases of various etiology lead to cirrhosis, including liver damage 
induced by toxins, alcohol, viral infection, autoimmune disorders, metabolic and genetic 
disorders (2). According to recent epidemiological surveys, non-alcoholic fatty liver disease 
(NAFLD) is emerging as the leading cause of chronic liver disease in developed countries, 
whereas viral hepatitis is the prevailing etiology of cirrhosis in developing countries (1, 3). 
Based on advancing knowledge, NAFLD has been suggested to be termed Metabolic 
Associated Fatty Liver Disease (MAFLD) (4). Regardless of the etiology, the pathogenic 
mechanisms leading to liver cirrhosis are similar and start with chronic inflammation and the 
development of fibrosis. Liver fibrosis is defined as an intermediate stage in chronic liver 
diseases and, histologically, varies from fibrous expansion of portal tracts to bridging fibrosis. 
The histological alterations in the progression of chronic liver diseases is shown in Figure 1. 
These histopathological phenomena are the basis of the pathological scoring systems, e.g. 
the Ishak score and NAFLD activity score from the Non-alcoholic Steatohepatitis Clinical 
Research Network (NAS CRN) (5, 6). 
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Figure 1. Histology of different stages of chronic liver diseases. 
In the stage of hepatitis, apoptotic and necrotic hepatocytes recruit infiltrating inflammatory cells. 
Unresolved hepatic inflammation induces activation of hepatic stellate cells, which form the fibrous tissue. 
Liver fibrosis is a dynamic process and varies from periportal or perisinusoidal fibrosis to bridging fibrosis. 
With the progression of fibrosis and regeneration of hepatocytes, liver lobules are segmented by fibrous 
septa, forming dissecting nodules. 
Excessive extracellular matrix (ECM) deposition is the hallmark of fibrosis. Important 
components of ECM are collagens, laminin, fibronectin and proteoglycans (7). Among the 
components of ECM, collagens are the most abundant. Collagens are mainly secreted by 
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profibrogenic myofibroblasts (7, 8). Collagen fibers have a triple-helix structure and contain 
the repeated peptide motif Gly-X-Y. Gly is glycine and X and Y can be any amino acid, 
although X is commonly a proline and Y is a hydroxyproline. The Gly-X-Y structure confers 
rigidity to collagen fibers, shown in Figure 2 (9). A cohort study demonstrated that the 
fibrosis stage, evaluated with the NASH Clinical Research Network (NASH CRN) Feature 
Scoring System, negatively correlates with long-term prognosis of patients with fibrosis (10). 
Therefore, it is important to diagnose and start therapy of fibrosis at an early stage to 
prevent progression of chronic liver disease. Multiple cell types are involved in the 
pathogenesis of liver fibrosis, making it difficult to select the right target cell type in the 
development of therapeutics for liver fibrosis. However, since myofibroblasts account for the 
pathological formation of fibrous tissue in the liver, inactivation and clearance of 
myofibroblasts are likely to alleviate liver fibrosis (11). 
 
Figure 2. Collagen structure. 
Collagens have a triple helix structure. Each chain of collagen contains the abundantly repeated peptide 
motif Gly-X-Y. Gly is glycine. X is commonly proline and Y is commonly hydroxyproline.  
Pathogenic myofibroblasts can originate from hepatic stellate cells (HSCs), portal 
fibroblasts, circulating monocytes and bone marrow-derived mesenchymal cells and 
hepatocytes might also transdifferentiate to fibroblast-like cells during 
epithelial-to-mesenchymal transition (12, 13). Studies in animal models of liver fibrosis 
suggest that HSC are main precursors of myofibroblasts (14). HSC are the most abundant 
non-parenchymal cells in the liver and account for 5%-8% of the total cell population in the 
healthy liver (15). HSCs originate from mesothelial cells during embryonic development (16). 
HSCs are located in the space of Disse, which is the space between the sinusoidal 
endothelium and hepatocytes. In the healthy state, HSCs maintain a lipocyte-like phenotype 
and store retinyl esters. These HSCs are termed quiescent HSCs (qHSCs). About 80% of 
vitamin A in the human body is stored in qHSCs in large intracellular lipid droplets (17). Upon 
liver injury, qHSCs are stimulated by various stimuli and transdifferentiate into 
myofibroblast-like cells. The process of transdifferentiation of HSCs is termed activation and 
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transdifferentiated HSCs are termed activated HSCs. Activated HSCs (aHSCs) lose the 
ability to store retinyl esters, their lipid droplets disappear and they acquire a stretched 
morphology during activation (18). In contrast to qHSC, aHSCs show an increased ability to 
proliferate, migrate and contract and start secreting high amounts of ECM (11). HSCs are 
highly responsive to pro-inflammatory signals from inflammatory cells, but in addition, they 
also secrete various cytokines and chemokines themselves. In turn, these HSC-derived 
factors act on inflammatory cells during the pathogenesis of liver fibrosis, thereby forming an 
pathogenic amplifying loop (19, 20). During activation, HSCs lose the expression of the 
transcription factor peroxisome proliferator-activated receptor-gamma (PPARγ) and lecithin 
retinol acyltransferase (LRAT), but acquire expression of alpha-smooth muscle actin (αSMA) 
and collagen type 1 alpha-1 (COL1A1) (12). The differential expression of these proteins 
and distinct morphologies are common biomarkers used to differentiate between qHSC and 
aHSC.  
Mechanisms involved in the activation of hepatic stellate cells 
Activation of HSCs can be triggered by various endogenous and exogenous factors. 
Exogenous cytokines secreted from inflammatory cells or aHSCs themselves, including 
Transforming growth factor beta (TGF-β), Platelet-derived growth factor (PDGF) and 
Connective tissue growth factor (CTGF), have been demonstrated to activate HSCs (21, 22). 
In addition to cytokines, toxic compounds like ethanol and the released contents of necrotic 
cells are also activators of HSCs (22, 23). Furthermore, physical factors can contribute to 
the activation of HSCs, e.g. hypoxia and mechanical force have been demonstrated to 
contribute to the activation of HSCs (24, 25). 
TGF-β is a well-known cytokine that activates HSCs and promotes fibrogenesis. 
SMADs are the canonical downstream signaling proteins of TGF-β (26). Activation of TGF-β 
signaling in vivo consists of a series of complex processes. TGF-β is synthesized as a latent 
precursor that needs to be cleaved by proteases to be activated. The C-terminus of TGF-β 
binds to the N-terminus of the Latency Associated Protein (LAP) to form the TGF-β latent 
complex, which is released and deposited in the surrounding ECM. Various factors induce 
the release of active TGF-β from the ECM. Upon binding of TGF-β to the TGF-β typeⅡ
receptor, the TGF-β typeⅠreceptor is phosphorylated by the type Ⅱreceptor, leading to a 
conformational change in the TGF-β typeⅠreceptor, which leads tophosphorylation of 
downstream targets, such as SMAD2 and SMAD3 (27). TGF-β/SMAD3 promotes the 
transdifferentiation of HSC and enhances the gene expression of COL1A1. Subsequently, 
aHSCs acquire the ability to secrete cytokines, including TGF-β, that in turn activate qHSCs 
in a paracrine manner (28, 29). Recent evidence has revealed the interaction between 
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TGF-β and mammalian target of rapamycin (mTOR) in the regulation of the inflammatory 
response and metabolism (30). mTOR is the important subunit of two complexes, mTORC1 
and mTORC2. Over-activation of the mTORC1/p70S6K axis exacerbates liver fibrosis (31). 
The mTORC1/4E-BP1 axis has an important role in TGF-β-dependent collagen production 
(30). In HSCs, activation of mTOR signaling inhibits autophagy and increases HSC-derived 
extracellular vesicles release and fibrosis (32). These observations indicate an essential role 
of mTOR in the activation of HSCs. 
Dysregulated intracellular signal transduction and metabolism can generate HSC 
activating signals as well (33). Nitric oxide (NO) is the first discovered gasotransmitter and is 
involved in many physiological processes. NO is produced by Nitric Oxide Synthases (NOS) 
that convert arginine into citrulline. Three isoforms of NOS are known: neuronal NOS 
(nNOS), inducible NOS (iNOS) and endothelial NOS (eNOS), which are encoded by NOS1, 
NOS2 and NOS3, respectively. NOS isoforms are expressed or can be induced (iNOS) in a 
wide variety of cell types. NO is a direct scavenger of ROS and can alleviate oxidative stress 
(34). As a gasotransmitter, NO activates soluble guanylate cyclase (sGC) increasing the 
intracellular concentration of cyclic guanosine monophosphate (cGMP). Several studies 
have demonstrated that the activation of sGC suppresses the activation of HSCs (35, 36). 
Inhibition of iNOS activity promotes the activation of fibroblasts and prevents the reversal of 
liver fibrosis (37, 38), supporting a role for the NOS-dependent NO-sGC pathway in the 
activation of HSC.  
Arginase competes with NOS for the use of arginine as substrate in the cytoplasm. 
Arginase has two isoforms: Arginase-1 (ARG1) and Arginase-2 (ARG2). ARG1 is 
predominantly expressed in the cytoplasm of liver cells whereas ARG2 is localized in 
mitochondria of e.g. kidney cells (39). Differential arginine catabolism in macrophages is a 
well-known biomarker and regulator of macrophage polarization. Macrophage polarization is 
a process in which macrophages acquire different phenotypes in response to specific 
signals or stimuli. There are 2 distinct phenotypes of polarized macrophages: M1 phenotype: 
the classically activated pro-inflammatory macrophages, stimulated by e.g. 
lipopolysaccharide and the M2 phenotype: the alternatively activated pro-fibrogenic 
macrophages, stimulated by e.g. interleukin-4 (IL-4). M1 macrophages are characterized by 
iNOS expression, whereas M2 macrophages are characterized by ARG1 expression. 
Polarization of macrophages plays an important role in the modulation of fibrogenesis (40). 
Arginase converts arginine into ornithine, which is an amino acid that is not incorporated into 
proteins. In turn, ornithine can be converted by ornithine decarboxylase (ODC) into 
polyamines and by ornithine aminotransferase (OAT) into proline. Polyamines are 
necessary to maintain normal cell division and proline is the most abundant amino acid in 
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collagens and therefore essential in collagen synthesis (41). Since ornithine synthesis is 
dependent on arginase, it is very likely that arginase activity is involved in the activation of 
HSCs.  
Hydrogen sulfide (H2S) is another important gasotransmitter participating in a variety of 
physiological processes. H2S is generated by three enzymes: cystathionine γ-lyase (CSE), 
cystathionine β-synthase (CBS) and 3-mercaptopyruvate sulfurtransferase (3-MST). 
L-cysteine and L-homocysteine are the main substrates for H2S biosynthesis. H2S 
modulates the Phosphoinositide 3-kinases (PI3K)-Akt, STAT3, Protein kinase C (PKC), 
Nuclear factor E2-related factor 2 (Nrf2) and Nuclear factor kappa B (NF-κB) signaling 
pathways (42). Dysregulated H2S production is associated with liver fibrosis (43). H2S 
protects hepatocytes against apoptosis via inhibiting the JNK/MAPK pathway (44). 
Endogenously generated H2S promotes the bioenergetics of mitochondria and stimulates 
proliferation of HSCs (45). The heterogeneity in the observed effects of H2S probably 
derives from differential expression of H2S-producing enzymes in different cell types (44, 
45).  
Although the factors and mechanisms discussed above are key regulators of HSC 
activation, the full complexity of HSC activation, especially in vivo, is not completely 
elucidated yet. 
Mechanisms that reverse hepatic stellate cell activation 
Spontaneous resolution and regression of liver fibrosis has been observed in some 
cases upon removal of the injury (e.g. after hepatitis virus clearance). This phenomenon has 
also been demonstrated in experimental models of liver fibrosis (38). Once toxic stimuli are 
removed, most of the aHSCs are inactivated and revert to a quiescence-like phenotype 
without proliferation and collagen production. However, inactivated HSCs (iHSCs) have a 
gene expression profile that is different from both qHSCs and aHSCs. In addition, iHSCs are 
more sensitive to novel toxic stimuli, showing a stronger pro-fibrogenic response compared 
to aHSCs and qHSCs (46). A recent transcriptomic study demonstrated that some 
transcription factors, including members of the SRY-related HMG-box (SOX) and Signal 
Transducer and Activator of Transcription (STAT) families, are highly expressed in iHSCs 
(47). However, the reason why iHSCs exhibit a stronger response to injury remains unclear. 
Cellular senescence is described as a terminal cell fate in which proliferating cells 
acquire a permanent cell cycle arrest (48). HSC senescence has been observed both in 
pre-clinical fibrosis models as well as in clinical samples (49-51). Senescent cells are 
characterized by a high activity of senescence-associated β-galactosidase (SA-β-Gal), high 
expression of cell cycle arrest genes, including CDKN1A (P21CIP1), P53 and CDKN2A 
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(P16INK4A) and the expression of a senescence-associated secretory phenotype (SASP) 
(52). Senescent HSCs display reduced collagen production and cell proliferation. This 
suggests that induction of senescence in HSCs may be a promising strategy to resolve 
fibrosis (53). In experimental models of liver fibrosis, impaired senescence of HSCs in 
p53/p21 knockout mice has been shown to accelerate the progression of fibrogenesis (50). 
Senescent HSCs express MICA/ULBP2, which is a ligand for the NK cell receptor NKG2D 
that facilitates HSC clearance (54). Considering the advantages of cellular senescence, 
therapy-induced senescence has been proposed as a strategy to prevent or reverse liver 
fibrosis. Recently, curcumin, interleukin-22 and interleukin-10 have been demonstrated to 
alleviate liver fibrosis via inducing senescence of HSCs (55-57). However, it should be noted 
that accumulation of senescent cells and hepatocyte senescence may form a 
pro-inflammatory micro-environment that induces aging-related liver dysfunction. To avoid 
the disadvantages of senescence, clearing senescent cells, a process called senolysis, 
should be considered as a second-stage strategy (48, 58). 
 
Figure 3. Different markers of hepatic stellate cells (HSCs).  
During liver fibrosis, quiescent HSCs transdifferentiate into activated HSCs. Upon the removal of injurious 
stimuli, activated HSCs are inactivated into a quiescent-like phenotype (inactivated HSCs), but are highly 
responsive to novel injurious stimuli. Senescent HSCs acquire a less pro-fibrogenic phenotype, 
characterized by distinct markers like Senescence Associated β-Galactosidase (SA-β-Gal) activity, P21 
















The scope of this thesis 
Chapter 1 
In this chapter, we present a general introduction to liver fibrosis and hepatic stellate 
cells and discuss in more detail the various mechanisms and factors that are the subject of 
this thesis: cellular senescence, the gasotransmitters hydrogen sulfide and nitric oxide, 
arginine metabolism and TGF-β signaling. 
Chapter 2 
In this chapter, we review the current literature on senescence in hepatic stellate cells 
and the potential of induction of senescence as a therapeutic intervention to inhibit or 
reverse HSC activation and attenuate liver fibrosis. 
Chapter 3 
In this chapter, we study the potential of the bioactive coumarin-like compound 
esculetin to induce senescence in HSC. Biomarkers of HSC activation, proliferation and 
senescence were investigated to elucidate the association between cellular senescence 
and HSC inactivation. The PI3K-Akt signaling pathway was investigated in detail, since it 
proved to be a target of esculetin. 
Chapter 4 
In this chapter, differential expression of H2S-producing enzymes and production of H2S 
were investigated during HSC activation. Inhibitors of H2S-producing enzymes, e.g. DL-PAG 
and AOAA, were used to elucidate the role of H2S on HSC activation. In addition, we used 
the H2S donor GYY4137 to elucidate the effect of exogenous H2S on the activation of HSCs. 
Mitochondrial activity was analyzed to investigate the association between H2S and cellular 
bioenergetics. 
Chapter 5 
In chapters 3 and 4, we showed an association between H2S and HSC activation and 
an association between cellular senescence and HSC activation, respectively. In chapter 5, 
we combine this knowledge and investigated the association between induction of cellular 
senescence and decreased H2S production.  
Chapter 6 
Pirfenidone is a broad-spectrum anti-fibrotic drug that has been approved for the clinical 
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treatment of idiopathic pulmonary fibrosis. In addition, preclinical evidence has 
demonstrated an anti-fibrotic effect of pirfenidone on hepatic and nephrotic fibrogenesis. In 
view of the similar mechanisms of fibrogenesis, the effect of pirfenidone on primary human 
intestinal fibroblasts, as an in vitro model of intestinal fibrogenesis, was investigated. The 
TGF-β/mTOR signaling pathway was investigated to elucidate the mechanism of the 
anti-fibrotic effect of pirfenidone. 
Chapter 7 
In this chapter, differential expression of arginine-catabolizing enzymes was analyzed in 
HSC at different states of activation. The arginase inhibitor Nor-NOHA was used to block the 
arginase activity of HSCs to investigate its effect on collagen synthesis and HSC 
proliferation. 
Chapter 8 
The results of this thesis and future perspectives are discussed in this chapter. 
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Chronic liver diseases of diverse etiology, including toxic injury, viral infection, 
autoimmune disorders, metabolic and genetic disorders can evolve into liver fibrosis. Liver 
fibrosis is characterized by excessive accumulation of extracellular matrix (ECM) and is 
considered an intermediate stage which can still be reversed or advance to cirrhosis and 
end-stage liver disease (1). Epidemiological data demonstrate that cirrhosis leads to 1.03 
million deaths per year worldwide (2). Interventions at the stage of fibrosis are aimed to limit 
disease progression and prevent progression to cirrhosis.  
The main characteristic of liver fibrosis is the excessive production of ECM. ECM is 
produced by fibrogenic myofibroblast (3). Myofibroblasts are (almost) absent in normal 
tissue and only transiently activated during tissue injury to produce ECM and scar tissue in 
the process of controlled wound healing (4). The source of myofibroblasts can be epithelial 
cells, mesenchymal stromal cells (MSCs), fibrocytes, mesothelial cells, hepatic stellate cells 
(HSCs) and portal fibroblasts (PFs) (3). Among these, HSCs are the predominant source of 
myofibroblasts in various models of experimental fibrosis (3, 5, 6). 
The hepatic stellate cell is the most abundant non-parenchymal cell type in the liver (4). 
HSCs originate from mesothelial cells during embryonic development and reside in the 
subendothelial space of Disse (7). In normal healthy liver, HSCs store vitamin A and do not 
proliferate. These HSCs are termed quiescent hepatic stellate cells (qHSCs) and are 
characterized by the presence of lipid droplets containing vitamin A and the expression of 
platelet-derived growth factor receptor‑β (PDGFRβ), lecithin retinol acyltransferase (LRAT), 
desmin and glial fibrillary acidic protein (GFAP) (4). In response to profibrotic stimuli, qHSCs 
activate and transdifferentiate into myofibroblast-like cells and play an essential role in 
tissue repair. Compared to qHSCs, activated HSC (aHSC) acquire novel characteristics 
including proliferation, contractility, enhanced ECM synthesis, chemotaxis and generation of 
inflammatory signals (4). Activation of HSCs can be self-driven, e.g. when cultured in vitro 
on tissue culture plastic. Activated HSCs lose their cytoplasmic vitamin A droplets, acquire a 
stretched morphology and contractile properties and have different transcriptional 
characteristics, including increased expression of alpha actin 2 (ACTA2) and collagen type 1 
alpha 1 (COL1A1) and reduced expression of peroxisome proliferator-activated receptor 
gamma (PPARG) and GFAP (3).  
In experimental hepatic fibrosis, the fibrotic liver can revert to the normal state upon 
removal of the pro-fibrotic stimuli, a process known as fibrosis resolution (8, 9). During 
fibrosis resolution, aHSCs spontaneously initiate apoptosis or revert to the inactive 
phenotype. HSC apoptosis partially contributes to early resolution while inactivation of 
surviving aHSC accounts for mid to late stages of resolution (8-10). Inactivated HSCs 
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(iHSCs) downregulate expression of activation markers including COL1A1, ACATA2 and 
TIMP1, re-express quiescence markers like PPARG and restore vitamin A droplets. 
However, iHSCs are not identical to qHSCs since they do not completely revert to the 
quiescent phenotype. E.g. iHSCs do not restore transcription of GFAP and are more 
responsive to repeated fibrogenic stimuli compared to qHSCs (9). 
Cellular senescence is a physiological process in which proliferating cells enter a state 
of permanent or stable cell cycle arrest and do not respond to mitogens (11). Besides 
apoptosis, senescence is another fate of aHSCs in the reversal of fibrosis (12). Senescent 
HSCs acquire a less fibrogenic phenotype, thereby limiting the progression of fibrosis (12, 
13). Hence, induction of senescence in HSCs may serve as a promising anti-fibrotic strategy. 
In the following paragraphs, we review the characteristics, mechanisms and possible effects 
of cellular senescence on liver fibrosis. 
2.Characteristics of senescent cells 
Cellular senescence is a stable cell cycle arrest program, first described in primary 
human fibroblasts that had reached replicative exhaustion in vitro (14, 15). Replicative 
senescence was already associated with telomere length regulation. Due to the 
‘end-replication problem’ of DNA polymerase, telomeres become progressively shorter with 
every cell division (16, 17). Eventually, short telomeres are sensed as double-strand breaks 
(DSBs) by the DNA Damage Response (DDR) machinery leading to senescence via 
activation of the tumor suppressor protein p53 (18). Loss of proliferation is accompanied by 
changes in gene expression and cell morphology, consistently used as principle 
determinants of senescence in cell culture. Specifically, senescent cells display loss of DNA 
synthesis, enlarged and flattened cell morphology, enhanced β-galactosidase (SA-β-gal) 
activity, accumulation of heterochromatin foci (SAHFs) and a hypersecretory phenotype 
(Figure 1) (19). Senescence was originally thought to be an intrinsic cellular mechanism. 
Although this might be the case for replicative senescence, it is now established that other 
stressors may induce an indistinguishable senescence phenotype termed stress-induced 
senescence or premature senescence (19, 20). As the list of senescence types and effector 
pathways grows, it becomes more evident that the phenotypic markers of senescence vary 
depending on the context, the stimuli and the cell type (11, 21). Endogenous β 
galactosidase is a lysosomal enzyme, with maximum activity at pH 4.0-4.5 (15). SA-β gal 
activity is usually measured at pH 6.0 with the artificial substrate X-Gal and this assay is 
most commonly used to determine senescence. Determination of β- galactosidase activity 
at the suboptimal pH 6.0 demonstrates a high level of expression in senescent cells (16). 
However, this activity can also be detected in cells with increased lysosomal number and 
size, e.g. during autophagy. Contact inhibition in long-term cell cultures also induces 
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β-galactosidase activity in quiescent cells (14). Therefore, a high β-galactosidase activity is 
not specific for senescent cells and a combinatorial marker strategy for the identification of 
senescent cells should be preferred. Several studies have identified senescence-associated 
gene expression signatures (21-24), which revealed changes in cell-cycle regulators as 
expected. Two cell-cycle inhibitors that are often expressed by senescent cells are the 
cyclin-dependent kinase inhibitors (CDKIs) CDKN1a (also termed Waf1, encodes p21Cip1) 
and INK4a (also termed CDKN2a, encodes p16INK4a). On the other hand, senescent cells 
repress genes that encode proteins involved in cell-cycle progression; some of them are 
E2F targets (for example, replication-dependent histones, c-FOS, cyclin A, cyclin B and 
PCNA) (25, 26). Interestingly, the quest for senescence-specific gene expression signatures 
also revealed that besides changes in cell-cycle regulators, senescent cells exhibited 
changes in genes that appeared to be unrelated with growth arrest (21, 22, 27). These 
include the upregulation of multiple secreted factors that are known to alter the tissue 
microenvironment and are thought to contribute to age-related pathologies. The 
senescent-associated secretory phenotype (SASP) can trigger different and, sometimes, 
opposing effects in the microenvironment and surrounding cells. Work by Campisi's group 
suggests that factors secreted by senescent fibroblasts promote cancer progression (28-30), 
however, besides its implication in tumor clearance by the immune system (31), several 
studies suggest that the SASP also has an important role in establishing and maintaining 
the senescent state itself. Some of the factors secreted by senescent cells were shown to 
have tumor suppressive roles. The plasminogen activator inhibitor (PAI)-1 is necessary and 
sufficient for the induction of senescence (32). Insulin-like growth factor-binding protein 7 
(IGFBP7) was shown to mediate senescence induced by oncogenic BRAF (33). Likewise, 
pro-inflammatory cytokines and chemokines secreted by senescent cells, such as IL-8, 
CXCL1, IL-6, and their receptors have been shown to be upregulated during senescence 
and their depletion partially bypasses replicative and oncogene-induced senescence (34, 
35). Recent finding also described the SASP as a highly heterogeneous plethora of 
circulating factors, including cell-derived small extracellular vesicles or sEV (36). Facultative 
heterochromatin are condensed, transcriptionally silent chromatin regions that can reverse 
condensation to allow gene transcription (37). SAHF was first described in nuclei of 
senescent cells containing 30–50 bright, punctate DNA-dense foci that can be distinguished 
from chromatin of normal cells (38). SAHF are specialized domains of facultative 
heterochromatin, characterized by heterochromatic histone modifications and the presence 
of heterochromatic proteins, histone variant macro H2A, high-mobility group A (HMGA) 
proteins and late replicating regions in the genome (39). Histone methylation, specifically 
histone 3 lysine 4 trimethylation (H3K4me3) (activating) and H3K27me3 (repressing) are 
epigenetic modifications that are highly associated with gene transcription and linked to 
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lifespan regulation in many organisms (40). More than 30% of chromatin is reorganized in 
senescent cells. This reorganization includes the formation of large-scale domains (mesas) 
of H3K4me3 and H3K27me3 over lamin-associated domains (LADs), as well as depletion 
(canyons) of H3K27me3 outside of LADs, indicating profound changes in the transcriptional 
profile of senescent cells (41). 
 
 
Figure 1, Characteristics of senescent cells.  
The triggers, morphology, phenotype and biomarkers of cellular senescence are illustrated. ROS, reactive 
oxygen species; SASP, senescence associated secretory phenotype; SAHF, senescence associated 
heterochromatin foci; SA-β-Gal, senescence associated β galactosidase. 
3.Mechanisms that regulate hepatic stellate cell senescence 
3.1. DNA damage response 
Isolated primary HSCs can only be cultured for a limited number of passages and 
eventually undergo replicative senescence (42, 43). In addition, cellular senescence can be 
triggered by a variety of intrinsic stressors, e.g. lysosomal stress, the unfolded protein 
response (UPR), oncogene activation and reactive oxygen species (ROS) generation 
leading to unresolved DNA damage (44, 45).  
In a typical mammalian cell, the incidence of spontaneous DNA damage is estimated to 
be less than 2×105 lesions per day (46). The majority of damaged DNA can be repaired and 
is unlikely to drive the senescence process. However, a persistent DDR can drive cell 
senescence (47). Single-stranded and/or double-stranded DNA breaks (SSBs or DSBs, 
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respectively) are activators of the DDR (48). The Mre11-Rad50-Nbs1 (MRN) complex is the 
sensor of double-stranded DNA damage (49). Upon DSB, MRN complexes recruit and 
activate Ataxia-Telangiectasia Mutated (ATM) or ATM- and Rad3-related (ATR) kinases that 
activate CHK1 and CHK2 (check point kinase 1 and 2, respectively) (18, 50). Activated 
CHK1 promotes the degradation of CDC25A, a phosphatase that removes inhibitory 
modifications from cyclin dependent kinases (CDKs). ATM can phosphorylate p53 on 
multiple sites, including S15, which has been demonstrated to inhibit its interaction with the 
ubiquitin ligase MDM2, resulting in p53 stabilization and initiation of senescence (50). Upon 
SSB, poly-(ADP)ribose polymerase (PARP), predominantly PARP1, which senses the 
breaks, initiates DDR and probably induces p16-dependent cellular senescence (51). 
Senescence has a heterogeneous phenotype and is driven by multiple stressors. It is a 
highly coordinated and regulated process (Figure 2). A summary of the main regulators and 
pathways of senescence is presented in the subsequent paragraphs. 
3.2. NF-κB signaling 
The hierarchy of the networks inducing a secretory phenotype is still unclear. Yet the 
transcription of several SASP genes primarily depends on two transcription factors (TFs): 
nuclear factor-kappa B (NF-κB) and CCAAT/enhancer binding protein beta (C/EBPβ) (34, 
35, 52). 
The NF-κB transcription factor family consists of five proteins: p65 (RelA), RelB, c-Rel, 
p105/p50 (NF-κB1), and p100/52 (NF-κB2) that associate with each other to form distinct 
transcriptionally active homo- and heterodimeric protein complexes. In most cells, NF-κB 
dimers are sequestrated in an inactive form in the cytosol through their interaction with IκB 
proteins. Degradation of these inhibitors upon their phosphorylation by the IκB kinase (IKK) 
complex leads to nuclear translocation of NF-κB dimers and induces transcription of their 
target genes (53). NF-κB activation includes two major signaling pathways: the canonical 
and the non-canonical NF-κB signaling pathways. The canonical pathway is induced by 
inflammatory stimuli including TNFα, IL-1 or LPS and uses a large variety of signaling 
adaptors to engage IKK activity. The non-canonical pathway depends on NIK 
(NF-κB-inducing kinase)-induced activation of IKKα. The canonical pathway mediates the 
activation of NF-κB1/p50, RelA/p65 and c-Rel, whereas the non-canonical NF-κB pathway 
selectively activates p100-sequestered NF-κB members, predominantly NF-κB2/p52 and 
RelB (54). Among all the dimers, the p50/65 heterodimer is the most abundant. The 
proportion of NF-κB dimers varies depending on the cell type. In addition, not all 
combinations of NF-κB dimers are transcriptionally active. Only p65, RelB and c-Rel contain 
carboxy-terminal transactivation domains to induce NF-κB dependent gene transcription. 
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Homo- and heterodimers of p50 and p52 inhibit NF-κB dependent gene transcription via 
competition with other dimers to bind to the κB sites of genes (53). 
As mentioned before, the DNA damage response is essential for the induction of 
senescence. NF-κB is a master regulator of the genotoxic stress-induced cell response and 
both of the canonical and the non-canonical pathway can be activated by the DNA damage 
response (55). E.g., NF-κB-regulated gene expression increases in fibroblasts in response 
to UVA or UVB irradiation-induced DNA damage (56). Following DNA damage, ATM is 
activated and causes sustained NF-κB activation, independent of p53 signaling (57). In 
addition, the DNA damage response kinases ATM and ATR activate GATA4 which in turn 
activates NF-κB to facilitate senescence induction thus constituting a positive feedback loop 
(58). NF-κB and C/EBPβ are activated and enriched in the chromatin fraction in 
oncogene-induced senescent cells (35, 52). NF-κB also showed increased DNA-binding 
activity in replicative-, irradiation- and chemotherapy-induced senescent cells (52, 59-61). 
Depletion of the NF-κB subunit p65 reduced expression of many pro-inflammatory SASP 
factors in OIS and IR-induced senescence (52, 59). NF-κB directly controls transcription by 
binding to promoters of SASP components including IL-8, IL-6 and GM-CSF (59). C/EBPβ 
on the other hand is recruited specifically to the IL-6 promoter and C/EBPβ knockdown 
caused a collapse of the whole inflammatory network mainly due to disruption of IL-6 
autocrine signaling (35). NF-κB and C/EBPβ are critical regulators of the SASP. In fact it 
seems that DDR and p38 signaling converge to NF-κB activation (59). 
Sustained activation of NF-κB is required for the progression of senescence. In a 
mouse model of aging driven by Ercc1 deficiency and presenting as the failure to repair 
stochastic endogenous DNA damage, additional genetic depletion of p65 attenuates aging 
symptoms (62). Oxidative stress is well-known to induce DNA damage in cells (63). 
Over-activation of NF-κB via deletion of its inhibitor c-abl increases fibroblast resistance to 
apoptosis, indicating that NF-κB activation contributes to the anti-apoptotic phenotype of 
senescent cells (64). In line with this, loss of Nfkb1, one of the canonical NF-κB subunits, 
promotes nuclear translocation of the p65/p65 homodimer, leading to reduced apoptosis 
and increased accumulation of senescent cells with DNA damage (65). In addition, NF-κB 
signaling is known to control the senescence associated secretory phenotype and may play 
a key role in SASP-induced paracrine senescence (66, 67). In contrast, knockdown or 
pharmacological inhibition of NF-κB reduces the number of senescent cells (68, 69).  
3.3. PI3K-Akt pathway 
The phosphatidylinositol-3-kinase (PI3K) pathway regulates a wide range of target 
proteins and Akt is one of the main downstream targets of PI3K. The PI3K-Akt axis 
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modulates a variety of cellular process, including survival and proliferation and is also 
involved in cellular senescence. During induction of senescence, Akt phospho-Ser473 
(pS473) and phospho-Thr308 (pT308) are increased and accompanied by increased P53 
expression (70, 71). Hyperactivation of the PI3K-Akt pathway via PTEN depletion or 
PIK3CA mutant expression induces cellular senescence in the absence of DNA damage 
(72). Pharmacological inhibition of Akt by the PI3K inhibitor LY294002 reduces P21CIP1 
expression and SA-β-Gal positivity in fibroblasts (70).  
Akt has a variety of substrates, including Glycogen Synthase Kinase 3 (GSK3), 
Forkhead box O family transcription factors and Tuberous Sclerosis Complex 2, mTORC1 
etc (73). These downstream targets of Akt also influence cellular senescence in various 
ways. GSK3 is one of the main targets of Akt and is phosphorylated by active Akt at its two 
subunits GSK3α (Ser21) and GSK3β (Ser9) (73). Ser9 phosphorylated GSK3β increases 
stability of P21CIP1 post-translationally. Conversely, overexpression of a mutant GSK3β 
unable to phosphorylate Ser9 decreases P21CIP1 protein expression (74). Inability to 
phosphorylate FOXO3a by Akt inhibits transcription of the antioxidant enzyme SOD2 and 
consequently promotes ROS production, leading to DNA damage and cellular senescence 
(75). PI3K-Akt activation triggers mTOR and P53 activation (72). Significant activation of 
Akt-mTOR is also observed in replicative senescence (76). Furthermore, SASP components 
are regulated by the Akt-mTOR pathway in premature senescent cells (77). 
3.4. mTOR complexes 
mTOR is a serine/threonine protein kinase belonging to the PI3K-related kinase (PIKK) 
family. It is composed of two different protein complexes mTORC1 and mTORC2. mTORC1 
consists of three core components: mTOR, Raptor (regulatory protein associated with 
mTOR) and mLST8 (mammalian lethal with Sec13 protein 8, also known as GßL). mTORC2 
also contains mTOR and mLST8 but contains Rictor (rapamycin insensitive companion of 
mTOR) instead of Raptor (78). The two mTOR complexes regulate different cellular 
processes because they target different downstream kinases. mTORC1 promotes protein 
synthesis largely through the phosphorylation of two downstream kinases, p70S6 Kinase 1 
(S6K1) and eIF4E Binding Protein (4EBP) (79, 80). mTORC1 activates the sterol responsive 
element binding protein (SREBP) in response to low sterol levels to promote de novo 
lipogenesis (81). PGC1α (Peroxisome proliferator-activated receptor gamma coactivator 
1-alpha), a key regulator of mitochondria biogenesis is also regulated by mTORC1 (82). The 
mTORC2 complex mainly controls proliferation and survival, primarily by phosphorylating 
several members of the AGC (PKA/PKG/PKC) family of protein kinases (78). The most 
well-documented role of mTORC2 is to activate Akt via phosphorylation of Ser473 (83). 
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Recent research also suggested a positive feedback loop between Akt and mTORC2 (84). 
Furthermore, Akt-dependent phosphorylation of specific kinases including FoxO1/3a and 
TSC2 is also required for mTORC2 activation (78, 85).  
In senescent cells, mTORC1 signaling is dysregulated (82, 86). In normal cells, the 
removal of mitogenic cues such as growth factors and amino acids inactivates mTORC1. 
However, in senescent cells, mTORC1 acquires resistance to inactivation by nutrient 
starvation and growth factor removal (86, 87). Sensitivity of mTORC1 to amino acids is 
increased in replicative senescent cells (88). This phenomenon is in line with evidence that 
the Ras-related small GTP-binding protein Rag is activated by amino acids and in turn 
activates mTORC1 (78). Palmitate-induced lipotoxicity and accumulation of lipids is 
accompanied by increased expression of senescence markers, suggesting a link between 
lipogenesis and senescence (89, 90). It has also been demonstrated that high 
glucose-induced cellular senescence promotes intracellular lipid accumulation via the 
PI3K-Akt-mTOR pathway (91). In addition, mTORC1 directly regulates phosphorylation of 
p53 in PTEN-loss induced senescence (92). In contrast to the clear evidence of 
dysregulation of mTOR signaling in senescence, the results of mTORC1 inhibition to 
decrease senescence are inconsistent. Rapamycin has been reported to reduce oxidative 
stress-induced senescence by inhibiting SASP (93). However, although rapamycin and 
Torins decrease the number of SA-β-Gal positive cells they fail to restore the proliferation 
ability of senescent fibroblasts (94). Knockdown of Raptor decreases phosphorylation of 
S6K and expression of senescent markers including P16INK4A and SA-β-Gal (95). But S6K 
and 4EBP1 activities seem to be dispensable in PTEN-loss induced senescence (92). The 
interpretation of the heterogeneous effects of mTORC2 on senescence may be hampered 
by the lack of detailed knowledge of the role of mTORC2 on senescence (78, 96, 97). 
Another layer of complexity in understanding the role of mTOR in senescence is the role of 
mTOR in regulating autophagy (see next section). 
 3.5. Autophagy 
Autophagy is an evolutionary conserved, dynamic process that involves the scavenging 
of intracellular components and facilitates the turn-over of long-lived proteins. 
Macroautophagy is the most investigated type of autophagy. It begins with the formation of 
autophagosomes and ends with the fusion of the autophagosomes with lysosomes. 
Macroautophagy (which is usually referred to as autophagy) is essential to maintain 
intracellular homeostasis (98). The role of macroautophagy in senescence is complex. The 
complexity of macroautophagy in senescence is underscored by the phenomenon that both 
increasing as well as decreasing autophagy induces senescence. Macroautophagy is 
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enhanced in senescent cells (45). Nevertheless, impaired macroautophagy is sufficient to 
induce cellular senescence, which can be attenuated by mTOR inhibitors (99). Adding to the 
complexity is that macroautophagy interacts with various signaling transduction pathways 
that regulate senescence (98, 100). P38α activation triggers macroautophagosome 
formation and autophagic flux (101). Accumulation of P62 as a result of deficient 
macroautophagy increases activation of P38 (102). In CD8+ T cells, P38 inhibition increases 
macroautophagy independent of mTOR activity and decreases senescence (103). 
 Selective autophagy is the selective degradation of specific cargos, such as organelles 
and proteins. The mechanisms and molecules used in selective autophagy are diverse and 
specific for each cargo (organelle) (104). Selective autophagy is also linked to senescence 
(105). Dysfunctional mitochondria are degraded by mitophagy, which involves recognition of 
poly-ubiquitinated mitochondria by the autophagy receptors P62 and Optineurin (OPTN) or 
NDP52 (106). Impaired mitophagy increases mitochondrial ROS production and is involved 
in cellular senescence (107). Improving mitophagy by supplementation of NAD+ attenuated 
senescence and aging (108). 
Chaperone-mediated autophagy (CMA) is one of the main pathways of the 
lysosome-autophagy proteolytic system. CMA is a special kind of selective autophagy that 
requires the proteins targeted for degradation to contain a specific pentapeptide motif that is 
recognized by the heat shock cognate protein 71kDa (HSC70/HSPA8) (109). The 
chaperone-bound proteins are then transported to lysosomes, where they are recognized by 
the lysosome-associated membrane protein type 2a (LAMP2a) receptor (110). CMA 
delivers individual proteins for lysosomal degradation one at a time. In contrast, in 
macroautophagy, autophagosomes engulf and deliver larger structures for bulk degradation 
of cargo (110). Genetic ablation of growth hormone receptor in mice increases hepatic CMA 
and confers a longer life span to mice (111). CMA dysfunction is accompanied by aging and 
leads to an imbalance of proteostasis (112, 113). Defective CMA also leads to accumulation 
of CHK1 in response to cellular stress and potentiates genomic instability (114). In addition, 
NEF2L2/NRF2 has been demonstrated to be regulated by CMA which suggests a 
connection between redox balance and CMA (115). 
3.6. Hydrogen sulfide and redox homeostasis 
Excessive ROS generation is known to induce genetic instability leading to cellular 
senescence (45). Endogenous ROS can be generated by several sources. Mitochondria are 
the major source of ROS. Under normal physiological conditions most oxygen (O2) in 
organisms will acquire four electrons and four protons to form water by cytochrome c 
oxidase in the electron transport system of mitochondria. However, if molecular oxygen 
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undergoes sequential univalent reduction, highly reactive ·O2-, HO· and H2O2 will be formed 
(116). 
Hydrogen sulfide is one of various gasotransmitters that regulate a variety of cellular 
processes. The antioxidant effect of H2S has been extensively investigated. The 
desulfhydration of cysteine is considered to be the major source of H2S in mammals. The 
process is catalyzed by two pyridoxal-5’-phosphate- (PLP-) dependent enzymes, 
cystathionine β-synthase (CBS) and cystathionine 𝛾-lyase (CTH/CSE) (117). H2S improves 
redox homeostasis in various ways. In physiological conditions, the concentration of H2S is 
in the submicromolar range and not sufficient to serve as a direct reductant (117). It is 
speculated that H2S can be a direct scavenger of ROS at much higher concentrations, e.g. 
by exogenous administration of H2S or chemical H2S donors (118). H2S producing enzymes 
CSE and CBS can be upregulated by long-term supplementation of H2S donors in vivo (119). 
H2S increases glutathione biosynthetic pathways, increases the cellular glutathione pool 
and decreases homocysteine levels (120). Furthermore, increased H2S levels promote 
post-translational sulfhydration of KEAP1 to facilitate the release of NRF2, which is a 
transcription factor that increases transcription of various antioxidant genes (121). 
It has been demonstrated that H2S production is increased during activation of hepatic 
stellate cells and increases the bioenergetics of mitochondria (122). Genetic ablation of CSE 
in mouse embryonic fibroblasts stimulates cellular senescence by increasing oxidative 
stress. In these fibroblasts, H2S production is significantly reduced (123). Supplementation 
of H2S reduces senescence by scavenging intracellular ROS (124). Decreased levels of 
nicotinamide adenine dinucleotide (NAD+) are considered to be a cause of senescence and 
aging (125). Supplementation of exogenous H2S restores intracellular NAD+ level and 
induces SIRT1 expression to reduce senescence (126). Sirt1 is a member of the 
mammalian class III histone deacetylases and regulates PGC-1α activity in mitochondrial 
biogenesis (127). In addition, H2S has been shown to modulate various kinases involved in 
senescence (128). This evidence suggests that H2S regulates cellular senescence via 
various mechanisms. 
3.7. STAT3 pathway 
STAT3 is a member of the STAT (Signal Transducers and Activators of Transcription) 
family that has DNA binding activity and stimulates expression of innate immune mediators 
in the liver in response to interferon (129). It has been demonstrated that numerous 
cytokines and growth factors including IL-6, IL-10 family members, G-CSF (Granulocyte 
colony-stimulating factor) and growth factors that act through protein tyrosine kinase 
receptors (e.g. epidermal growth factor) are capable to activate STAT3 (130-132). In 
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addition to its transcriptional activities, non-transcriptional functions of STAT3 have been 
described as well. Mitochondrial STAT3 associates with mitochondria and regulates 
electron transport chain function as well as glycolysis and oxidative phosphorylation 
independent of its transcriptional action (133). Furthermore, STAT3 directly interacts with 
EIF2AK2 (Eukaryotic Translation Initiation Factor 2 Alpha Kinase 2) to inhibit autophagy 
(134). 
STAT3 is activated by extracellular inflammatory signals derived from SASP and 
regulates senescence. IL-6 is one of the well-established SASP components that regulates 
cellular senescence via activation of STAT3 (135). IL-22, a member of the IL-10 family, 
induces hepatic stellate cell senescence via phosphorylation of STAT3 and upregulation of 
SOCS3 (suppressor of cytokine signaling 3) (136). IL-10 is also able to promote hepatic 
stellate cell senescence via STAT3 (137, 138). Oxidative stress-induced senescence is 
accompanied by hyperactivity of the STAT3 pathway and disruption of the IL-6-STAT3 axis 
reduces cellular senescence (139). In addition, STAT3 interacts with mTOR to negatively 
regulate autophagy during cellular senescence (140). 
3.8. Adrenergic receptors signaling and cell proliferation 
Adrenergic receptors (AR) are a family of transmembran receptors coupled to 
G-proteins. Three types have been identified: alpha-1, alpha-2 and beta, each one 
characterized by its structure and function (156). Alpha-1 AR is coupled to the Gq protein 
and regulates PKC activation via diacylglycerol synthesis as well as calcium fluxes via PLC 
signaling and IP3 generation (157-161). Previous studies demonstrated an important 
relationship between intracellular calcium levels and senescence, which could be related to 
the alpha-1 AR response. It has been demonstrated that calcium levels increase in 
response to different inducers of senescence inducers like telomere shortening and 
oxidative stress. This dysregulation of intracellular calcium homeostasis was linked to 
the PLC/IP3/IP3R pathway in human mammary epithelial cells during the induction of 
senescence (162). In addition, the use of BAPTA-AM, a calcium chelator, reduces the 
number of cells with a senescent phenotype (163). Calmodulin (CaM), a calcium-dependent 
enzyme, controls different processes including cell division (164). This enzyme is required 
for G1 transit by regulating the activity of calcineurin a Ca 2+/ CaM-dependent protein, which 
increases the synthesis of cyclin D1 in fibroblasts (165). Thus,Ca 2+ appears to be important 
for both cell proliferation and senescence and its precise effects depends on the intracellular 
concentration and location which is associated with the activation and regulation of alpha 1 
AR. Protein kinase C (PKC) is part of the family of serine/threonine protein kinases and can 
modulate cell cycle progression (166), PKCη has been related to cell cycle arrest during G1 
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phase, since it induces the phosphorylation of p21 at Ser146 and the dephosphorylation of 
Thr160 of Cdk2 in keratinocytes, (167). PKCα also showed and effect on the cell cycle 
during the transition from G1 to S phase, by decreasing the expression of cyclin D1 
(168-169) and increasing the expression of p21 (168, 170, 171). PKCδ is also able to 
promote cellular senescence in TIG-1 cells, increasing the activity of β-galactosidase (172). 
However, in addition to the role of some PKC isoforms in senescence, PKC isoforms are 
also important for cell growth. PKCα has growth-stimulatory effects which has been 
observed in different cell types including hepatocytes (173-174). Apparently, the effect of 
protein kinase C depends mainly on the isoform as well as the cell type in which it is present. 
Beta AR are coupled to the Gs protein and regulate cAMP production and protein kinase A 
activation. It has been demonstrated that the β AR agonist isoproterenol promotes 
proliferation of U251 cells and this effect was inhibited bypropranolol, a selective antagonist 
of beta AR.However, the mechanism of the antagonism of beta AR has not been fully 
elucidated yet (175). Moreover, it has also been demonstrated that propranolol decreases 
the proliferation of breast cancer cells by increasing expression of p53, reducing expression 
of bcl-2 and increasing apoptosis (176). In hepatic stellate cells, activation of ARs is mainly 
related to proliferation (177). This proliferative effect is mainly linked to the activation of 
alpha-1 AR and the downstream response involves PI3K and the Erk family of mitogen 
activated protein kinases. In addition, hepatic stellate cells are able to produce and release 
catecholamines, including norepinephrine, which is important for autocrine stimulation of 
their proliferation (178-179). Doxazosin, a selective alpha 1 AR antagonist, has antifibrotic 
properties in the liver by reducing the deposition of the extracellular matrix and reduction of 
the stellate cell marker α-smooth muscle actin. (180). However, whether doxazosin has a 
direct effect on alpha 1 AR on HSCs remains to be elucidated. We hypothesize that the 
antagonism of adrenergic receptors may be linked to the resolution of fibrosis via the 
induction of senescence of HSC since decreased collagen production and decreased 
proliferation have been observed in senescent HSCs.  
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Figure 2. The major pathways that regulate cellular senescence.  
PI3K, Phosphoinositide 3-kinase. GSK3β, Glycogen synthase kinase 3 beta. mTOR, The mammalian target 
of rapamycin. ROS, Reactive oxygen species. NF-κB, Nuclear factor kappa B. H2S, Hydrogen sulfide. IL-22, 
Interleuikin-22. STAT3, Signal transducer and activator of transcription 3. 
4. Consequences of cellular senescence in liver fibrosis 
In the CCl4 (carbon tetrachloride) model of liver fibrosis, senescent cells mainly derive 
from activated hepatic stellate cells (12). Activated hepatic stellate cells that undergo 
replicative senescence exhibit a less fibrogenic phenotype and are prone to spontaneous 
apoptosis (13). Induced premature senescence of aHSCs decreases fibrogenesis in vivo 
(12, 136, 141). Senescent HSCs express cell surface ligands for receptors on NK cells that 
promote the elimination of senescent HSCs (142). It has been suggested that the SASP of 
senescent HSCs initiates cellular senescence of surrounding non-senescent HSCs (143, 
144). These data underscore the biological rationale of therapy-induced HSC senescence 
as a strategy to treat liver fibrosis. Accumulation of senescent cells is termed chronic 
senescence and has a significant impact on the microenvironment and tissue homeostasis. 
Excessive SASP secreted by accumulating senescent cells in tissue may induce 
senescence in neighboring non-senescent cells and cause infiltration of inflammatory cells, 
exacerbating local inflammation (45). Hence, in view of the long-term disadvantages of 
senescence, the induction of senescence in non-HSC liver cell types should be considered 
and, if possible, avoided. 
Senescence of hepatocytes has been observed in various liver diseases including 
chronic viral hepatitis, alcohol-related liver disease, non-alcoholic fatty liver disease (NAFLD) 
and genetic haemochromatosis (45). Replicative senescence of hepatocytes has been 
described in both normal and fibrotic liver. In fibrotic liver, the number ofsenescent cells is 
higher than in non-fibrotic liver (145). In biopsies of NAFLD patients, P21CIP1 positive 
hepatocytes are present and correlate with the grade of fibrosis (146). Apart from direct 
injury or aging, cytokine-induced senescence of hepatocytes appears to be the most 
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important cause of senescence in hepatocytes (147, 148). Hepatocyte senescence is 
involved in the pathogenesis of chronic liver diseases. Hepatocyte-specific senescence 
promotes intracellular fat accumulation in hepatocytes in experimental NAFLD models and 
positively correlates with the grade of steatosis (149). In contrast, senescent hepatocytes in 
chronic alcohol-induced injury appears to be more resistant to apoptosis and steatosis (148). 
Since the accumulation of senescent cells is the cause of aging-related disorders, the 
specific removal of senescent cells may help to attenuate these symptoms and increase 
life-span. Senolytics are (therapeutic) agents that selectively target senescent cells and 
induce death of senescent cells only, a phenomenon termed senolysis (150). Senolysis of 
senescent hepatocytes has been shown to improve liver regeneration and decrease the 
expression of P21CIP1 and SASP (151). Nevertheless, genetic ablation of P21 in the liver 
enhances DNA damage, cholestasis and carcinogenesis (152). The effect of hepatocyte 
senescence in carcinogenesis is bidirectional. Hepatocyte senescence is considered as a 
tumor-suppressing mechanism because of the accompanying permanent proliferation arrest 
(153). On the other hand, senescent hepatocytes that escape from the senescent state and 
re-enter the cell cycle are pre-malignant and promote tumorigenesis (154).  
It is not clear whether senescent HSCs drive hepatocyte senescence but senescent 
HSCs interact with macrophages to create a tumor-suppressing microenvironment (144). 
IL-10 and IL-22 have been shown to induce senescence of HSCs (136, 138). Senescent 
HSCs promote recruitment of NK cells in the liver (142). Whereas infiltrating B-lymphocytes 
inhibit senescence of HSCs, they exacerbate fibrogenesis and maintain a tumorigenic 
inflammatory microenvironment (155). These data suggest that the immune 
microenvironment of liver cells is to a large extent determined by the interaction of 
senescent HSCs and (infiltrating) immune cells. 
5. Conclusions and future perspectives 
Hepatic stellate cell activation is involved in the pathogenesis of liver fibrosis. Senescent 
HSCs acquire a less fibrogenic phenotype and exhibit permanent proliferation arrest. This 
phenomenon favors resolution of fibrosis. HSC senescence can be triggered by various 
stimuli. Different stimuli induce slightly different biomarkers of senescence in HSCs. Among 
the biomarkers, P21CIP1, P53, SA-β-Gal and SASP can be used to identify senescent HSCs 
in vivo and in vitro.  
Senescent HSCs acquire genetic and epigenetic changes that profoundly alter their 
cellular signaling pathways and intracellular biological processes. For instance, both 
increased as well as decreased autophagy are involved in senescence induction. mTOR 
inhibitors failed to reverse all aspects of the senescent phenotype, suggesting a complex 
regulation of signaling pathways leading to senescence. 
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Evidence that promoting HSC senescence reduces fibrogenesis is the rationale for 
exploring induction of senescence as a strategy for the treatment of liver fibrosis. However, 
it should be noted that accumulation of senescent hepatocytes may lead to hepatic 
dysfunction. This potential detrimental consequence requires a comprehensive evaluation 
of the effects of inducing HSC senescence in the liver. Furthermore, the interaction between 
senescent HSCs and immune cells, including macrophages, lymphocytes and NK cells, 
demonstrates that the elimination of senescent HSCs is determined to a large extent by 
immune cells. This indicates that maintaining the proper micro-environment in the liver is 
key to the success of immune clearance of senescent HSCs. Finally, in the end, inducers of 
senescence may only be successfully applied in combination with senolytics to minimize the 
disadvantages and detrimental effects of accumulated senescent cells. In conclusion, more 
studies should be conducted to clarify role of HSC senescence in liver fibrosis. 
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Background: Activation of hepatic stellate cells (HSC) leads to initiation and 
progression of liver fibrosis. HSC senescence is inversely correlated with HSC proliferation 
and activation. Therefore, induction of HSC senescence may be a strategy to treat liver 
fibrosis. The natural compound esculetin, a coumarin-derivative, has been shown to inhibit 
HSC activation and proliferation, however its effect on senescence is unknown. Aim: to 
investigate the effect of esculetin on HSC activation and senescence. Methods Primary rat 
HSCs were used in all experiments. Real-time cell analyzer and BrdU incorporation assay 
were used to determine HSC proliferation. Gene expression of the senescence-associated 
genes Cdkn1a (p21), P53, activation markers Acta2, Col1a1 and quiescence markers Pparg 
and Lrat were measured by RT-qPCR. Senescence associated β-Galactosidase (SA-β-Gal) 
staining was used to identify senescent HSCs. Akt/GSK3β phosphorylation and P21Cip1 
expression was probed by Western blotting. Results: Esculetin increased percentage of 
SA-β-Gal positive cells and mRNA level of Cdkn1a and Il6 in HSCs. Proliferation of HSCs 
was inhibited and mRNA expression of fibrogenic genes Acta2 and Col1a1 was reduced by 
esculetin, while Pparg mRNA expression was restored in esculetin-treated HSCs. Activated 
HSCs pre-treated with esculetin followed by washout still exhibited less proliferation and 
activation and increased expression of senescence markers and SA-β-Gal staining. Protein 
expression of P21Cip1, accompanied by phosphorylation of Ser473 Akt and Ser9 GSK3β was 
increased by esculetin. The effect of esculetin was dependent on PI3K-Akt signaling. 
Conclusions: Esculetin induces HSC senescence and reverses the fibrogenic phenotype 
of HSCs. The induction of senescence depends on PI3K-Akt-GSK3β signaling. Inadequate 
induction of senescence preserves fibrogenic phenotype of HSCs. Esculetin could be a 
potential therapeutic drug for liver fibrosis by the novel mechanism of inducing senescence. 
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Liver fibrosis is a dynamic pathological process characterized by the accumulation of 
excessive extracellular matrix (ECM) resulting from chronic liver injury of any etiology, 
including chronic viral hepatitis, alcoholic liver disease (ALD) and non-alcoholic fatty liver 
disease (NAFLD). The prevalence of liver fibrosis varies from 0.7% to 25.7% in different 
cohorts (1). Advanced liver fibrosis has a high risk to progress to cirrhosis, which is 
estimated to result in 1.03 million deaths per year worldwide (2). Activation of hepatic 
stellate cells (HSC) plays a pivotal role in the initiation and progression of hepatic fibrosis in 
experimental and human liver injury (3). Activated HSCs acquire a myofibroblast-like 
phenotype with enhanced proliferation, contractility, matrix synthesis, altered matrix 
degradation and pro-inflammatory signaling to form scar tissue in injured liver (3, 4). It is a 
consensus that if activation of HSCs is prevented or reversed, liver fibrosis can be slowed 
down or even reversed. 
Currently, there is a strong interest in bioactive natural compounds that are able to 
prevent or reverse HSC activation. Esculetin, a coumarin derivative, has been demonstrated 
to attenuate hepatic steatosis and inflammation (5, 6). Esculetin has been shown to inhibit 
proliferation of vascular smooth muscle cell and cancer cells (7, 8). Moreover, esculetin has 
been demonstrated to attenuate liver fibrosis via inhibition of the activation of hepatic 
stellate cells (Bai et al; in preparation). Interestingly, cell cycle arrest, which is a 
characteristic of cellular senescence, has also been observed in esculetin-treated cells (9).  
Cellular senescence is a specific phenomenon characterized by the induction of 
permanent growth arrest of proliferating cells in response to various cellular stresses (10). It 
has been shown that induction of cellular senescence is negatively correlated with 
proliferation and activation of HSCs (11, 12). In addition, there is a specific set of secretory 
proteins released by senescent cells, collectively defined as the senescence associated 
secretory phenotype (SASP). SASP displays a characteristic secretory proteome, including 
specific cytokines and chemokines, to promote tissue regeneration through the induction of 
cell plasticity and stemness (13). Inadequate senescence induction in experimental models 
of fibrosis exacerbate progression of fibrosis (11, 14). Therefore, induction of stellate cell 
senescence can be a therapeutic strategy for liver fibrosis.  
Several studies have demonstrated that natural compounds can induce HSC 
senescence and attenuate experimental liver fibrosis (15, 16). In view of the reported effects 
of esculetin on cell proliferation, we hypothesized that esculetin can induce HSC 
senescence and consequently alleviate liver fibrosis. In vitro experiments were conceived 
and performed on primary rat HSC to verify our hypothesis.  
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Materials and Methods 
Rats and cell isolation 
Primary rat HSCs were isolated from 350-500g specified pathogen-free male Wistar 
rats (Charles River, Wilmington, MA, USA). Rats were housed under standard animal 
laboratory conditions with free access to food and drinking water. All experiments were 
carried out according to the guidelines for welfare of laboratory animals from the Committee 
for Care and Use of laboratory animals of the University of Groningen. Cells were isolated 
via portal vein perfusion with Pronase-E (Merck, Amsterdam, the Netherlands) and 
Collagenase-P (Roche, Almere, the Netherlands) until complete digestion of the liver, 
followed by gradient centrifugation on 13% (w/v) Nycodenz (Axis-Shield POC, Oslo, 
Norway). Isolated cells were cultured in Iscove’s Modified Dulbecco’s Medium 
supplemented with Glutamax (Thermo Fisher Scientific, Waltham, MA, USA), 20% heat 
inactivated fetal calf serum (Thermo Fisher Scientific), 1% MEM Non Essential Amino Acids 
(Thermo Fisher Scientific), 1% Sodium Pyruvate (Thermo Fisher Scientific) and antibiotics: 
50 µg/mL gentamycin (Thermo Fisher Scientific), 100 U/mL penicillin (Lonza, Vervier, 
Belgium), 10 µg/mL streptomycin (Lonza) and 250 ng/mL fungizone (Lonza) in an incubator 
containing 5% CO2 at a 37°C. 
Experimental design 
Isolated quiescent HSCs were cultured in culture medium for 7 days for 
culture-activation. Activated HSCs were then seeded at 70% confluency in plates. Unless 
otherwise stated, all treatments were performed in fresh medium. Esculetin (Alfa Aesar, MA, 
USA) and the pan-PI3k inhibitor LY294002 (Calbiochem, Darmstadt, Germany) were diluted 
in DMSO to prepare stock solutions. Each experimental condition was performed in duplicate 
and repeated at least 3 times. 
Quantitative Real-Time Polymerase Chain Reaction 
Gene expression levels were quantified by real-time reverse transcription polymerase 
chain reaction. Total mRNA was isolated from cells using Tri-reagent (Sigma Aldrich) 
according to the manufacturer’s protocol. Concentration of RNA was determined by 
Nano-Drop 2000c (Thermo Fisher Scientific). cDNA was synthesized from 0.5-2.5 µg RNA 
by MLV reverse transcriptase and RNase Out (Sigma-Aldrich). Gene expression was 
determined by TaqMan probes and primers by real-time polymerase chain reaction on the 
QuantStudioTM 3 system (Thermo Fisher Scientific). Relative gene expression was 
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calculated via the 2-𝚫𝚫Ct method. The primers and probes are shown in Table 1. All samples 
were measured in duplicate using 36b4 as housekeeping gene.  
Table 1.  





























































Senescence-associated β-galactosidase staining 
Senescent cells were identified by Senescence-associated β-galactosidase staining kit 
(Cell Signaling Technology, Danvers, Massachusetts, USA) according to the supplier’s 
instruction. Briefly, after treatment, activated HSCs were fixated and stained by X-gal 
solution (pH= 5.9-6.1) for 24 hr at 370C in a dry incubator. After incubation, the 
β-galactosidase staining solution was removed and wells were rinsed in 70% glycerol and 
images were evaluated on the EVOS xl cell imaging (Thermo Fisher Scientific) microscope 
(200x magnification).  
Cell proliferation assay 
Cell proliferation was determined by Real Time Cell Analysis system xCELLigence 
(RTCA DP; ACEA Biosciences, Inc., CA, USA) and results were confirmed using the BrdU 
incorporation assay (Roche Diagnostic Almere, the Netherlands). Using the xCELLigence 
system, cell confluence was monitored in real-time and cell index was measured in E-plates. 
Cells were seeded in 96 well plates and treated as described before. Incorporation of BrdU 
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in proliferating cells was detected by chemiluminescence using Synergy-4 (Bio-Tek). 
Western blot analysis 
Protein samples were prepared in lysis buffer (HEPES 25 mmol/L, KAc 150 mmol/L, 
EDTA pH 8.0 2mmol/L, NP-40 0.1%, NaF 10 mmol/L, PMSF 50 mmol/L, aprotinin 1 µg/µL, 
pepstatin 1 µg/µL, leupeptin 1 µg/µL, DTT 1 mmol/L). Protein concentration was quantified 
by Bio-Rad protein assay (Bio-Rad; Hercules, CA, USA) according to the manufacturer’s 
protocol using bovine serum albumin (BSA) to prepare a standard curve. Gel 
electrophoresis was performed with 10-20 µg protein using the Mini-Protein® TGX™ 
precast 4-15% gels (Bio-Rad), followed by transblotting to 0.2 µm nitrocellulose membrane 
(Bio-Rad). Proteins were detected using the primary antibodies listed in table 2. Protein 
band intensities were determined and detected using the Chemidoc MR (Bio-Rad) system.  
Table 2.  
Protein Species  Dilution  Company 
β-Actin Polyclonal rabbit 1:1000 4970, Cell Signaling 
COL1α1 Polyclonal goat 1:2000 1310-01, Southern Biotech 
ACTA2 Polyclonal rabbit 1:2000 Ab5694, Abcam 
Phospho-AKT (Ser473) Polyclonal rabbit 1:1000 9271L, Cell Signaling 
Phospho-AKT (Thr 308) Polyclonal rabbit 1:1000 sc-16646-R, Santa Cruz 
Total AKT Polyclonal rabbit 1:2000 9272, Cell Signaling 
Phospho-GSK3β(Ser9) Polyclonal rabbit 1:1000 9336, Cell Signaling 
Total GSK3β Monoclonal rabbit 1:2000 9315, Cell Signaling 
P21(Gene is Cdkn1a) Monoclonal rabbit 1:1000 ab109199, Abcam 
GAPDH Monoclonal mouse 1:1000 CB1001, Calbiochem 
Statistical analysis 
Data are presented as mean ± standard deviation (mean±SD) and mean ± standard 
error of means (mean±sem). Each result was obtained from at least three independent 
experiments. Statistical significance was determined by Mann-Whitney U test between the 
two groups, one-way ANOVA or Kruskal-Wallis followed by post-hoc Dunnet’s test for 
multiple comparison test and two-way ANOVA followed by Tukey’s multiple comparison. 
P<0.05 was considered statistically significant (*: p<0.05, **: p<0.01, ***: p<0.001, ****: 
p<0.001, ns: p>0.05). Data analysis was performed using GraphPad Prism 7 (GraphPad 
Software, San Diego, CA, USA).  
  
550886-L-bw-Zhang













Figure 1. Esculetin induces senescence of primary HSCs. 
A. Senescence Associated β-Galactosidase staining. Quiescent qHSCs (D1) and activated aHSCs (D7) 
were treated with 50 μmol/L esculetin or vehicle for 48 hr. Magnification: 200x. B. aHSCs were treated with 
50 μmol/L esculetin or vehicle for 48 hr and mRNA expression of Cdkn1a, Tp53 and Il6 was determined and 
shown as mean±sem. 
Freshly isolated quiescent HSCs become activated during cell culture (17). D1 and D7 
cultured HSCs represent quiescent HSCs (qHSC) and activated HSCs (aHSC), respectively. 
Senescence associated β-Galactosidase (SA-β-Gal) staining was used to determine cell 
senescence. As shown in Figure 1A, esculetin treatment increased the number of β-Gal 
positive cells in both qHSCs and aHSCs. Senescence associated genes Cdkn1a, Tp53 and 
Il6 mRNA expression were measured as markers of senescence, shown in Figure 1B. 
Expression of Cdkn1a and Il6 was increased four-fold and two-fold, respectively, in 
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esculetin-treated aHSCs. In contrast, Tp53 mRNA expression was not affected by esculetin.  
 
Figure 2. Esculetin inhibits proliferation and activation of primary hepatic stellate cells. 
A. xCELLigence proliferation assay. Activated primary HSCs were cultured and treated with 50 μmol/L 
esculetin or vehicle for 96 hr. Normalized cell index is shown as mean±sd. B. BrdU incorporation assay. 
Activated primary HSCs were cultured in 96-well plates and treated by 50 μmol/L esculetin or vehicle for 72 
hr. Data are shown as mean±sem, n = 3. C, D. Quiescent primary HSCs were treated by 50 μmol/L 
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esculetin or vehicle for 48 hr. Data are shown as mean±sem, n = 4. E. Expression of collagen type I and 
αSMA protein was determined by Western blotting in aHSCs treated for 72 hr with 0, 50 and 100 μmol/L 
esculetin, respectively. 
Uncontrolled proliferation of aHSCs is one of most important characteristics during 
fibrosis progression (3). Therefor we investigated whether esculetin had anti-proliferative 
effects. As shown in Figure 2A, esculetin inhibited the proliferation of aHSCs significantly 
after 48 hr of incubation. To verify whether the decreased cell index was the result of 
inhibition of proliferation, we performed the BrdU incorporation assay. As shown in Figure 
2B, incorporation of BrdU in proliferating HSCs was reduced by 70% in esculetin-treated 
cells, which demonstrated that esculetin inhibited DNA replication in S-phase cells. Next, we 
examined whether esculetin could prevent activation of qHSCs. As shown in Figure 2C, 
expression of the activation markers Acta2 and Col1a1 was decreased by about 40% and 
60%, respectively upon treatment with esculetin. In contrast, esculetin-treated qHSCs had 
more than two-fold higher expression of the quiescence marker Pparg than vehicle treated 
cells. Lrat expression did not change upon esculetin treatment as shown in Figure 2D. 
Collagen type1 but not αSMA protein expression in aHSCs was inhibited by esculetin in a 
dose-dependent manner. Moreover, we performed immunofluorescence microcopy to 
determine intracellular collagen expression. The result was in line with the Western blotting 
results of Figure 2D as shown in supplemental Figure S1. 
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Figure 3. Esculetin induced long-lasting senescence of primary HSCs.  
A. Graphical illustration of wash-out strategy of different groups. B. xCELLigence proliferation assay. 
Primary HSCs were seeded into plates and treated by wash-out strategy as indicated. C. Doubling time of 
cell index before and after wash-out was calculated and depicted as mean±sd. D. PCNA protein expression, 
determined by Western blotting using GAPDH as loading control. E. SA-β-Gal staining. Magnification 200X. 
Since cellular senescence is characterized as stable cell-cycle arrest, we designed a 
wash-out strategy to determine the proliferation potential of HSCs as illustrated in Figure 3A. 
aHSCs pretreated with esculetin for 48 hr exhibited much lower proliferation ability 
compared to vehicle-treated ones in the subsequent 48 hr wash-out period as shown in 
Figure 3B. Furthermore, doubling time was sharply increased in esculetin pre-treated 
groups after wash-out as shown in Figure 3C. Proliferating cell nuclear antigen (PCNA) 
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stimulates DNA polymerases and promotes DNA synthesis and its expression is used as a 
marker for cell replication (18, 19). In line with the proliferation data, expression of PCNA in 
esculetin pre-treated groups was significantly lower than in non-pretreated ones after the 48 
hr wash-out period as shown in Figure 3D. In addition, the number of β-Galactosidase 
positive cells in esculetin pre-treated groups remained higher than non-treated groups in 




Figure 4. Esculetin induces senescence progression in aHSCs.  
aHSCs were treated with esculetin, followed by wash-out protocol and mRNA levels were measured by 
RT-qPCR. Data are shown as mean±sem; n=3. 
As shown in Figure 4, aHSCs pre-treated by esculetin following wash-out generally 
maintained a similar transcription profile compared to cells continuously treated with 
esculetin. However, compared to non-treated cells, pre-treated aHSCs demonstrated a 50% 
and 40% reduction of expression of Acta2 and Col1a1, respectively. Additionally, expression 
of Cdkn1a, Il6 and Mmp9 mRNA was increased 2-3 fold while Tp53 tended to increase but 
not significantly in esculetin pre-treated aHSCs.  
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Figure 5. Esculetin induces senescence via the PI3K-Akt-GSK3β pathway.  
A. aHSCs were treated with esculetin and harvested at 0, 12, 24 and 48 hr after treatment. B. aHSCs were 
treated with or without 2 μmol/L LY294002 followed by treatment with 50 μmol/L esculetin or vehicle for 24 
hr. C. SA-β-Gal staining. aHSCs were treated with or without 2 μmol/L LY294002 followed by 50 μmol/L 
esculetin or vehicle for 48 hr. 
Cooperation between intracellular Akt and P21Cip1 is essential for the induction of 
senescence (20). Phosphorylation at the Ser473 site activates Akt kinase. GSK3β is its main 
target and is phosphorylated at Ser9 by active Akt (21). We hypothesized that esculetin 
treatment activates Akt in HSCs. Therefore, we investigated phosphorylation of Akt at 
Ser473 and phosphorylation of its downstream target GSK3β at Ser9 as well as P21Cip1 by 
Western blot at different time points after esculetin treatment (Figure 5A). Phosphorylation 
of Akt-Ser473 and GSK3β-Ser9 was induced within 48 hr of esculetin treatment, in line with 
increased expression of P21Cip1. PI3K is one of the kinases able to activate Akt and 
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LY294002 is a non-selective inhibitor of PI3K that is used to block Akt activity (20). As shown 
in Figure 5B, phosphorylation of Akt-Ser473 and Akt-Thr308 was efficiently inhibited in 
aHSCs treated with esculetin in combination with LY204002 compared to esculetin alone. 
Phosporylation of GSK3β-Ser9 and expression of P21Cip1 were also downregulated by 
LY294002. While total Akt and total GSK3β amount were not changed in any of the 
experimental conditions, LY294002 decreased phosphorylation of Akt as expected. The 
number of β-Gal positive cells was markedly diminished in aHSCs treated by the 
combination of esculetin and LY294002 compared to esculetin alone, shown in Figure 5C.  
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Figure 6. Inhibition of PI3K restores pro-fibrogenic phenotype in esculetin-treated aHSCs. 
A. xCELLigence assay. aHSCs were treated with 2 μmol/L LY294002 or vehicle combined with or without 
esculetin for 72 hr after which medium was refreshed. B. Doubling time before and after wash-out (72 hr 
periods) were calculated and shown as median and quartile. C-E. aHSCs were treated by esculetin or 
vehicle with or without LY294002 for 72 hr. Collagen type I and αSMA were assessed by Western blotting.  
Considering that the senescence phenotype is repressed by PI3K inhibitor, we 
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investigated whether the anti-senescent PI3K inhibitor could also affect the fibrogenic 
phenotype of HSCs which was suppressed by esculetin. In the first 72 hr, the PI3K inhibitor 
inhibited proliferation of aHSCs and did not rescue the impaired proliferation of 
esculetin-treated aHSCs. However, after wash-out and addition of fresh medium, aHSCs 
treated with esculetin in combination with PI3K inhibitor proliferated more rapidly than cells 
treated by esculetin or PI3K inhibitor alone as shown in Figure 6A,B. Likewise, collagen 
expression was restored by PI3K inhibitor in esculetin-treated aHSCs, as shown in Figure 
6C-D, while expression of αSMA was not significantly changed in any of the experimental 
conditions. 
Disscussion 
Liver fibrosis is characterized by the excessive deposition of extracellular matrix (ECM) 
in the liver. Activated hepatic stellate cells are the main source of excessive matrix 
production in response to liver injury (2). Transdifferentiation of quiescent stellate cells into 
activated stellate cells is characterized by increased proliferation, contractility, chemotaxis 
and matrix synthesis (3). Activated HSCs have a specific phenotype, including increased 
expression of αSMA and collagen and decreased expression of PPARγ and LRAT (4). 
Cellular senescence of HSCs was observed in a model of experimental liver fibrosis and is 
thought to slow down the progression of fibrosis (11). Cellular senescence is characterized 
by a specific phenotype: P21Cip1, P16INK4A and P53 are important effectors of the cell cycle 
arrest in senescence induction (10). Senescence-associated β-Galactosidase (SA-β-Gal) is 
increased as a consequence of lysosomal stress and is one of the well-established markers 
to identify senescent cells (22, 23). Senescent cells secrete a specific proteome consisting 
of cytokines, proteinases and chemokines, collectively known as senescence associated 
secretory phenotype (SASP). Among the components of the SASP is interleukin-6 (IL6), one 
of the essential cytokines that contribute to senescence in a paracrine manner (24). In 
contrast to fibrogenic HSCs, senescent HSCs exhibit decreased expression of αSMA and 
collagen and increased expression of inflammatory cell receptor ligands facilitating their 
clearance by the immune system (11, 16). The phenotype and biological properties of 
senescent HSCs suggest that inducing senescence of HSCs might be considered as a 
therapeutic strategy for liver fibrosis (12). In this study, we demonstrate that the 
coumarin-derivative esculetin induced a senescence-like phenotype in HSCs as 
demonstrated by increased mRNA expression of Cdkn1a (P21) and Il6 and an increased 
number of SA-β-Gal positive cells. In our experimental protocol, an increase in P53 mRNA 
level was not observed. Because P21 is an established downstream target of and 
transcriptionally controlled by P53 (25), we assume that P53 might be changed in a 
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posttranslational manner to induce the expression of P21. 
 Since cellular senescence of HSCs was induced by esculetin, the fibrogenic 
phenotype of HSCs was also investigated to explore the association between senescence 
and fibrogenesis. P21, encoded by the gene CDKN1A, is the checkpoint of cell cycle 
progression in G1/S and G2/M transitions (26). Real-time xCELLigence assay as well as 
BrdU incorporation revealed that esculetin inhibited mitosis and DNA replication in HSCs. In 
line with this, P21 expression was increased upon treatment with esculetin in aHSCs.  
Primary quiescent HSCs cultured in vitro on tissue culture plastic undergo activation 
into a fibrogenic phenotype characterized by active proliferation, increased expression of 
the fibrogenic markers Acta2 and Col1a1 and gradual loss of Pparg and Lrat (27). In our 
study, the increased expression of Acta2 and Col1a1 was inhibited by esculetin whereas 
expression of the quiescence marker Pparg was preserved. The expression of the 
quiescence marker Lrat was not affected by esculetin. Interestingly, it has been 
demonstrated that depletion of Lrat may not be an important factor in the acquisition of the 
fibrogenic phenotype (28). These results confirm the reciprocal regulation of the senescent 
and fibrogenic phenotype by esculetin in HSCs. 
Cellular senescence has been described as a time-dependent process: initiation and 
maintenance of senescence are highly regulated by different signaling pathways (20, 29). 
The complete senescence phenotype depends on the combined action of various signaling 
pathways. For instance, P21Cip1 initiates senescence whereas P16INK4A accounts for 
maintaining growth arrest (10). Permanent cell cycle arrest and non-responsiveness to 
mitogens and growth factors are essential to the senescent phenotype (10). We performed 
wash-out experiments to investigate the response of esculetin-treated HSCs to mitogens 
and growth factors in the absence of the senescence inducer. Our results show that the 
ability to proliferate remains inhibited in senescent cells. In line with this, protein expression 
of PCNA, which represents the S-phase of cells undergoing DNA replication (18), was also 
inhibited in senescent cells. Additionally, the SA-β-Gal staining demonstrated that during the 
wash-out period, the senescence phenotype did not reverse to the fibrogenic phenotype by 
the mitogens and growth factors present in medium. This phenomenon was also observed 
in co-cultures of senescent cells and proliferating cells (30). During the wash-out period, the 
expression levels of the senescence markers Cdkn1a, Il6 and Mmp9 remained at almost the 
same high level as in esculetin pre-treated cells with or without additional esculetin. These 
results indicate that the maintenance of the senescent phenotype is not dependent on the 
inducer itself (esculetin). This is in accordance with the mechanism described as 
SASP-induced non-cell-autonomous effect (14). Non-cell autonomous refers to the 
non-intrinsic mechanism and is attributed to e.g. the cell microenvironment (14, 31). The 
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mRNA expression of Acta2 and Col1a1 remained lower than in non-treated cells, 
demonstrating that the suppressed fibrogenic phenotype results from induced senescence. 
Induction of senescence is a highly regulated biological process with different signaling 
pathways involved. Cooperation between Akt and P21 has been demonstrated to be 
essential in the initiation of cellular senescence (20, 32). Phosphorylation of Ser473 and 
Thr308 are well-known posttranslational modifications in the activation of Akt. GSK3β is the 
first downstream target of Akt and is phosphorylated by active Akt at Ser9. In addition, it has 
been demonstrated that phosphorylation at Ser9 of GSK3β is necessary to maintain protein 
expression of P21 (33) and that it correlates positively with cellular senescence (34). In our 
study, we observed that during the period of senescence induction, phosphorylation at 
Ser473 of Akt was accompanied by phosphorylation at Ser9 of GSK3β and increased 
gradually with time, indicating the existence of an Akt-GSK3β axis in senescence induction. 
PI3K is one of the main upstream activators of Akt and its non-selective inhibitor has been 
shown to reverse the inhibition of proliferation of fibroblasts in response to 
oncogene-induced senescence (20). LY294002 has been shown to inhibit phosphorylation 
at Ser9 of GSK3β and consequently to reduce P21 expression (33). Using PI3K inhibition, 
we could establish the importance of the PI3K-Akt-GSK3β pathway in the induction of 
senescence of esculetin-treated HSCs: LY294002 reduced phosphorylation at Ser473 and 
Thr308 of Akt and Ser9 of GSK3β as well as expression of P21 expression which was 
increased by esculetin treatment. In accordance with the reduced P21 expression, a sharp 
reduction in the number of SA-β-Gal positive cells was observed in esculetin-treated cells 
after LY294002 pretreatment. Therefore, it can be concluded that esculetin-induced HSC 
senescence depends on an intact PI3K-Akt-GSK3β pathway. 
 In addition to senescence induction, the PI3K-Akt pathway participates in a variety of 
biological processes including cell survival and proliferation (21). The PI3K inhibitor 
LY294002 failed to rescue the proliferative ability of HSC which was inhibited by esculetin. 
However, the ability of HSCs to respond to mitogens and growth factors was preserved 
during the wash-out period. Furthermore, collagen synthesis was completely rescued by the 
PI3K inhibitor. It should be noted that non-selective inhibition of PI3K also inhibited 
proliferation of HSC but did not affect collagen synthesis. These results suggest that 
concurrence of proliferation inhibition and loss of fibrogenic phenotype of HSCs is not 
indispensable for the induction of senescence. 
In conclusion, esculetin induces HSC senescence and consequently inactivates HSC 
activation in vitro. The induction of senescence depends on an intact PI3K-Akt-GSK3β 
signaling pathway. In addition, our results demonstrate that inadequate induction of 
senescence can prevent inactivation and preserve the fibrogenic phenotype of HSCs. In this 
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regard, esculetin could be a potential therapeutic drug for liver fibrosis. 
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Bioactive coumarin-derivative esculetin decreases hepatic stellate cell activation via induction of cellular 










Supplementary figure 1, Immunofluorescence staining for collagen type I.  





















Processed on: 10-11-2020 PDF page: 74
550886-L-bw-Zhang














Hydrogen sulfide stimulates activation of hepatic 
stellate cells through increased cellular 
bio-energetics 
 
Turtushikh Damba1, Mengfan Zhang1, Manon Buist-Homan1,2, Harry van Goor3, 
Klaas Nico Faber1,2, Han Moshage1,2 
1Dept. Gastroenterology and Hepatology, 2Dept. Laboratory Medicine and 3Dept. 
Pathology and Medical Biology, University of Groningen, University Medical Center 
Groningen, Groningen, the Netherlands 
 
Correspondence: Han Moshage; a.j.moshage@umcg.nl 
 
Acknowledgment: Mongolian State Training Fund 
Published in Nitric Oxide 92 (2019) 26-33 
 
550886-L-bw-Zhang
Processed on: 10-11-2020 PDF page: 76








Abbreviations: Acta2, alpha-actin-2; Akt, protein kinase B; AOAA, amino-oxyacetic acid; 
ATP, adenosine triphosphate; BDL, bile duct ligation; BrdU, 5-bromo-2’-deoxyuridine; CBS, 
cystathionine β-synthase; cDNA, complementary deoxyribonucleic acid; CO, carbon 
monoxide; CTH, cystathionine γ-lyase; Col1α1, collagen type 1 alpha 1; DL-PAG, 
DL-Propargylglycine; ECAR, Extra-cellular acidification rate; ECM, extracellular matrix; 
FCCP, trifluoromethoxy carbonylcyanide phenylhydrazone; GAPDH, glyceraldehyde 
3-phosphate dehydrogenase; H2O2, hydrogen peroxide; HBSS, Hanks’ balanced salt 
solution; H2S, hydrogen sulfide; HSCs, hepatic stellate cells; MPST, 3-mercaptopyruvate 
sulfur transferase; NaHS, sodium hydrosulfide; NASH, nonalcoholic steatohepatitis; NO, 
nitric oxide; mRNA, messenger ribonucleic acid; OCR, Oxygen consumption rate; p38 
MAP-Kinase, P38 mitogen-activated protein kinases; PDGF-BB, platelet-derived growth 
factor BB; PLP, Pyridoxal phosphate; TGFβ1, transforming growth factor beta 1;  
Highlights 
• CTH expression and H2S production are increased during activation of hepatic 
stellate cells 
• Exogenous H2S increases hepatic stellate cell proliferation while inhibitors 
of H2S production reduce proliferation and expression of fibrogenic markers 
• The effect of H2S on hepatic stellate cells correlated with increased cellular 
bioenergetics 
















Hepatic fibrosis is caused by chronic inflammation and characterized as the excessive 
accumulation of extracellular matrix (ECM) by activated hepatic stellate cells (HSCs). 
Gasotransmitters like NO and CO are known to modulate inflammation and fibrosis, 
however, little is known about the role of the gasotransmitter hydrogen sulfide (H2S) in liver 
fibrogenesis and stellate cell activation. Endogenous H2S is produced by the enzymes 
cystathionine β-synthase (CBS), cystathionine γ-lyase (CTH) and 3-mercaptopyruvate sulfur 
transferase (MPST) (1). The aim of this study was to elucidate the role of endogenously 
produced and/or exogenously administered H2S on rat hepatic stellate cell activation and 
fibrogenesis. Primary rat HSCs were culture-activated for 7 days and treated with different 
H2S releasing donors (slow releasing donor GYY4137, fast releasing donor NaHS) or 
inhibitors of the H2S producing enzymes CTH and CBS (DL-PAG, AOAA). The main 
message of our study is that mRNA and protein expression level of H2S synthesizing 
enzymes are low in HSCs compared to hepatocytes and Kupffer cells. However, H2S 
promotes hepatic stellate cell activation. This conclusion is based on the fact that production 
of H2S and mRNA and protein expression of its producing enzyme CTH are increased 
during hepatic stellate cell activation. Furthermore, exogenous H2S increased HSC 
proliferation while inhibitors of endogenous H2S production reduce proliferation and fibrotic 
makers of HSCs. The effect of H2S on stellate cell activation correlated with increased 
cellular bioenergetics. Our results indicate that the H2S generation in hepatic stellate cells is 
a target for anti-fibrotic intervention and that systemic interventions with H2S should take into 
account cell-specific effects of H2S.  
Key words: hydrogen sulfide, H2S, cystathionine γ-lyase, CTH, CSE, hepatic fibrosis, 
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Chronic inflammation occurs in many liver diseases, e.g. non-alcoholic steatohepatitis 
(NASH), viral infection or chronic alcohol consumption. Liver fibrosis can be viewed as an 
uncontrolled wound healing response. Hepatic stellate cells (HSCs) play an important role in 
the onset and perpetuation of liver fibrosis. Under normal conditions, HSCs are quiescent 
and are the principal vitamin A storing cells in the liver (1). In conditions of chronic 
inflammatory liver injury, quiescent hepatic stellate cells (qHSCs) transform into proliferative 
myofibroblast-like cells called activated HSCs (aHSCs). During activation, HSCs lose their 
vitamin A content and start to produce large amounts of extracellular matrix (ECM) (2). 
When the inflammatory response is not suppressed, the excessive accumulation of ECM 
can lead to hepatic fibrosis, cirrhosis and eventually hepatocellular carcinoma. At present, 
there is no effective treatment for hepatic fibrosis, leaving liver transplantation as the only 
viable treatment option. Therefore, it is important to understand the mechanisms that lead to 
hepatic stellate cell activation and hepatic fibrosis (3,4). Gasotransmitters like nitric oxide 
(NO) and carbon monoxide (CO) have been shown to play an important role in chronic liver 
inflammation and liver fibrosis (5,6). Recently, interest has been focused on another 
gasotransmitter, hydrogen sulfide (H2S) (7–9). 
In the last two decades, H2S has been identified as a gasotransmitter that is generated 
in many mammalian cells and is involved in various physiological and pathophysiological 
processes as a signaling molecule similar to NO and CO (10). H2S has also been implicated 
to modulate inflammation and fibrosis, although its role in liver fibrosis and hepatic stellate 
cell activation is still not completely elucidated.  
H2S is produced intracellularly from cysteine and methionine by the enzymes 
cystathionine β-synthase (CBS), cystathionine γ-lyase (CTH) and 3-mercaptopyruvate sulfur 
transferase (MPST) (11,12). It has been shown to regulate hepatic fibrosis via its 
anti-oxidative and anti-inflammatory properties and by inducing cell-cycle arrest, apoptosis, 
vasodilation and reduction of portal hypertension (8,9,13–16). However, most of these 
experiments were performed in in vivo conditions and did not focus directly on the process 
of fibrogenesis and HSCs activation. Furthermore, conflicting results have been reported 
depending on the concentration or type of H2S donor used. Based on the H2S release rate, 
H2S releasing donors can be categorized as fast (NaHS; Na2S) or slow (GYY4137; ADT-OH) 
releasing donors, often yielding contrasting results (17–19). For instance, some studies 
reported pro-inflammatory and anti-apoptotic properties of H2S and in some studies H2S 
was shown to increase mitochondrial bioenergetics and promote cell proliferation (20–23). 
Therefore, there are still major gaps in our understanding of the actual effects of H2S on 
HSCs and liver fibrosis. 
The aim of the current study was to elucidate the effects of H2S on HSCs by 
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investigating how endogenously produced and/or exogenously administered H2S affects 
primary rat HSCs and its proliferation. Furthermore, we tried to elucidate the dynamics of 
endogenous production of H2S and H2S synthesizing enzymes during HSCs activation.  
Materials and methods 
Hepatic stellate cell isolation and culture  
Specified pathogen-free male Wistar rats were purchased from Charles River 
(Wilmington, MA, USA) and housed in a 12hr light-dark cycle under standard animal 
housing conditions with free access to chow and water. HSCs were isolated from rats 
weighing 350 to 450 g, anesthetized by isoflurane and a mixture of Ketamine and 
Medetomidine. The liver was perfused via the portal vein with a buffer containing Pronase-E 
(Merck, Amsterdam, the Netherlands) and Collagenase-P (Roche, Almere, the Netherlands). 
The HSC population was isolated by density centrifugation using 13% Nycodenz 
(Axis-Shield POC, Oslo, Norway) solution. Isolated HSCs were cultured in Iscove’s Modified 
Dulbecco’s Medium supplemented with Glutamax (Thermo Fisher Scientific, Waltham, MA, 
USA), 20% heat inactivated fetal calf serum (Thermo Fisher Scientific), 1% MEM Non 
Essential Amino Acids (Thermo Fisher Scientific), 1% Sodium Pyruvate (Thermo Fisher 
Scientific, Waltham, MA, USA) and antibiotics: 50 µg/mL gentamycin (Thermo Fisher 
Scientific), 100 U/mL Penicillin (Lonza, Vervier, Belgium), 10 µg/mL streptomycin (Lonza) 
and 250 ng/mL Fungizone (Lonza) in an incubator containing 5% CO2 at a 37°C (24). 
Quiescent HSCs (day 1) spontaneously activate when cultured on tissue culture plastic and 
reached complete activation (increased proliferation, loss of retinoids and increased 
synthesis of extracellular matrix components) after 7 days of culture. Day 3 cultured HSCs 
are considered intermediately activated. 
Experimental design  
Culture-activated HSCs (aHSCs) were treated with H2S donors or inhibitors for 72 hrs. 
All treatments with H2S donors and inhibitors were performed in fresh medium containing 20% 
FCS and other supplements. H2S releasing donors GYY4137 (kind gift from Prof. Matt 
Whiteman, University of Exeter, United Kingdom) and NaHS (Sigma-Aldrich, Zwijndrecht, 
the Netherlands) were diluted in distilled water and prepared freshly. NaHS was added 
every 8 hrs to the cells because of its rapid evaporation. The CBS inhibitor 
O-(carboxymethyl) hydroxylamine, AOAA (Sigma-Aldrich) was prepared as a 200 mmol/L 
stock solution and diluted in distilled water at neutral pH. CTH inhibitor DL-propargylglycine, 
DL-PAG (Sigma-Aldrich) was freshly prepared.  
550886-L-bw-Zhang
Processed on: 10-11-2020 PDF page: 80








Measurement of H2S concentration 
The accumulation of H2S in the culture medium was measured as described previously 
(25,26). After 72 hrs incubation, medium samples were collected in 250 µL of 1% (wt/vol) 
zinc acetate and distilled water was added up to 500 µL. Next, 133 µl of 20 mmol/L 
N-dimethyl-p-phenylenediamine sulfate in 7.2 mmol/L hydrogen chloride and 133 µl 30 
mmol/L ferric chloride in 1.2 mmol/L hydrogen chloride were added. After incubation for 10 
minutes at room temperature, protein was removed by adding 250 µL trichloroacetic acid 
and centrifugation at 14000 g for 5 minutes. Spectrophotometry was performed at 670 nm 
light absorbance (BioTek Epoch2 microplate reader) in 96 well-plates. All samples were 
assayed in duplicate and normalized to the number of cells. Concentrations were calculated 
against a calibration curve of NaHS (5–400 µmol/L) in culture medium. 
Quantitative Real-time Polymerase Chain Reaction  
Hepatic stellate cell RNA was isolated using Tri-reagent (Sigma-Aldrich) according to 
the manufacturer’s protocol. RNA concentrations were measured by Nano-Drop 2000c 
(Thermo Fisher Scientific, Waltham, MA, USA) and 1.5 µg of RNA was used for reverse 
transcription (Sigma-Aldrich). cDNA was diluted in RNAse-free water and used for real-time 
polymerase chain reaction on the QuantStudioTM 3 system (Thermo Fisher Scientific). All 
samples were analyzed in duplicate using 18S and 36b4 as housekeeping genes. The 
mRNA levels of Cth, Cbs, Mpst (Invitrogen) were quantified using SYBR Green (Applied 
Biosystems), other genes were quantified by TaqMan probes and primers. Relative gene 
expression was calculated via the 2-𝚫𝚫Ct method. The primers and probes are shown in Table 
1. 
Table 1. Primer sequences 







































GGG CTA CCA TGC CAA 
CTT CTG 
GAG GGC AAG GAC CTT 
GCT GTA 
CCT GCC CCT ACA TTT GGA GCC 
TGG A 
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Cell toxicity determination by Sytox Green 
Cell necrosis was measured by Sytox Green nucleic acid staining (Invitrogen, the 
Netherlands) at a dilution of 1:40.000 in culture medium or HBSS for 15 minutes at a 37°C. 
Necrotic cells have ruptured plasma membranes, allowing entrance of non-permeable Sytox 
green into the cells. Sytox green then binds to nucleic acids. Fluorescent nuclei were 
visualized at an excitation wavelength of 450-490nm by a Leica microscope. Hydrogen 
peroxide 1 mmol/L was used as a positive control.  
Cell proliferation measurement 
Proliferation of aHSCs was measured by Real-Time xCELLigence system (RTCA DP; 
ACEA Biosciences, Inc., CA, USA ) and by colorimetric BrdU cell proliferation ELISA kit 
(Roche Diagnostic Almere, the Netherlands). Cells were seeded in a 16-well E-plate and 
treated as indicated. Cell index was determined by measuring the change of impedance on 
the xCELLigence system.  
For BrdU incorporation assay, aHSCs were seeded in a 96-well plate and treated as 
indicated. BrdU incorporation was determined according to manufacturer’s instructions and 
quantified by light emission chemiluminiscence using the Synergy-4 machine (BioTek).  
Western Blot analysis 
Cells were seeded in 6-well plates and treated as described. Protein lysates were 
collected by scraping in cell lysis buffer (HEPES 25 mmol/L, KAc 150 mmol/L, EDTA pH 8.0 
2mmol/L, NP-40 0.1%, NaF 10 mmol/L, PMSF 50 mmol/L, aprotinin 1 µg/µL, pepstatin 1 
µg/µL, leupeptin 1 µg/µL, DTT 1 mmol/L). Total amount of protein in lysates was measured 
by Bio-Rad protein assay (Bio-Rad; Hercules, CA, USA). For Western blotting, 20-30 µg 
protein was loaded on SDS-PAGE gels. Proteins were transferred to nitrocellulose transfer 
membranes using Trans-Blot Turbo Blotting System for tank blotting. Proteins were detected 
using the following primary antibodies: monoclonal mouse anti-GAPDH 1:5000 (CB1001, 
Calbiochem), polyclonal goat anti-COL1α1 (1310-01, Southern Biotech), monoclonal mouse 
anti-ACTA2 1:5000 (A5228, Sigma Aldrich), polyconal rabbit anti-CTH 1:1000 (12217-1-AP, 
Proteintech), monoclonal mouse anti-CBS 1:1000 (sc-271886, Santa Cruz), monoclonal 
mouse anti-MPST 1:1000 (sc-374326, Santa Cruz) . Protein band intensities were 
determined and detected using the Chemidoc MR (Bio-Rad) system.  
Cellular bioenergetics analysis 
Mitochondrial activity and production of ATP was assessed by XF24 Extracellular Flux 
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Analyzer (Seahorse Bioscience, Agilent Technologies, Santa Clara SA, USA). aHSCs were 
seeded in Seahorse XF24 cell culture plates and treated as indicated for 48hrs. Oxygen 
Consumption Rate (OCR) and Extra-Cellular Acidification Rate (ECAR) were assessed after 
the addition of glucose (5 mmol/L), oligomycin (1 μmol/L), FCCP (0,25 μmol/L) and a 
mixture of antimycin (1 μmol/L), rotenone (1 μmol/L), 2-Deoxy-D-glucose (100 mmol/L). 
Results were normalized for the protein concentration of each sample.  
Bile duct ligation 
Male Wistar rats were anaesthetized with halothane/O2/N2O and subjected to bile duct 
ligation (BDL) as described by Kountouras J et al (27). At the indicated times after bile duct 
ligation (BDL), the rats (n = 4 per group) were sacrificed, livers were perfused with saline 
and removed. Control rats received a sham operation (SHAM). Specimens of these livers 
were snap-frozen in liquid nitrogen for isolation of mRNA and protein. 
Statistical analysis 
Results are presented as mean ± standard deviation (mean ± SD). Every experiment 
was repeated at least 3 times. Statistical significance was analyzed by Mann-Whitney test 
between the two groups and Kruskal-Wallis followed by post-hoc Dunn’s test for multiple 
comparison test. Statistical analysis was performed with GraphPad Prism 7 (GraphPad 
Software, San Diego, CA, USA).  
Results 
Hydrogen sulfide production is increased upon activation of hepatic stellate cells  
In order to determine the dynamics of H2S production and H2S producing enzymes 
during HSC activation, mRNA expression of H2S synthesizing enzymes was measured in 
quiescent (q) and activated (a) HSCs and compared to the expression of these enzymes in 
hepatocytes and Kupffer cells. As shown in Figure 1, the H2S producing enzymes Cth, Cbs 
and Mpst were expressed at low levels in qHSCs compared to hepatocytes and Kupffer 
cells. Upon activation, Cth gene expression increased in HSCs (Fig 1A) while Cbs and Mpst 
mRNA levels were not changed (Fig 1B,C). In line with this, the accumulation of H2S in 
culture medium was increased during HSC activation (Fig 1D). This result is denormalized 
due to comparable results with Figure 3. However, concentration of H2S in quiescent and 
activated HSCs were similar when we normalized by the number of cells. Western blotting 
results showed similar trend as observed for the mRNA expression data. Protein expression 
of CTH was increased during HSCs activation (Fig 1E). 
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Figure 1. Expression of H2S producing enzymes and H2S production in hepatic stellate cells  
Cth, Cbs and Mpst mRNA expression was determined in HSCs at day 1, 3, and 7 and compared to primary 
rat hepatocytes and Kupffer cells (A-C). The cytosolic enzymes Cth and Cbs were abundantly expressed in 
hepatocytes, while their expression was relatively low in HSCs. Upon HSCs activation, Cth expression was 
induced 7-fold, and Mpst slightly upregulated, whereas expression of Cbs was downregulated. Expression 
levels are relative to 18S expression. D. Production of H2S in activated and quiescent HSCs. The 
production of H2S was increased upon activation of HSCs. Results were normalized with respect to the 
number of cells. E. Protein expressions of CTH, CBS, MPST of HSCs at different time point and 
hepatocytes and Kupffer cells. Equal protein loading was confirmed by Ponceau S staining and Western 
blot for GAPDH.  
Effect of H2S on activation markers in hepatic stellate cells 
In order to avoid confounding effects of cell toxicity, we optimized the concentration of 
H2S donors and inhibitors by Sytox green staining. At concentrations twice as high as used 
in the experiments, none of the donors or inhibitors were toxic to HSCs (Figure 2).  
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Figure 2. H2S releasing donors and enzyme inhibitors are not toxic for hepatic stellate cells 
Toxicity of the compounds was checked by Sytox Green staining. Hydrogen peroxide (1 mmol/L; 6 hr 
exposure) was used as a positive control. The compounds DL-PAG (Cth inhibitor), AOAA (Cbs inhibitor), 
GYY4137 (slow releasing donor) and NaHS (fast releasing donor) were not toxic for HSCs. Duration of the 
treatment was 24hrs.  
 We next evaluated the effect of H2S on activation markers in aHSCs. Inhibitors of H2S 
producing enzymes (DL-PAG, AOAA) decreased the expression of the fibrogenic markers 
Col1α1 and Acta2 (Fig 3A). The H2S donors GYY4137 and NaHS did not affect the 
expression of Col1α1. However, GYY4137 slightly, but significantly, reduced Acta2 mRNA 
expression (Fig 3B). Interestingly, both of the two enzyme inhibitors also downregulated the 
expression of Cth mRNA. The changes in mRNA expression were reflected in similar 
changes in protein expression of COL1α1 but not ACTA2 (Fig 3C). Accumulation of H2S in 
culture medium was reduced by inhibitors, whereas GYY4137 increased H2S accumulation. 
Because of the fast release, no accumulation of H2S was measured in NaHS-treated group 
(Fig 3D).  
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Figure 3. mRNA and protein expression of HSC activation markers in response to H2S donors and 
enzyme inhibitors 
The H2S synthesizing enzyme inhibitors DL-PAG and AOAA downregulated Col1α1, Acta2 and Cth mRNA 
expression while the H2S donors GYY4137 and NaHS did not affect Cth and Col1α1 mRNA expression (A, 
B). In contrast, GYY4137, but not NaHS reduced Acta2 mRNA expression slightly. 18S was used as a 
housekeeping gene. The inhibitors also reduced COL1α1 protein level but not ACTA2 protein level (C). 
GAPDH was used as loading control for protein analysis. The accumulation over 72 hr of H2S in culture 
medium was measured in the experimental groups (D). DL-PAG and AOAA significantly reduced the 
accumulation of H2S. Because of its fast release, no accumulation of H2S was measured in the 
NaHS-treated group. Accumulation of H2S was detected with the slow releasing donor GYY4137.  
H2S promotes hepatic stellate cell proliferation 
The effect of H2S on rat HSC proliferation was assessed using real-time cell analyzing 
xCelligence and BrdU incorporation ELISA assays. H2S donors promote, whereas H2S 
synthesizing enzyme inhibitors inhibit aHSCs proliferation, indicating a stimulatory effect of 
H2S on HSC proliferation (Figure 4). 
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Figure 4. H2S promotes the proliferation of activated hepatic stellate cells  
Culture-activated HSCs were treated with H2S donors and enzyme inhibitors over period of 72 hrs. Cell 
proliferation was monitored by real-time xCELLigence system (A) and confirmed with BrdU incorporation 
ELISA assay (B). Inhibition of endogenous production of H2S suppressed cell proliferation, whereas H2S 
donors increased aHSCs proliferation. Data are presented ±SD.  
H2S increases cell metabolic activity  
H2S at low concentrations can increase cellular bioenergetics as an electron donor in 
mitochondrial oxidative phosphorylation (20,28). Since enhanced bioenergetics is 
associated with HSC activation, we investigated the effect of H2S on the bioenergetics of 
aHSCs. Two parameters of cellular metabolic activity, oxygen consumption rate (OCR) for 
mitochondrial oxidative phosphorylation and extracellular acidification rate (ECAR) for 
glycolysis, were determined using the Seahorse Extracellular Flux analyzer (Figure 5). The 
H2S donors GYY4137 and NaHS increased both the OCR and ECAR and ATP production, 
whereas the enzyme inhibitors DL-PAG and AOAA decreased metabolic activity of HSCs 
and ATP production.  
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Figure 5. H2S increases mitochondrial oxidative phosphorylation and glycolysis in aHSCs 
Effect of H2S donors and enzyme inhibitors on bioenergetics of aHSCs. Treatments with donors and 
inhibitors was for 48hrs. OCR and ECAR are represented as mean ± SEM of a representative experiment 
(A, B). Results were normalized with respect to the total amount of protein. Fold change of normalized 
maximal and basal level of OCR and ECAR between conditions were analyzed in 3 different experiments. 
For each experiment, every condition was repeated at least two times (C, D). Production of ATP was 
calculated using Seahorse XF Cell Mito Stress Test Report Generator software. Fold change of ATP 
production in experimental groups was calculated in 3 independent experiments (E).  
Cth is specifically induced in hepatic stellate cells during fibrogenesis 
We next evaluated the expression of H2S synthesizing enzymes in the bile duct ligation 
model, an experimental model of chronic inflammation leading to fibrosis (29). mRNA levels 
of all H2S synthesizing enzymes, Cth, Cbs and Mpst, decreased progressively in the bile 
duct ligation model (Figure 6 A-C). As expected, expression of the profibrogenic cytokine 
TGFβ1 increased progressively in the bile duct ligation model (Figure 6D). We next 
evaluated the effect of TGFβ1 on the mRNA expression of H2S synthesizing enzymes in 
different liver cell populations. TGFβ1 decreased mRNA expression of all H2S synthesizing 
enzymes in hepatocytes. In contrast, TGFβ1 increased mRNA expression of Cth in HSCs 
and did not change the mRNA expression of Cbs and Mpst in HSCs (Figure 6 E-G). 
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Figure 6. mRNA expression of Cth, Cbs and Mpst in the bile duct ligation model of liver fibrosis and 
their regulation by TGFβ1 in different liver cell populations  
Comparison of H2S synthesizing enzymes mRNA levels during fibrosis in vivo and in vitro. Cth, Cbs, Mpst 
were downregulated in total liver in the BDL model of liver fibrosis (A,B,C). Tgfβ1 expression is increased in 
fibrosis (D). 36b4 was used as a housekeeping gene. TGFβ1 reduced the expression of H2S synthesizing 
enzymes in hepatocytes (F,G), but it specifically induced Cth mRNA expression in HSCs in vitro (E).  
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The main message of our study is that H2S promotes hepatic stellate cell activation. 
This conclusion is based on the fact that production of H2S and expression its producing 
enzyme cystathionine γ-lyase (CTH) expression are increased during hepatic stellate cell 
activation and on the fact that exogenous H2S increased HSC proliferation while inhibitors of 
endogenous H2S production reduce proliferation of HSCs. Although the inhibitors we used 
are not completely specific for one of the H2S producing enzymes, e.g. the CBS inhibitor 
AOAA is also a potent inhibitor of CTH (30). it is important to note that reducing H2S 
production leads to reduced stellate cell activation. In addition, since CTH is the sole 
enzyme to upregulated during HSCs activation, it is likely that the effect of AOAA is 
mediated via inhibition of CTH.  
The effect of H2S on stellate cell activation correlated with increased cellular 
bioenergetics. Previous in vivo studies reported that H2S has anti-fibrotic properties due to 
its antioxidant and/or anti-inflammatory actions and its ability to reduce portal hypertension 
in the liver. In models of (experimental) fibrosis and cirrhosis, reduced expression of H2S 
producing enzymes are observed and an anti-fibrotic effect as well as reduction of portal 
hypertension of systemically administered H2S donors has been reported (7,13–15). In line 
with this, in vitro studies, using the fast-releasing H2S donor NaHS have demonstrated that 
H2S inhibits stellate cell proliferation, possibly via decreasing the phosphorylation of p38 
MAP-Kinase and increasing the phosphorylation of Akt (9,15). In another study, the natural 
H2S donor diallyl trisulfide suppressed activation of HSCs through cell cycle arrest at the 
G2/M checkpoint associated with downregulation of cyclin B1 and cyclin-dependent kinase 
1 in primary rat HSCs (8). However, the results described above were obtained using 
potentially toxic, fast-releasing H2S donors, which is not representative of the continuous 
production of low levels of H2S by cells. Furthermore, the use of systemically administered 
donors or inhibitors does not allow to distinguish effects of H2S on different cell types 
present within one organ. Therefore, we applied 2 different H2S releasing donors, GYY4137 
and NaHS at concentrations 5 times as lower as in some in vitro studies. Furthermore, most 
studies used exogenous H2S donors to study the role of H2S in stellate cell activation and 
fibrogenesis and the importance of endogenous production of H2S in HSC activation has not 
been properly addressed. Therefore, we also used 2 inhibitors of H2S synthesizing enzymes 
(DL-PAG and AOAA) and we determined H2S production by HSCs during the process of 
activation (8,9).  
Our observations of increased expression of H2S synthesizing enzyme CTH and 
increased H2S production during HSC activation indicates a role for H2S in HSC activation 
and fibrogenesis. Indeed, inhibition of endogenous H2S production in HSCs reduced 
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proliferation and expression of activation markers. These results are in line with the 
observation that platelet-derived growth factor BB (PDGF-BB) induced proliferation of rat 
mesangial cells via induction of CTH (31) and the observation that homocysteine, a 
precursor in H2S synthesis, enhances activation of rat HSCs via activation of the PI3K/Akt 
pathway (32). In contrast, an anti-fibrotic role has been proposed for 
cystathionine-β-synthase (CBS), another PLP-dependent enzyme which is involved in H2S 
synthesis in the liver (33).  
Since our results demonstrated a pro-fibrogenic effect of H2S on HSCs, whereas most 
in vivo studies reported an anti-fibrotic role for H2S, we investigated in more detail the H2S 
generating capacity in different liver cell types. First, we determined that expression of 
H2S-synthesizing enzymes in hepatocytes and Kupffer cells is much higher than in HSCs. 
Next, we determined the expression of H2S-synthesizing enzymes in the bile duct ligation 
model of liver fibrosis. We observed a down-regulation of total hepatic expression of both 
Cth and Cbs in our bile duct ligation model. As expected, the pro-fibrogenic cytokine Tgfβ1 
was increased in the bile duct ligation model. Finally, we studied the effect of TGFβ1 on the 
expression of H2S-synthesizing enzymes in different liver cell types. Of note, we observed 
that TGFβ1 decreases Cth and Cbs mRNA expression in hepatocytes, but increased Cth 
mRNA expression in stellate cells. These findings could explain the contradictory results 
between in vivo and in vitro studies with regard to the role of H2S in fibrogenesis: since 
hepatocytes are the major source of H2S in total liver, the increased expression of Tgfβ1 will 
lead to an overall reduction in the hepatic expression of Cth and Cbs and H2S production, 
whereas at the same time it will increase expression of Cth and H2S production in hepatic 
stellate cells. The cell-specific and local increase in H2S generation also explains the effect 
of H2S donors and inhibitors of H2S-synthesizing enzymes on HSC proliferation and 
activation. Recently, Szabo et al reported that a low exogenous dose of H2S or 
endogenously produced H2S increases mitochondrial oxidative phosphorylation (35,36). In 
accordance, Katalin et al described that low concentrations of H2S stimulates mitochondrial 
bio-energetics via S-sulfhydration of ATP- synthase in HepG2 and HEK293 cell lines (20). 
Activation of stellate cells is also accompanied by increased bioenergetics (37). We have 
extended these findings by demonstrating that H2S increases cellular bioenergetics in 
hepatic stellate cells. 
In summary, we demonstrate that stellate cell activation is accompanied by increased 
generation of H2S via induction of the H2S-synthesizing enzyme CTH, leading to increased 
cellular bioenergetics and proliferation of HSCs. In addition, the response of 
H2S-synthesizing enzymes to the fibrogenic cytokine Tgfβ1 is liver cell-type specific. Our 
results indicate that the H2S generation in hepatic stellate cells is a target for anti-fibrotic 
intervention and that systemic interventions with H2S should take into account cell-specific 
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responses to H2S.  
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Background: In fibrogenesis, quiescent hepatic stellate cells (HSCs) transdifferentiate 
into myofibroblast-like cells. These activated HSCs are the main producers of extracellular 
matrix during fibrogenesis. Recent studies indicate that the induction of cellular senescence 
in HSCs leads to the resolution of liver fibrosis. Cellular senescence is characterized by 
irreversible cell-cycle arrest, resulting in arrested cell proliferation and the acquisition of a 
senescence associated secretory phenotype (SASP). The PI3K-Akt signaling pathway is an 
important regulator of cellular senescence. Previously, we have shown that the 
gasotransmitter hydrogen sulfide (H2S) promotes HSC activation and fibrogenesis. We 
hypothesize that the inhibition of endogenous H2S production induces cellular senescence 
and reduces activation of HSCs. Methods: Rat HSCs were isolated and cultured for 7 days 
for complete activation and then treated with H2S slow releasing donor GYY4137 and/or 
DL-propargylglycine (DL-PAG), an inhibitor of the H2S producing enzyme CTH, as well as 
the PI3K inhibitor LY294002. Results: CTH expression was significantly increased in fully 
activated HSCs compared to quiescent HSCs. Inhibition of CTH by DL-PAG reduced 
proliferation and expression of fibrotic markers Col1a1 and Acta2 in HSCs. DL-PAG 
increased the expression of the cell-cycle arrest markers Cdkn1a, p53 and increased the 
expression of the senescent associated secretory phenotype (SASP) marker Il6. 
Additionally, the number of senescent positive β-galactosidase HSCs was increased. The 
H2S donor GYY4137 partially restored the proliferation of senescent HSCs and attenuated 
the DL-PAG-induced senescent phenotype. Induced senescence by DL-PAG was 
dependent on intact PI3K-Akt signaling. The non-selective PI3K inhibitor LY294002 partially 
reduced the senescence phenotype of HSCs induced by DL-PAG. Conclusion: Inhibition of 
endogenous H2S production reduces hepatic stellate cell activation via induction of cellular 
senescence in a PI3K-Akt dependent manner. Our results suggest that cell specific 
inhibition of H2S could be novel target for anti-fibrotic therapy via induced cell senescence.  
Key words: hydrogen sulfide, H2S, cystathionine γ-lyase, CTH, liver fibrosis, hepatic 
stellate cells, cellular senescence, TGFβ1  
Abbreviations: HSCs, Hepatic Stellate Cells; SASP, Senescence Associated 
Secretory Phenotype; DL-PAG, DL-propargylglycine; CTH, Cystathionine γ-lyase; SA-β-gal, 
Senescence Associated β-Galactosidase staining; 
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Liver fibrosis is characterized by the excessive deposition of extracellular matrix (ECM) 
in the liver. Activated hepatic stellate cells (HSCs) are the main producers of ECM in liver 
fibrogenesis. In physiological conditions, quiescent HSCs (qHSCs), located in the space of 
Disse, store 50-80% of whole-body vitamin A in the form of lipid droplets. In chronic 
inflammatory liver diseases, qHSCs transdifferentiate into myofibroblast-like cells, termed 
activated HSCs (aHSCs). Once activated, HSCs lose their vitamin A droplets, start to 
proliferate and produce excessive amounts of ECM (1, 2). In addition, the key fibrogenic 
cytokine transforming growth factor (TGFβ) is released and increases the production of 
ECM by HSCs (3). Reversal of activated HSCs into the quiescent stage and/or induction of 
apoptosis of activated HSCs are considered as potential strategies to cure liver fibrosis (4, 
5). 
Cell senescence is defined as irreversible cell cycle arrest accompanied by increased 
cytokine secretion, termed Senescence-Associated Secretory Phenotype (SASP) (6). 
Cellular senescence is regulated by various pathways including P53/P21Cip1 and PI3K-AKT 
signaling. P21Cip1 (mRNA: Cdkn1a) is an essential cell cycle checkpoint regulator that 
arrests cell proliferation at the G1 phase and initiates senescence (7). In the absence of Akt 
kinase activity, P21Cip1 is unable to arrest the cell cycle and initiate senescence (8). It has 
been reported that induction of senescence in activated HSCs reverses the fibrogenic 
phenotype of activated HSCs (9). Therefore, recent interest has been focused on inducing 
cellular senescence as a new mechanism for the resolution of liver fibrosis (10). It has been 
reported that some bioactive anti-fibrotic compounds induce cellular senescence via P53 
and YAP or via increased Natural Killer cell activation (4, 11). In addition, some anti-fibrotic 
proteins and cytokines, e.g. the matricellular protein CCN1 and the cytokines IL-10 and 
IL-22 have been reported to induce senescence via an integrin-dependent mechanism, via 
the generation of ROS or via the activation of p53 and/or p21cip1 (12-14).  
Hydrogen sulfide (H2S) is one of the gaseous signaling molecules along with nitric oxide 
and carbon monoxide. The liver is an essential organ for H2S production and clearance. 
Hepatic H2S is involved in mitochondrial biogenesis and bioenergetics, insulin sensitivity, 
lipoprotein synthesis and glucose metabolism (15). Endogenous H2S is synthesized by the 
enzymes cystathionine γ-lyase (CTH), cystathionine β-synthase (CBS) and 
3-mercaptopyruvate sulfur transferase (MPST) (1). We previously reported that CTH 
expression and the generation of H2S are increased during HSCs activation and that H2S 
promotes activation of HSCs: inhibition of CTH decreased HSCs proliferation and showed 
anti-fibrotic effects (16). It has been demonstrated that the gasotransmitter hydrogen sulfide 
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(H2S) has potent anti-senescence effects on endothelial cells via the induction of splicing 
factors HNRNPD and SRSF2 (17). Therefore we hypothesized that the inhibition of 
endogenous production of H2S in activated HSCs is anti-fibrogenic via the induction of 
senescence. 
Materials and Methods 
Rats 
Primary hepatic stellate cells (HSCs) were isolated from 400-500 g specified 
pathogen-free male Wistar rats (Charles River, Wilmington, MA, USA). Animals were 
housed under standard condition in a 12 hr light-dark cycle with free access to chow and 
water. All experiments were approved by the Committee for Care and Use of laboratory 
animals of the University of Groningen.  
Hepatic Stellate Cell isolation  
In order to isolate the HSCs, rats were anesthetized and perfused via the portal vein 
with Pronase-E (Merck, Amsterdam, the Netherlands) and Collagenase-P (Roche, Almere, 
the Netherlands). After perfusion, the digested liver was removed and the cell suspension 
centrifuged on 13% w/v Nycodenz (Axis-Shield POC, Oslo, Norway) to obtain HSCs. 
Following isolation, HSCs were cultured in Iscove’s Modified Dulbecco’s Medium 
supplemented with Glutamax (Thermo Fisher Scientific, Waltham, MA, USA), 20% heat 
inactivated fetal calf serum (Thermo Fisher Scientific), 1% MEM Non Essential Amino Acids 
(Thermo Fisher Scientific), 1% Sodium Pyruvate (Thermo Fisher Scientific) and antibiotics: 
50 µg/mL gentamycin (Thermo Fisher Scientific), 100 U/mL Penicillin (Lonza, Verviers, 
Belgium), 10 µg/mL streptomycin (Lonza) and 250 ng/mL Fungizone (Lonza) in an incubator 
containing 5% CO2 at a 37°C. HSCs were culture-activated for seven days on tissue culture 
plastic. 
Experimental design 
Activated HSCs (aHSCs) were seeded at a density resulting in a confluency of around 
90% at the end of each treatment. Depending on the assay, the duration of the treatments 
was 48 to 72 hr. Unless otherwise stated, all treatments were performed in fresh medium 
containing 20% FCS (v/v) and other supplements as described above. Hydrogen sulfide 
(H2S) slow-releasing donor GYY4137 (kind gift of prof. Matt Whiteman, University of Exeter, 
United Kingdom) and the pharmacological inhibitor of CTH DL-propargylglycine (DL-PAG; 
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Sigma-Aldrich, Zwijndrecht, the Netherlands) were freshly prepared prior to administration. 
PI3K inhibitor LY294002 (Calbiochem, Darmstadt, Germany) was diluted in DMSO to 
prepare a stock solution. Each experimental condition was performed in duplicate wells and 
repeated at least 3 times.  
Quantitative Real-Time Polymerase Chain Reaction 
Cellular mRNA was isolated by Tri-reagent (Sigma Aldrich) according to manufacturer’s 
protocol. Total RNA concentration was determined by Nano-Drop 2000c (Thermo Fisher 
Scientific). 0.5 to 2.5 µg of RNA was used for preparation of cDNA using MLV reverse 
transcriptase and RNase Out (Thermo). cDNA was diluted in RNAse-free water and used for 
real-time polymerase chain reaction on the QuantStudioTM 3 system (Thermo Fisher 
Scientific). All samples were analyzed in duplicate using 36b4 as housekeeping gene. The 
mRNA levels of Cth, Cbs, Mpst (Thermo Fisher Scientific) were quantified using SYBR 
Green (Applied Biosystems), other genes were quantified by TaqMan probes and primers. 
Relative gene expression was calculated via the 2-𝚫𝚫Ct method. The primers and probes are 
shown in table 1. 
Table 1. 






































no probe, qPCR with Sybr green 
Tgfβ1 
GGG CTA CCA TGC CAA 
CTT CTG 
GAG GGC AAG GAC CTT 
GCT GTA 
CCT GCC CCT ACA TTT GGA 
















p53 CCATGAGCGTTGCTCTG CAGATACTCAGCATACGG CGGCCTGGCTCCTCCCCAAC 
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Senescence-associated β-galactosidase staining 
Culture-activated HSCs were treated as described before. Cellular senescence was 
determined by Senescence-associated β-galactosidase staining kit (Cell Signaling 
Technology, Danvers, Massachusetts, USA) according to manufacturer’s protocol. After 
fixation, senescent cells were stained by X-gal solution (pH= 5.9-6.1) for 24 hr at 37°C in a 
dry incubator. Images were captured by digital phase contrast microscopy. 
Cell proliferation assay 
Cell proliferation was determined by BrdU incorporation assay (Roche Diagnostic 
Almere, the Netherlands) and Real-Time xCelligence assay (RTCA DP; ACEA Biosciences, 
Inc., CA, USA). Cells were seeded in 96 well plates and treated as described. Incorporation 
of BrdU was detected by chemiluminescence using Synergy-4 (Bio-Tek). For xCelligence, 
aHSCs were seeded in 16 well E-plates. Real-time cell proliferation was measured as a cell 
index in the xCelligence system.  
Western blot analysis 
Cells were seeded and treated as described. Protein lysates were scraped in cell lysis 
buffer (HEPES 25 mmol/L, KAc 150 mmol/L, EDTA pH 8.0 2 mmol/L, NP-40 0.1%, NaF 10 
mmol/L, PMSF 50 mmol/L, aprotinin 1 µg/µL, pepstatin 1 µg/µL, leupeptin 1 µg/µL, DTT 1 
mmol/L). Concentration of protein was measured by Bio-Rad protein assay (Bio-Rad; 
Hercules, CA, USA). 10-20 µg protein was loaded on SDS-PAGE gels. Proteins were 
transferred to nitrocellulose transfer membranes using Trans-Blot Turbo Blotting System for 
tank blotting. Proteins were detected using the primary antibodies listed in table 2. Protein 
band intensities were determined and detected using the Chemidoc MR (Bio-Rad) system.  
Table 2.  
Protein Species Dilution Company 
β-Actin Polyclonal rabbit 1:1000 4970, Cell Signaling 
COL1α1 Polyclonal goat 1:2000 1310-01, Southern Biotech 
ACTA2 Monoclonal mouse 1:5000 A5228, Sigma Aldrich 
P21Cip1 (CDKN1A) Polyclonal rabbit 1:1000 Sc-471, Santa Cruz 
CTH Polyclonal rabbit 1:1000 12217-1-AP, Proteintech 
CBS Monoclonal mouse 1:1000 sc-271886, Santa Cruz 
MPST Monoclonal mouse 1:1000 sc-374326, Santa Cruz 
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GAPDH Monoclonal mouse 1:1000 CB1001, Calbiochem 
p-Akt(Ser473) Polyclonal rabbit 1:1000 9271L, Cell Signaling 
p-Akt(Thr308) Polyclonal rabbit 1:1000 sc-16646-R, Santa Cruz 
Total Akt Polyclonal rabbit 1:1000 9272, Cell Signaling 
Immunofluorescence microscopy 
Cells were cultured on glass coverslips and fixed with 4% paraformaldehyde/PBS. 5 
min incubation with 1% Triton X-100 was used to permeabilize cells. Nonspecific antibody 
binding sited were blocked by 0.5% BSA/PBS for 30 min. After blocking, cells were 
incubated by primary antibody against collagen type 1 (1310-01, Southern Biotech) 1:400 
diluted in 0.5% BSA/PBS for 1 hr at room temperature.Coverslips were washed 3 times by 
PBS and then incubated with secondary antibody Alexa fluorophore (Molecular Probes) 
1:400 diluted in 0.5% BSA/PBS for 1 hr at room temperature. Coverslips were mounted with 
fluorescence mounting medium containing DAPI (Vectashield, Burlingame, CA, USA). 
Images were captured by Zeiss 410 inverted laser scanning microscope. 
Statistical analysis 
Data are presented as mean ± standard deviation (mean ± SD) of at least three 
independent experiments. Statistical significance was analyzed by Mann-Whitney test 
between the two groups and one-way ANOVA or Kruskal-Wallis followed by post-hoc Dunn’s 
test for multiple comparison test. P<0.05 was considered statistically significant. Analysis 
was performed using GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA).  
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TGFβ1 increases CTH expression in activated hepatic stellate cells  
 
Figure 1. CTH mRNA and protein expression is increased by the pro-fibrogenic cytokine TGFβ1.  
A-E. Relative gene expression of endogenous H2S producing enzymes Cth, Cbs, Mpst and hepatic stellate 
cell activation markers Col1α1, Acta2 (mean ± SD) were measured at 12, 24 and 48 hr in serum-free 
medium with or without treatment with 5 ng/ml TGFβ1. Expression levels were calculated relative to 36b4 
house-keeping gene. F. Protein expression of CTH, CBS, MPST and stellate cell activation markers 
COL1α1 and ACTA2. β-actin was used as loading control. Results are represented as mean ± SD; *P<0.05, 
**P<0.005.  
We previously reported that the expression of the endogenous H2S synthesizing 
enzyme cystathionine γ-lyase (CTH) and the production of H2S (CTH/H2S) were increased 
during transdifferentiation of quiescent hepatic stellate cells (qHSCs) into activated hepatic 
stellate cells (aHSCs) (16). Here, we investigated the effect of the pro-fibrogenic cytokine 
TGFβ1 on the expression of the H2S producing enzymes CTH, CBS, and MPST (Fig 1A-E). 
The fibrogenic cytokine TGFβ1 significantly increased the mRNA and protein expression of 
CTH but not of CBS and MPST. As expected, the expression of the fibrogenic markers 
Col1α1 and Acta2 mRNA were increased upon treatment of HSCs with TGFβ1.  
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CTH inhibition reverses activation of hepatic stellate cells 
 
Figure 2. The CTH inhibitor DL-PAG reverses activation of HSCs.  
A. mRNA levels of the activation markers Col1α1 and Acta2 were reduced in activated HSCs after 72 hr 
treatment with DL-PAG. Cth expression was also reduced by DL-PAG. 36b4 was used as housekeeping 
gene. B, C. Immunofluorescence staining and Western blotting of COL1α1 (magnification 200x) in activated 
HSCs. β-actin was used as loading control. Results are expressed as mean ± SD; *P<0.05, **P<0.005, 
***P<0.0005. 
Since CTH expression was increased by TGFβ1, we hypothesized that inhibition of 
CTH could inhibit TGFβ1-driven transdifferentiation of HSCs. As shown in Fig. 2A, inhibition 
of CTH reduced the expression of the fibrogenic markers Acta2 and Col1a1. In addition, 
protein level of collagen type 1 was also reduced by DL-PAG as shown by 
immunofluorescence and Western blot (Fig. 2B-C). 
CTH inhibition induces cellular senescence in hepatic stellate cells 
To determine whether the anti-fibrotic effect of CTH inhibition correlated with the 
induction of senescence, we investigated markers of senescence in DL-PAG treated HSCs. 
CTH inhibition decreased protein expression of CTH and P21Cip1 (Fig 3A). The mRNA 
expression of the cell cycle arrest markers Cdkn1α and p53 as well as the senescence 
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associated secretory phenotype (SASP) marker IL-6 were increased upon CTH inhibition 
(Fig 3B). In addition, inhibition of CTH by DL-PAG increased the number of senescence 
associated β-galactosidase positive (SA-β-gal) cells (Fig 3C). In order to investigate 
whether the proliferation arrest induced by DL-PAG was irreversible, we performed 
wash-out experiments. In the first 48 hr, DL-PAG inhibited HSC proliferation. After refreshing 
the medium (and removing DL-PAG), the proliferation ability remained impaired compared 
to non-treated HSCs (Fig 3D). 
 
Figure 3. Inhibition of CTH induces cellular senescence.  
A. Protein expression of H2S synthesizing enzyme CTH is decreased and cell cycle arrest marker P21Cip1 is 
increased upon CTH inhibition at 24 hr. GAPDH is used as loading control. B. mRNA expression of 
senescence markers Cdkn1α, p53 and SASP marker IL-6 after 72 hr treatment of aHSCs with DL-PAG. 
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36b4 was used as housekeeping gene. C. SA-β-gal staining (magnification 200x) after 48 hr treatment of 
HSCs with DL-PAG. D. Cell proliferation was measured by the xCELLigence system. Cells were treated for 
48 hr followed by the addition of fresh medium. Cell proliferation is represented by cell index. Results are 
represented as mean ± SD; *P<0.05, **P<0.005 
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H2S donor GYY4137 restores proliferation ability of senescent HSCs 
Since inhibition of the endogenous H2S synthesizing enzyme CTH showed anti-fibrotic 
effects via the induction of cellular senescence, we hypothesized that supplementation of 
exogenous H2S reverses induction of senescence. To test the hypothesis, HSCs were 
treated with both the inhibitor of CTH, DL-PAG and different concentrations of the H2S 
slow-releasing donor GYY4137. P21Cip1 expression, SA-β-galactosidase positive cell and 
mRNA expressions of Cdkn1α, p53 and Il6 were does-dependently reduced by GYY4137 
(Fig 4A-C). In addition, the impaired proliferation of HSCs treated with DL-PAG was 
improved by the H2S donor GYY4137 (Fig 4D).  
 
Figure 4. H2S donor GYY4137 partially reversed the pro-senescence effect of DL-PAG.  
A. P21Cip1 expression in HSCs treated with DL-PAG with or without different concentrations of GYY4137 at 
24 hr. B. Cell proliferation was measured by BrdU incorporation assay. C. mRNA expression of senescence 
markers Cdkn1α, p53, IL-6. 36b4 was used as housekeeping gene. D. SA-β-Gal staining of HSCs treated 
with DL-PAG with or without GYY4137 (magnification 200x). Results are represented as mean ± SD; 
*P<0.05, **P<0.005. Abbreviation: GYY, GYY4137. 
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PI3K-Akt pathway is involved in DL-PAG induced senescence 
We next investigated the signaling pathway involved in the anti-senescence effect of 
H2S. Akt activity is essential for induction of P21Cip1-dependent cellular senescence (6, 8, 
18). In order to determine the role of Akt in DL-PAG induced senescence, the pan-PI3K 
inhibitor LY294002 was applied to block Akt activity in HSCs. LY294002 decreased the level 
of Akt phospho-Ser473 and Akt phospho-Thr308 in HSCs. At the same time, LY294002 
attenuated the DL-PAG-induced increased expression of the senescence marker P21cip1 
(Fig 5A). In addition, the DL-PAG-induced increase in mRNA expression of cell cycle arrest 
markers Cdkn1α, p53 and SASP marker IL-6 which was attenuated by the PI3K inhibitor 
(Fig 5B). The downregulation of CTH expression by DL-PAG was not reversed by 
LY294002 (Fig 5B). The attenuation of DL-PAG-induced expression of P21Cip1 by the PI3K 
inhibitor correlated with an attenuation of the DL-PAG-increased number of SA-β-Gal 
positive cells (Fig 5C). Also, the DL-PAG-induced downregulation of the pro-fibrotic marker 
Acta2, but not Col1a1, was reversed by PI3K inhibitor LY294002 (Fig 5B). Finally, the PI3K 
inhibitor LY294002 improved the proliferation ability of DL-PAG treated aHSCs (Fig 5D). 
Taken together, the results demonstrate that senescence induced by CTH/H2S inhibition is 
mediated via PI3K-Akt signaling. 
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Figure 5. DL-PAG induced cellular senescence is mediated via PI3K-AKT signaling.  
A. protein expression of Akt phosphorylation at Serine 471, total Akt and senescence marker P21Cip1 at 24 
hr. β-Actin was used as loading control. COL1α1 and β-actin protein expression at 72 hr. B. mRNA 
expression of senescence markers Cdkn1α, p53, IL-6, and fibrotic marker Acta2. 36b4 was used as 
housekeeping gene. C. SA-β-Gal staining of non-treated HSCs and HSCs treated by DL-PAG with or 
without PI3K inhibitor for 48 hr (magnification 200x). D. Real-time cell proliferation was measured using the 
xCELLigence system. Results are represented as mean ± SD; *P<0.05, **P<0.005.Abbreviation: LY29., 
LY294002.
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Cellular senescence has been identified as a promising therapeutic strategy for the 
treatment of liver fibrosis due to its potential to inactivate HSCs (9, 19). Senescence can be 
induced in HSCs in response to a variety of stimuli, such as matricellular protein CCN1 and 
the cytokines IL-10 and IL-22. In addition, cell cycle arrest marker p53 double knockout 
(p53-/-) mice contain more fibrotic tissue compared to wild type mice due to impaired cellular 
senescence (9, 11). However, the specific signaling pathways in HSCs that account for the 
induction of senescence remain to be fully elucidated. Previously, we have shown that 
hydrogen sulfide (H2S) promotes stellate cell activation (16). It has also been shown that 
H2S hampers senescence in various cell types, including endothelial cells and fibroblasts via 
the induction of splicing factors like HNRNPD and posttranslational modification of Keap1 
(17, 20). In the present study, we demonstrate a causal relationship between the induction 
of senescence by inhibiting H2S production and the (partial) reversal of stellate cell 
activation: inhibition of CTH reverses activation of stellate cells and induces a senescent 
phenotype, whereas H2S donors promote stellate cell activation and (partially) reverse the 
senescent phenotype. Moreover, we demonstrate that the induction of the senescent 
phenotype in HSCs by inhibition of H2S is dependent on PI3K-Akt signaling, since an 
inhibitor of PI3K is capable to partially reverse the senescent phenotype and restore the 
fibrogenic phenotype.  
TGFβ1 plays a central role in fibrogenesis: it promotes stellate cell activation and 
increases the production of extracellular matrix (ECM) (3). We previously reported that 
expression of CTH/H2S is increased during transdifferentiation of quiescent HSCs into 
activated stellate cells (16). In addition, previous studies reported that H2S shows 
anti-fibrotic effects via pro-apoptotic, anti-oxidant and anti-inflammatory effects in HSC-T6 
cells and in rat primary HSCs (21, 22). However, in these studies a rather high concentration 
of the fast releasing NaHS donor was used, which could be toxic. In another study,the 
natural compound diallyl trisulfide (DATS) was used as a H2S donor, which could be different 
fromH2S alone (23). Furthermore, accumulating evidences support the notion that H2S slow 
releasing donors better reflect endogenous H2S levels within biological systems over a 
longer time course (24). 
In the present study we demonstrate that TGFβ1 time-dependently stimulated the 
protein and mRNA expression of CTH. In contrast, TGFβ1 did not change CBS and MPST 
expression. We did not observe increased production of H2S in response to TGFβ1 
treatment, probably because endogenous H2S production was already at a high level in the 
culture-activated HSCs or the lack of sensitivity of our method. Our observation of increased 
expression of CTH upon stimulation with TGFβ1 is in line with several reports on the effect 
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of growth factors (PDGF) on fibrogenic markers and proliferation in fibroblasts during skin 
wound healing and overexpression of CTH in proliferating cancer cells (25-27). These 
results suggest that CTH has the potency to regulate cell proliferation and activation via 
endogenous H2S production in fibroblasts and cancer cells as well as in HSCs.  
PI3K-dependent signaling has been demonstrated to be an essential regulator of 
cellular senescence (6). Activation of the PI3K-Akt axis permits the induction of P21Cip1 
dependent senescence (8, 18, 28). As downstream target and substrate of Akt, 
Ser9-phosphorylated GSK3β stabilizes P21Cip1 and Ser9 phosphorylation of GSKβ is 
positively correlated with the proportion of senescent cells (29, 30). The PI3K inhibitor 
LY294002 inhibits Akt kinase activity, phosphorylation of GSK3β and restores the 
proliferation ability of oncogene Ras-induced senescent fibroblasts (8, 30). In our present 
study, a similar effect of LY294002 was observed in DL-PAG-treated senescent HSCs. 
LY294002 downregulated the cell cycle arrest marker Cdkn1a, the number of SA-β-Gal 
positive cells and SASP in DL-PAG treated HSCs. Furthermore, LY294002 reversed the 
downregulation of the fibrogenic marker Acta2 in DL-PAG-treated HSCs. These results 
demonstrate that the inactivation of HSCs results from the induction of HSC senescence. 
Nevertheless, neither the senescent phenotype and proliferation arrest induced by DL-PAG 
nor the downregulation of CTH was completely rescued by the PI3K inhibitor. This suggests 
that the PI3K-Akt signaling pathway accounts for part of the senescent phenotype. In 
addition to PI3K-Akt signaling, mitochondrial dysfunction may be a driving factor in the 
induction of cellular senescence (31). This is in line with our previous observation that H2S 
improves mitochondrial function and hence, the lack of the H2S may contribute to 
mitochondrial dysfunction and senescence (17).  
To date, several studies have reported that H2S shows anti-senescence and anti-aging 
effects via splicing factors HNRNPD, SRSF2 and upregulation of SIRT1 in endothelial cells 
(17, 32, 33). In addition, Yang et al., reported that CTH knockout mice display increased 
senescence, whereas exogenous H2S posttranslationally S-sulfhydrates the transcription 
factor Keap1 to stimulate anti-oxidant systems and reverse senescence in fibroblasts (20). 
In line with these reports, the DL-PAG-increased senescence markers P21cip1, β-gal staining 
and decreased HSCs proliferation were dose-dependently and partially reversed by the H2S 
slow releasing donor GYY4137. Since the senescent phenotype is the integrative effect of 
both senescent and non-senescent cells, the modulation of single signaling pathways may 
affect both cell populations and lead to a partially reversed phenotype. The restoration of 
DNA synthesis by DL-PAG can be attributed to H2S, a phenomenon we reported before (16). 
These results demonstrate that H2S has a central role in HSCs senescence and inhibition of 
H2S signaling shows anti-fibrotic effects via induction of senescence.  
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In summary, our results suggest that CTH and endogenous H2S generation are 
increased during fibrogenesis. Inhibition of CTH shows anti-fibrotic effects through 
increased cellular senescence and this cellular senescence is regulated through PI3K-Akt 
pathways.   
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 Intestinal fibrosis is a common complication of inflammatory bowel disease. So far, 
there is no safe and effective drug for intestinal fibrosis. Pirfenidone is an anti-fibrotic 
compound available for the treatment of idiopathic pulmonary fibrosis. Here, we explored 
the anti-proliferative and anti-fibrotic properties of pirfenidone on primary human intestinal 
fibroblasts (p-hIFs). p-hIFs were cultured in the absence and presence of pirfenidone. Cell 
proliferation was measured by a real-time cell analyzer (xCELLigence) and BrdU 
incorporation. Cell motility was monitored by live cell imaging. Cytotoxicity and cell viability 
were analyzed by Sytox green, Caspase-3 and Water Soluble Tetrazolium Salt-1 (WST-1) 
assays. Gene expression of fibrosis markers was determined by quantitative reverse 
transcription PCR (RT-qPCR). The mammalian target of rapamycin (mTOR) signaling was 
analyzed by Western blotting and type I collagen protein expression additionally by 
immunofluorescence microscopy. Pirfenidone dose-dependently inhibited p-hIF proliferation 
and motility, without inducing cell death. Pirfenidone suppressed mRNA levels of genes that 
contribute to extracellular matrix production, as well as basal and TGF-β1-induced collagen I 
protein production, which was associated with inhibition of the rapamycin-sensitive 
mTOR/p70S6K pathway in p-hIFs. Thus, pirfenidone inhibits the proliferation of intestinal 
fibroblasts and suppresses collagen I production through the TGF-β1/mTOR/p70S6K 
signaling pathway, which might be a novel and safe anti-fibrotic strategy to treat intestinal 
fibrosis. 
Keywords: intestinal fibrosis; pirfenidone; mTOR; TGF-β1; collagen; fibroblast; 
inflammatory bowel disease  
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Inflammatory bowel diseases (IBD), e.g., Crohn’s Disease and ulcerative colitis, are 
complex diseases, characterized by chronic and recurrent inflammation in the intestine (1). 
Typically diagnosed in early adulthood, patients require life-long disease management 
without a curative therapy available at this moment. The prevalence of IBD has increased 
significantly in the past decades and is expected to increase even further, especially in 
countries adopting a Western lifestyle (2). Intestinal fibrosis is a severe and common 
complication of IBD and is increasingly recognized as a therapeutic problem (3). Chronic 
inflammation leads to damage to the intestinal tissue. In response, intestinal myofibroblasts 
become activated and secrete extracellular matrix (ECM) such as collagen and fibronectins 
under the regulation of TGF-β1 and several other pro-fibrotic and anti-fibrotic factors. 
Intestinal fibrosis develops when the ECM production exceeds the co-induced ECM 
degradation and may lead to organ stenosis and malfunction (3,4). Despite the introduction 
of novel therapeutics for IBD in the past two decades, the incidence of fibrosis-induced 
intestinal strictures has not significantly changed in these patients (5). Up to 30–60% of 
Crohn’s disease patients experience intestinal stenosis and bowel obstruction. Short 
strictures can be dilated by endoscopic balloon dilatation, but approximately 75% of subjects 
need redilatation and 30–40% require surgical resection (5–8). While this improves quality 
of life directly after surgery, stenotic bowel obstruction is bound to recur in approximately 50% 
of the patients within 20 years (9). Thus, there is an urgent need to elucidate the 
pathophysiological mechanisms of intestinal fibrosis at the cellular and molecular level in 
order to develop safe and effective drugs to prevent and treat intestinal fibrosis. TGF-β1 has 
been identified as an important factor during fibrogenesis as it promotes ECM protein 
synthesis and inhibits ECM degradation (10). Also, TGF-β1 is known to activate mTORC1 
signaling pathway, which is a central regulator of cell metabolism, proliferation, and protein 
synthesis (11,12). Important downstream execution proteins are 4E-BP1, a translation 
repressor protein, and p70S6K that targets the S6 ribosomal protein (13,14). 
Pirfenidone is a pyridone compound with anti-fibrotic properties in idiopathic pulmonary 
fibrosis (IPF), liver cirrhosis, and cardiac fibrosis (15–17). Moreover, pirfenidone significantly 
suppressed TGF-β1-induced ECM synthesis in a mouse model with renal fibrosis (18). In a 
phase III randomized, double-blind, placebo-controlled, and multinational clinical trial 
(ASCEND), pirfenidone significantly improved progression-free survival and reduced the 
number of IPF patients who had a decline in forced vital capacity (17). 
In this study, we investigated the effect of pirfenidone on primary human intestinal 
fibroblasts (p-hIFs), including its effect on TGF-β1-mediated mTOR-p70S6K1 signaling. 
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Materials and Methods 
Primary human Intestinal Fibroblast (p-hIFs) Isolation and Culture 
The procurement of a part of the colon for research was approved by the National 
Discussion of the Procurement Teams (Landelijk OveRleg Uitname Teams) from the Dutch 
Transplantation Association (Nederlandse Transplantatie Vereniging) and performed after 
written informed consent from the relatives. All the procedures were performed according to 
Helsinki Declaration. Primary human colon fibroblasts were isolated and cultured as 
previously described (19). Fresh transplantation surgical specimens from morphological 
normal ascending colon tissue were obtained from the donor. Colon tissue was cut into 
small pieces and placed in T25 cell culture flasks with culture medium: Dulbecco’s Modified 
Eagle Medium containing 20% heat-inactivated fetal calf serum, 1X MEM Non-Essential 
Amino Acid, 100 µg/mL gentamycin, 200 u/mL of penicillin, 200 µg/mL of streptomycin, and 
2.5 µg/mL of Amphotericin B (all Gibco™ by Life technologies, Bleiswijk, The Netherlands) 
in a humidified incubator at 37 °C and 5% CO2. After p-hIFs grew from the tissue, the tissue 
was removed from the flask. The confluency of the p-hIFs reached up to 70–80% after 
approximately 3–4 weeks. All experiments were performed with at least 3 independent p-hIF 
isolates. 
Proliferation Assays 
Real-Time Cell Analysis (RCTA) 
Experiments of p-hIF proliferation were performed using the xCELLigence Real-Time 
Cell Analysis (RTCA, xCELLigence RTCA DP, ACEA Biosciences Inc., San Diego, CA, USA) 
as previous described (20). p-hIFs were seeded in an E-16 plate with a density of 2500 
cells/well in 200 µL culture volume. E-16 plates carry sensor microelectrodes to measure 
electronic impedance that represents the cell confluency. The impedance of electron flow 
caused by adherent cells is reported using a unitless parameter called Cell Index (CI), 
where CI = (impedance at time point n – impedance in the absence of cells)/nominal 
impedance value. The impedance was recorded at 15 min intervals to continuously monitor 
the proliferation of p-hIFs. p-hIFs were refreshed with new medium and treated with different 
concentrations of pirfenidone after 18 h. Results were analyzed by RTCA Software (Version 
1.2, ACEA Biosciences Inc.). 
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BrdU Assay  
The BrdU assay was performed according to the standard protocol of the manufacturer 
(Roche, Mannheim, Germany). p-hIFs were seeded in a 96-well plate overnight and were 
treated with pirfenidone (0, 0.5, 1, 2 mg/mL) for 72 h. BrdU (10 μmol/L) was added and 
incubated in the final 24 h. After fixation, p-hIFs were incubated with 100 µL/well 
anti-BrdU-POD working solution for 90 min at room temperature. After 15 min of incubation 
with the substrate solution, the proliferation measurement was conducted using the BrdU 
incorporation ELISA kit (all from Roche, Mannheim, Germany). 
p-hIFs Cell Counting 
p-hIFs were seeded in 6-well plates with a density of 8 × 105 cells/well. After exposure 
to various concentrations of pirfenidone for 72 h, wells were washed with PBS and p-hIFs 
were dissociated using trypsin. Then p-hIFs were centrifuged and resuspended in a small 
volume of culture medium. Numbers of p-hIFs were quantified using a TC20 cell counter 
(Bio-Rad Laboratories, Inc., Hercules, CA, USA). 
Real-Time Imaging of Cell Motility 
p-hIFs were seeded in a 8-well chamber plate (Lab-Tek II, 155409, Thermo Scientific, 
Waltham, MA, USA) in 250 µL medium at a density of 1000 cells/well and cultured overnight, 
after which they were exposed to 0, 1, and 2 mg/mL pirfenidone for 24 h. Next, the plate 
containing the p-hIFs was transferred to a live cell imaging platform in a DeltaVision 
microscope (GE Healthcare Bio-sciences, Marlborough, MA, USA) and p-hIF motility was 
monitored for 15 h. Images were taken every 5 min using a 40 × oil objective with DIC 
channels and cell motility was analyzed with Imaris software (Version 8.0, Oxford 
Instruments, Zurich, Switzerland; https://imaris.oxinst.com/downloads). 
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Cytotoxicity and Cell Viability Assays 
Sytox Green Assay 
p-hIFs were seeded in the 96-well plate with a density of 2500 cells/well. p-hIFs were 
exposed to pirfenidone for 72 h. p-hIFs exposed to H2O2 (5 mmol/L) were included as 
positive (necrotic) control group (21). Sytox Green (10 µM; Life Technologies) nucleic acid 
stain was added to tested wells for 15 min, followed by fluorescence microscopy using a 
Leica DMI6000 microscope (Leica Microsystems GmbH, Wetzlar, Germany). 
Caspase-3 Assay 
Caspase-3 activity (as marker for apoptosis) was quantified as described earlier (22). 
After 72 h of treatment with pirfenidone, p-hIFs were scraped and cell lysates were obtained 
after three times of freezing (−80 °C) and thawing (37 °C) followed by centrifugation for 5 
min at 12,000× g. 20 µg protein per sample was used to quantify caspase-3 activity. 
WST-1 Assay 
The p-hIF cell viability assay was quantified using the Cell Proliferation Reagent Water 
Soluble Tetrazolium Salt-1 (WST-1, 11644807001 Roche) according to the manufacturer’s 
protocol. p-hIFs were seeded in a 12-well plate with a density of 4 × 104 cells/well and were 
exposed to pirfenidone for 72 h. Thus, 10 µL of WST-1 solution per 100 µL medium was 
added to the growing p-hIFs and was next incubated at 37 °C for 90 min after which the 
WST-1-containing medium was transferred to a new 96-well plate for analysis. 
Quantitative Real–Time PCR (RT-qPCR) 
p-hIFs were seeded in 6-well plates with a density of 8 × 105 cells/well and were 
exposed to pirfenidone with or without TGF-β1 for 72 h. Total mRNA was extracted from 
scraped p-hIFs using TRIzol reagent (Sigma-Aldrich, Zwijndrecht, The Netherlands). RNA 
concentrations were determined with a NanoDrop 1000 spectrophotometer (Thermo Fisher 
Scientific, Wilmington, DE, USA). RT-qPCR was performed using 7900HT fast Real-Time 
PCR system (Applied Biosystems, Bleiswijk, The Netherlands) as previously described (23). 
The TaqMan primers and probes and SYBR green primers used are shown in 
Supplementary Table S1 and S2. 18S was used to normalize the mRNA level. 
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Immunofluorescence Microscopy (IF) 
p-hIFs were seeded in 12-well plates (4 × 105 cells/well) containing coverslips. After 72 
h of different treatments, coverslips were rinsed with PBS, fixed with 4% paraformaldehyde 
for 10 min, and permeabilized with 0.1% Triton X-100 for 10 min at room temperature. 
Non-specific antibody binding was blocked with 3% bovine serum albumin/PBS solution for 
30 min. Then, coverslips were incubated with primary collagen I antibody (1:1000, 1310-01, 
Southern Biotech, Birmingham, UK) for 1 h at 37 °C. Afterward, coverslips were rinsed with 
PBS three times and incubated with Alexa-Fluor488-conjugated rabbit anti-goat secondary 
antibodies (1:400 A11008; Molecular Probes, Leiden, The Netherlands) for 30 min. Nuclei 
were stained with Mounting Medium with 4’,6-diamidino-2-phenylindole (DAPI H-1200 
Vector Laboratories, Peterborough, UK). Images were taken using a Leica DMI6000 
fluorescence microscope (Leica Microsystems GmbH). 
Western Blotting 
p-hIFs were lysed with cell lysis buffer containing 25 mM HEPES, 150 mM KAc, 2 mM 
EDTA, and 0.1% NP-40 (all from Sigma-Aldrich) supplemented with protease inhibitors on 
ice. Protein concentrations were quantified using the Bio-Rad protein assay (Bio-Rad). 
Equal quantities of protein were separated by 5–12% gradient sodium dodecyl sulfate 
polyacrylamide gel electrophoresis. Proteins were transferred to membranes with the 
Trans-Blot Turbo transfer system (Bio-Rad). After 1 h of blocking using 2% bovine serum 
albumin/PBS-Tween, membranes were incubated with the primary antibody (antibodies 
catalog numbers and dilutions supplied in Supplementary Table S3) at 4 °C overnight. Then 
membranes were washed with three times of PBS-Tween and incubated with 
horseradish-peroxidase conjugated secondary antibody for 1 h. Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) was used as the reference protein. The signals were 
detected by chemidoc XRS system and Image Lab version 3.0 (Bio-Rad). 
Statistical Analysis 
Statistical analyses were performed with Graphpad Prism 7 (Graphpad Software, San 
Diego, CA, USA). All data presented as mean ± SEM. Statistical differences between two 
groups were analyzed by using unpaired t-test. If more than two groups were evaluated, the 
groups were analyzed by using one-way ANOVA with Dunnett or Turkey test. A p-value < 
0.05 was considered as statistically significant. 
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Pirfenidone Suppresses the Proliferation of p-hIFs, Which is Reversible 
Primary hIFs (p-hIFs) were cultured in a real-time cell analysis (RTCA, xCELLigence) to 
analyze the effect of pirfenidone on cell proliferation. The p-hIFs were allowed to attach to 
the culture plate for 18 h, represented by stabilization of the Cell Index (CI). Next, the p-hIFs 
were treated with increasing concentrations of pirfenidone (0, 0.5, 1, and 2 mg/mL) for 72 h, 
which revealed that pirfenidone dose-dependently reduced the increase in CI (green, purple 
and blue lines) when compared to untreated control p-hIFs (red line in Figure 1A). In line, 
pirfenidone dose-dependently reduced BrdU incorporation (Figure 1B; all **** p < 0.0001 
when compared to untreated control p-hIFs) and cell numbers (-34%, -72%, and -97% at 0.5, 
1.0, and 2.0 mg/mL, respectively; Figure 1C, all **** p < 0.0001). Video-assisted imaging of 
p-hIFs revealed that pirfenidone also suppressed the motility of individual p-hIF, albeit only 
significantly at the highest concentration of 2 mg/mL (Figure 1E,F). Pirfenidone treatment 
did not evidently affect the typical spindle-shaped cell morphology of p-hIFs (Figure 1D,E). 
Moreover, pirfenidone did not induce significant levels of necrotic p-hIF cell death (Figure 
2A), nor did it induce caspase-3 activity as a measure of apoptotic cell death (Figure 2B). 
Still, 72 h pirfenidone treatment dose-dependently reduced the metabolic activity of p-hIFs, 
as quantified in WST-1 assays (Figure 2C; **** p < 0.0001 for at all tested concentrations). 
As pirfenidone did not appear cytotoxic for p-hIFs, we next analyzed whether p-hIFs 
proliferation is reversible after cessation of pirfenidone treatment. p-hIFs were pre-treated 
for 72 h with 2 mg/mL pirfenidone inhibiting cell proliferation and upon refreshing the 
medium without pirfenidone the p-hIFs regained normal proliferation rates after a lag-phase 
of approximately 48 h (Figure 2D). Notably, the cell index of pirfenidone pre-treated p-hIFs 
reached the same level after 96 h as compared to non-treated p-hIFs (see for reference 
Figure 1A). 
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 6  Figure 1. Pirfenidone suppresses the proliferation of primary human intestinal fibroblasts (p-hIFs). 
(A) Intestinal fibroblasts were seeded in the xCELLigence system for 18 h and were then exposed to 
increasing concentrations of pirfenidone (0, 0.5, 1, and 2 mg/mL) for 72 h. Cell index curves showed 
pirfenidone dose-dependently inhibited the proliferation of fibroblasts. (B) Pirfenidone dose-dependently 
decreased BrdU incorporation (n=3, **** p < 0.0001 for all groups) and (C) p-hIF cell numbers (n = 3, **** p 
< 0.0001 for all groups) after 72 h exposure. (D) Bright field images showing pirfenidone inhibited the 
proliferation of p-hIFs, while maintaining their spindle like morphology. (E) Stills of real-time cell imaging 
tracking the movement of individual p-hIFs after 0, 5, 10 and 15 h in the absence or presence of pirfenidone. 
(F) Quantification of p-hIF motility in each group shown in E. Motility was tracked every 5 min for 15 h in 
total. * p < 0.05; Data are shown in mean ± SEM. Scale bars = 100 μm. 
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Figure 2. Pirfenidone does not induce cell death and reversibly suppresses the proliferation of 
human primary intestinal fibroblasts. 
 (A) Bright field (top panels), Sytox Green nucleic staining (middle panels) and overlay images (bottom 
panels) of p-hIFs exposed for 72 h to 2 mg/mL pirfenidone or for 24 h to 5 mmol/L H2O2 (positive control for 
necrosis) showing that less than 1% of pirfenidone-exposed p-hIFs were necrotic (representative image of 
n = 3). (B) Pirfenidone did not induce caspase-3 activity compared to anti-Fas-exposed (1 ug/mL for 9 h) 
p-hIFs (positive control for apoptotic cell death) (n = 3). (C) Water Soluble Tetrazolium Salt-1 (WST-1) assay 
showed pirfenidone dose-dependently suppressed the total metabolic activity of p-hIFs as proxy for total 
cell number (**** p < 0.0001, n = 3). (D) Pirfenidone (2 mg/mL for 72 h)-induced inhibition of p-hIF 
proliferation was reversible even refreshing the cells with pirfenidone-free medium, as analyzed in real-time 
in the xCELLigence. Scale bars = 50 μm. 
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Pirfenidone Suppresses Extracellular Matrix Protein (ECM) Expression in 
p-hIFs 
In order to determine whether pirfenidone also affects ECM production, p-hIFs were 
exposed to pirfenidone for 72 h and mRNA levels of genes encoding ECM proteins, as well 
as collagen I protein production were analyzed by RT-qPCR, IF, and Western blot analysis 
(Figure 3). Pirfenidone dose-dependently reduced COL1A1, COL3A1, COL4A1, COL6A1, 
FN1 (encoding fibronectin 1) and ELN (encoding elastin) mRNA levels, while it did not affect 
ACTA2 (encoding alpha-smooth muscle actin; α-SMA) expression (Figure 3A–G). Untreated 
p-hIFs contained high levels of (intracellular) collagen I, which was dose-dependently 
reduced by pirfenidone and was virtually absent after 72 h exposure with 2 mg/mL 
pirfenidone (Figure 3H), also when analyzed by Western blotting (Figure 3I,J). When 72 
h-pirfenidone treated p-hIFs were exposed to normal medium again, collagen I protein 
reappeared (Figure 3K), but even after 96 h collagen I protein levels were still clearly lower 
compared to p-hIFs that were not pretreated with pirfenidone (Figure 3I,L). 
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Figure 3. Pirfenidone inhibits Extracellular Matrix Protein (ECM) production. (A–G)  
Intestinal fibroblasts were treated with increasing (maximum 2 mg/mL) concentrations of pirfenidone for 72 
h. Pirfenidone suppressed COL1A1, COL3A1, COL4A1, COL6A1, FN1, and ELN mRNA levels, but not 
ACTA2 levels (* p < .05, n = 3). (H) Immunofluorescent images showing that pirfenidone dose-dependently 
suppressed intracellular levels of collagen I. (I) p-hIFs were exposed for 72 h to pirfenidone (Lanes 1–4) 
and subsequently cultured in pirfenidone-free medium for 96 h (Lanes 5–8). (J–L) Western blot analysis 
showed that pirfenidone concentration-dependently and reversibility suppressed collagen I protein levels in 
p-hIFs. The relative abundance of the tested proteins was normalized to that of Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). ** p < 0.01, *** p < 0.001, **** p < 0.0001; Data are presented as mean ± SEM. 
Scale bars = 50 μm. Refresh+, refresh medium. 
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Pirfenidone Reduces TGF-β1-Induced COL1A1 mRNA Expression and 
Collagen I Synthesis 
Exposure of p-hIFs to TGF-β1 (2.5 ng/mL for 72 h) strongly increased COL1A1 mRNA 
levels (>4-fold; Figure 4A), which was accompanied by increased collagen I protein levels 
(Figure 4B–D). Co-treatment with pirfenidone completely blocked the TGF-β1-induced 
expression of collagen 1, both at mRNA (pirfenidone at 1 and 2 mg/mL) and protein level 
(pirfenidone at 1 mg/mL) (Figure 4A–C). IF revealed that TGF-β1 induced collagen I protein 
accumulation in intestinal fibroblasts. Collagen I remained detectable in TGF-β1 + 
pirfenidone cotreated p-hIFs but it appeared to accumulate perinuclear, in comparison to 















Figure 4. Pirfenidone suppresses basal and TGF-β1-induced collagen I expression in p-hIFs.  
(A) TGF-β1 (2.5 ng/mL) induces COL1A1 mRNA levels. Pirfenidone dose-dependently suppresses 
TGF-β1-induced COL1A1 mRNA levels (* p < 0.05, n = 3) which was accompanied with a reduction in 
collagen I protein expression levels (B–C). (* p < 0.05, n = 3; GAPDH is included as protein loading control) 
(D) Immunofluorescence microscopy revealed that TGF-β1 enhanced the cellular surface area positive for 
collagen I, which was reduced again by pirfenidone leading to a perinuclear location of collagen I. ** p < 
0.01, *** p < 0.001; Data are presented as mean ± SEM. Scale bars = 50 μm. 
Pirfenidone Inhibits TGF-β1-Mediated Phosphorylation of 
TGF-β1/mTOR/p70S6K Signaling Pathway in p-hIFs 
In order to delineate the molecular signaling pathways that underlie the 
anti-proliferative/anti-fibrotic effects of pirfenidone, we analyzed its effect on Smad2/3, p38 
MAPK and mTOR phosphorylation in p-hIFs in the presence and absence of TGF-β1. As 
shown in Supplementary Figure S1, both TGF-β1 and pirfenidone did not significantly affect 
phosphorylation of Smad2/3 and p38 MAPK in p-hIFs. Besides activation of the 
Smad-signaling (24–29), TGF-β1 may also signal via mTOR (30,31), the latter not being 
studied earlier in intestinal fibroblasts. Indeed, TGF-β1 enhanced mTOR phosphorylation (at 
6 h) in p-hIFs, as well as downstream signaling factor p70S6K (at 6 and 12 h) (Figure 5A). In 
contrast, TGF-β1 did not affect the levels of phosphorylated 4E-BP1 at any of the analyzed 
time points (6, 12, and 24 h TGF-β1 exposure) (Figure 5A). Pirfenidone (1 mg/mL) strongly 
suppressed both basal and TGF-β1-induced phosphorylation of mTOR and p70S6K, while it 
hardly affected 4E-BP1 phosphorylation (Figure 5B). Similar effects were observed for 
rapamycin (100 nmol/L, Figure 5B), the classical mTOR signaling pathway inhibitor. In line, 
rapamycin (100 nmol/L) also suppressed basal and TGF-β1-induced expression of collagen 
I in p-hIFs (Figure 5C). 
Taken together, our data show that pirfenidone suppressed proliferation of p-hIFs and 
collagen I production by p-hIFs. Pirfenidone inhibits TGF-β1-induced mTOR signaling that 
may aid in the inhibition of p-hIFs proliferation and collagen production. 
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Figure 5. Pirfenidone suppresses the TGF-β1/mTOR/p70S6K signaling pathway.  
(A) p-hIFs were cultured for 6, 12, and 24 h in the absence or presence of TGF-β1 (2.5 ng/mL). Levels of 
total and phosphorylated mTOR, p70S6K, and 4E-BP1 were assessed by Western blot analysis. TGF-β1 
enhanced the levels of p-mTOR (at 6 h) and p-p70S6K (at 6–12 h). (B) p-hIFs were exposed to TGF-β1 (2.5 
ng/mL), pirfenidone (1 mg/mL), rapamycin (100 nmol/L), or combinations of those compounds for 6 h and 
analyzed by Western blotting. Pirfenidone and rapamycin inhibited basal and TGF-β1-induced 
phosphorylation of mTOR and p70S6K. (C–D) Rapamycin (100 nmol/L for 72 h) inhibited basal and 
TGF-β1-induced collagen I production in p-hIFs. * p < 0.05, ** p < 0.01, *** p < 0.001, n = 3; GAPDH is 
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included as protein loading control. 
Discussion 
In this study, we show that pirfenidone dose-dependently and reversibly inhibits the 
proliferation and excessive production of ECM components, in particular collagen I. We 
show for the first time that pirfenidone suppresses basal and TGF-β1-induced mTOR 
signaling in p-hIFs, a pathway known to contribute to organ fibrosis. Thus, pirfenidone is a 
relevant drug to explore further for the treatment of intestinal fibrosis, a condition often 
associated with chronic intestinal diseases, such as IBD. 
Intestinal inflammation triggers the activation of myofibroblasts that are central players 
in tissue repair, as they migrate into damaged tissue and control production and turnover of 
the extracellular matrix in support of all the other tissue-resident cell types. However, chronic 
inflammation leads to overactivation and proliferation of myofibroblasts that produce 
excessive amounts of ECM causing fibrosis (32,33). Therefore, suppressing myofibroblast 
proliferation and/or ECM production is an important therapeutic target to control and prevent 
intestinal fibrosis. An earlier study analyzed p-hIFs from CD patients and found that 
pirfenidone inhibited cell proliferation, but did not affect collagen (I-V) production (34). The 
p-hIFs were exposed to the same concentrations of pirfenidone as we did, however, only for 
24 h. Moreover, only secreted collagen (in the medium) was quantified and no difference 
were found for untreated and pirfenidone-treated p-hIFs. Given the fact that pirfenidone did 
not affect collagen production in their study, they concluded that it may be of limited clinical 
value for treating intestinal fibrosis. We, however, found that pirfenidone dose-dependently 
suppresses COL1A1, COL3A1, ELN (all >90%) and COL4A1, COL6A1 and FN1 (>50%) 
mRNA levels, as well as collagen I protein production by p-hIFs, along with inhibiting cell 
proliferation. The key difference probably is that we treated the p-hIF for 72 h and the most 
pronounced effect of pirfenidone, also on cell proliferation, is observed only 24 h after the 
treatment started, especially at the lower concentrations of pirfenidone (Figure 1A). In 
addition, we show that TGF-β1-induced collagen I production is effectively suppressed by 
pirfenidone. Our results are largely in line with earlier observations using human intestinal 
fibroblast cell lines and rat and mouse primary intestinal fibroblasts. Pirfenidone was shown 
to suppress TGF-β1-induced COL1A1 and ACTA2 expression in a human intestinal 
myofibroblast cell lines either by activating the transient receptor potential ankyrin 1 channel 
(24), by inhibiting Smad/PI3K/AKT (27) signaling or the MAPK pathway (25). Many studies 
have analyzed the effect of pirfenidone on tissue fibrosis in organs other than the intestine, 
and multiple pathways have been implicated with most focus on Smad-related signaling 
pathways (summarized in Figure 6) (18,24–30,36,37). However, compared to the earlier 
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studies using intestinal fibroblasts, we found that a 6 h exposure to TGF-β1 (2.5 ng/mL) did 
not significantly induce phosphorylation of Smad 2/3 or p38-MAPK in p-hIFs. This may be 
because we exposed the p-hIFs to lower concentrations TGF-β1 compared to the other 
studies (5-10 ng/mL; (24–27)). TGF-β1 induces Smad2/3 phosphorylation within minutes 
(24) and elevated levels are still detectable after 24–48 h exposure (25–27). Still, the extent 
of Smad2/3 phosphorylation is time-dependent and the time-point we chose (6 h of TGF-β1 
treatment) may not have been optimal. Sun et al. also examined the effect of pirfenidone on 
“untreated” human intestinal fibroblasts and found that this did not lower Smad 2/3 
phosphorylation, which is in line with our data. Notably, phosphorylated Smad2/3 and p38 
MAPK were detectable in control-cultured p-hIFs, which may indicate a higher basal 
activation state compared to CCD-Co18 (25), InMyoFib (24) and HUM-CELL-d022 (27) 
fibroblasts. A possible effect of pirfenidone on mTOR signaling has so far not been studied 
for intestinal fibrosis. We show that 2.5 ng/mL TGF-β1 quickly enhances mTOR 
phosphorylation, followed by downstream p70S6K phosphorylation. This suggests that the 
mTOR pathway was more sensitive to the stimulation of TGF-β1 than Smad 2/3 and 
p38-MAPK pathways in p-hIFs. Rapamycin-sensitive mTOR signaling plays an important 
role in regulating cell growth, cell proliferation, protein synthesis, transcription and 
autophagy (38). p70S6K is one of the main key substrates of mTOR and promotes protein 
synthesis at the ribosome (39). Pirfenidone inhibited both basal and TGF-β1-induced mTOR 
and p70S6K phosphorylation which may suppress collagen production. Indeed, treating 
p-hIFs with rapamycin, the prototypical inhibitor on mTOR (40) also suppressed both basal 
and TGF-β1-induced collagen I production in p-hIFs. This supports the relationship between 
mTOR signaling and collagen I production in p-hIFs and suggests that pirfenidone, at least 
in part, acts via mTOR to suppress ECM production and p-hIF proliferation. 
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Figure 6. Overview of signaling pathways involved in the development of tissue fibrosis that are 
affected by pirfenidone.  
Previously reported pathways are presented in blue. The mTOR pathways studied in this work is presented 
in red. 
It is important to note that besides anti-fibrotic activity, pirfenidone has also been shown 
to act as an anti-inflammatory and an anti-oxidant agent in IPF patients (41,42). Here, we 
specifically focused on the potential anti-fibrotic action of p-hIFs, but the anti-inflammatory 
and anti-oxidant activities of pirfenidone may synergize in its therapeutic effect in patients 
with IBD. One important aspect of pirfenidone has to considered, as it has been reported to 
cause some gastrointestinal side effects in IPF patients, including nausea, vomiting, 
dyspepsia and diarrhea (43,44). Current therapies for IBD, however, are also pursuing 
intestine-specific delivery of drugs. The ColoPulse technology is such a novel approach 
which allows controlled release of drugs at the terminal ileum and colon (45). Systemic and 
gastrointestinal side effects of pirfenidone may be minimized using such approach, 
concomitant with a higher drug-efficacy of pirfenidone on intestinal inflammation and fibrosis 
(46). 
In this study, we made use of p-hIFs from healthy tissue, which were exposed to 
TGF-β1, being a “master cytokine” in the development of tissue fibrosis. It remains to be 
determined to what level this exactly resembles the phenotype of fibroblasts residing in 
stenotic intestinal tissue in vivo. In addition, future studies need to establish the 
interindividual, as well as location-specific differences between intestinal fibroblasts and 
their value as in vitro models to study intestinal fibrosis. 
In summary, we show that pirfenidone suppresses the proliferation and collagen 
production of primary intestinal fibroblasts, and it does so, at least in part, by inhibiting 
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mTOR/p70S6K signaling. This study suggests that pirfenidone might be a potential new 
therapeutic drug for the treatment of intestinal fibrosis. 
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Supplementary tables:  
Table S1. TaqMan primers and probes for Real-time Quantitative PCR analysis. 
Gene TaqMan primers and probes 
18S Forward: CGGCTACCACATCCAAGGA 
Reverse: CCAATTACAGGGCCTCGAAA 
Probe: CGCGCAAATTACCCACTCCCGA 
COL1A1 Forward: GGCCCAGAAGAACTGGTACATC 
Reverse: CCGCCATACTCGAACTGGAA 
Probes: CCCCAAGGACAAGAGGCATGTCTG 
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Table S2. SYBR green primer sequences used for Real-time Quantitative PCR Analysis. 
Gene SYBR green primers  
COL3A1 Forward: CTGGACCCCAGGGTCTTC 
Reverse: CATCTGATCCAGGGTTTCCA 
COL4A1 Forward: AGGAGAGAAGGGCGCTGT 
Reverse: TCCAGGTAAGCCGTCAACA 
COL6A1 Forward: GAAGAGAAGGCCCCGTTG 
Reverse: CGGTAGCCTTTAGGTCCGATA 
FN1 Forward: CTGGCCGAAAATACATTGTAAA 
Reverse: CCACAGTCGGGTCAGGAG 















Table S3. Antibodies catalog numbers and dilutions. 
Antibody Cat no. (dilution) Company 
GAPDH CB1001 (1:1000) Calbiochem 
Phospho-mTOR 2971 (1:1000) Cell Signaling 
mTOR 2983T (1:1000) Cell Signaling 
Phospho-p70S6K Thr389 9205 (1:1000) Cell Signaling 
p70S6K 9202S (1:1000) Cell Signaling 
Phospho-4E-BP1 Ser65 9451 (1:1000) Cell Signaling 
4E-BP1 9644T (1:1000) Cell Signaling 
Phosho-Smad2 (S465/467)/3 (S423/425) 8828 (1:1000) Cell Signaling 
Smad2/3 3120 (1:1000) Cell Signaling 
Phosho-p38 MAPK 9211 (1:1000) Cell Signaling 
p38 MAPK 9212 (1:1000) Cell Signaling 
Polyclonal Rabbit Anti-Mouse Immunoglobulins P0260 (1:2000) DAKO 
Polyclonal Rabbit Anti-Goat Immunoglobulins P0160 (1:2000) DAKO 
Polyclonal Goat Anti-Rabbit Immunoglobulins P0448 (1:2000) DAKO 
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Figure S1. Pirfenidone does not suppress Smad2/3 and p38 MAPK phosphorylation in p-hIFs. 
(A) p-hIFs were exposed to pirfenidone (1 mg/ml) and/or, TGF-β1 (2.5 ng/ml) for 6 h. Total and 
phosphorylated Smad2/3 and p38 MAPK were assessed by Western blot analysis. Compared with the 
control group, TGF-β1 or pirfenidone did not pronouncedly change levels of phosphorylated Smad2/3 or 
p38 MAPK in p-hIFs. (B) Shows the quantification of the signal intensity-ratios of P‐Smad2/3 to Smad2/3 















Supplementary References for Figure 6: 
1. Kurahara LH, Hiraishi K, Hu Y, et al. Activation of Myofibroblast TRPA1 by Steroids 
and Pirfenidone Ameliorates Fibrosis in Experimental Crohn's Disease. Cellular and molecular 
gastroenterology and hepatology. 2018;5(3):299-318. 
2. Sun Y, Zhang Y, Chi P. Pirfenidone suppresses TGFbeta1induced human intestinal 
fibroblasts activities by regulating proliferation and apoptosis via the inhibition of the Smad and 
PI3K/AKT signaling pathway. Molecular medicine reports. 2018;18(4):3907-3913. 
3. Li G, Ren J, Hu Q, et al. Oral pirfenidone protects against fibrosis by inhibiting 
fibroblast proliferation and TGF-beta signaling in a murine colitis model. Biochemical 
pharmacology. 2016;117:57-67. 
4. Sun YW, Zhang YY, Ke XJ, Wu XJ, Chen ZF, Chi P. Pirfenidone prevents 
radiation-induced intestinal fibrosis in rats by inhibiting fibroblast proliferation and 
differentiation and suppressing the TGF-beta1/Smad/CTGF signaling pathway. European journal 
of pharmacology. 2018;822:199-206. 
5. Li Z, Liu X, Wang B, et al. Pirfenidone suppresses MAPK signalling pathway to reverse 
epithelial-mesenchymal transition and renal fibrosis. Nephrology. 2017;22(8):589-597. 
6. Ji X, Naito Y, Weng H, et al. Renoprotective mechanisms of pirfenidone in 
hypertension-induced renal injury: through anti-fibrotic and anti-oxidative stress pathways. 
Biomedical research. 2013;34(6):309-319. 
7. Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C. Effect of pirfenidone 
on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of 
primary human lung fibroblasts. European journal of pharmaceutical sciences : official journal 
of the European Federation for Pharmaceutical Sciences. 2014;58:13-19. 
8. Boehme SA, Franz-Bacon K, DiTirro DN, Ly TW, Bacon KB. MAP3K19 Is a Novel 
Regulator of TGF-beta Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary 
Fibrosis. PloS one. 2016;11(5):e0154874. 
9. Kurita Y, Araya J, Minagawa S, et al. Pirfenidone inhibits myofibroblast 
differentiation and lung fibrosis development during insufficient mitophagy. Respiratory 
research. 2017;18(1):114. 
550886-L-bw-Zhang
Processed on: 10-11-2020 PDF page: 148








10. Molina-Molina M, Machahua-Huamani C, Vicens-Zygmunt V, et al. Anti-fibrotic 
effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial 


























Processed on: 10-11-2020 PDF page: 150
550886-L-bw-Zhang






















Increased arginase-1 expression during hepatic 
stellate cell activation promotes fibrogenesis 
Mengfan Zhang, Zongmei Wu, Manon Buist-Homan, Han Moshage 
 
Department of Gastroenterology and Hepatology, University Medical Center 
Groningen, University of Groningen, Groningen, the Netherlands 
 
Correspondence: Han Moshage; a.j.moshage@umcg.nl 
 
550886-L-bw-Zhang
Processed on: 10-11-2020 PDF page: 152









Background Activation of hepatic stellate cells (HSC) is one of the essential 
pathogenetic mechanisms of liver fibrosis. Unresolved excessive extracellular matrix 
deposition (ECM) characteristic of liver fibrosis can exacerbate to cirrhosis. Collagen is 
the most abundant constituent of ECM and proline is the most abundant amino acid of 
collagen. Arginine is a non-essential amino acid. It is the precursor in the biosynthetic 
pathway of proline. Arginine is the exclusive substrate of both nitric oxide synthase (NOS) 
and arginase. NOS is an M1 (pro-inflammatory) marker of macrophage polarization 
whereas arginase-1 (Arg1) is an M2 (pro-fibrogenic) marker of macrophage polarization. 
Differential expression of NOS and Arg1 has not been studied in HSCs yet. The aim of this 
study was to identify the expression profile of arginine catabolic enzymes during HSC 
activation and to investigate the possibility to inhibit HSC activation and fibrogenesis via 
targeting arginine metabolism. Methods Isolated primary rat HSCs were culture for 7 
days to achieve complete activation, and transcription and translation of iNOS and Arg1 
were investigated. The arginase inhibitor Nor-NOHA was used to investigate the effect of 
Arg1 inhibition on collagen production and cell proliferation in activated HSCs. Results l 
During HSC activation, iNOS expression decreased whereas Arg1 expression increased. 
Inhibition of Arg1 in activated HSCs efficiently inhibited collagen production while cell 
proliferation remained unchanged. Conclusion: HSC activation is accompanied by a 
switch of arginine catabolism from iNOS to Arg1. Inhibition of Arg1 decreases collagen 
synthesis. Arg1 can be a therapeutic target for the inhibition of liver fibrogenesis. 
Key words:Arginine, proline, iNOS, Arg1, Hepatic stellate cell, Fibrosis 
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Liver fibrosis is the result of an uncontrolled wound healing response in chronic liver 
diseases of various etiology. Liver fibrosis is characterized by the accumulation of 
excessive amounts of extracellular matrix (ECM) in the liver (1). Although liver fibrosis is 
still reversible, advanced liver fibrosis has a high probability to progress to cirrhosis and 
even hepatocellular carcinoma (2). In these terminal stages, scar tissue formed by 
unresolved ECM deposition segments hepatic lobules, causing architectural changes that 
eventually cause hepatic failure with severe complications (1). In view of the poor 
prognosis of cirrhosis, therapy is aimed at the stages preceding cirrhosis including 
(reversible) fibrosis. However, no medication to treat liver fibrosis is currently approved for 
clinical application.  
Fibrogenesis is the key pathogenetic mechanism of liver fibrosis and is attributed to 
excessive production of ECM by myofibroblasts. In chronic liver diseases of various 
etiology, hepatic stellate cells are the major source of myofibroblasts (3). The hepatic 
stellate cell is the most abundant non-parenchymal cell type in the liver. In the healthy liver, 
hepatic stellate cells (HSC) maintain a quiescent state and store retinoids. Upon 
continuous liver injury, the quiescent hepatic stellate cells (qHSC) transdifferentiates into 
the activated hepatic stellate cell (aHSC) and acquire the ability to proliferate, migrate and 
contract. Furthermore, they secrete large amounts of various ECM components to 
contribute to wound repair (4, 5). In the pathological condition, ECM secretion by aHSC is 
uncontrolled and ECM accumulates in the perisinusoidal space (6). The grade of liver 
fibrosis correlates with the long term prognosis of patients (7). Preclinical evidence 
suggests that reversal of the activated state of aHSCs to reduce the deposition of ECM is 
a promising strategy to slow down or even reverse liver fibrosis (4). Collagen is one of the 
major components of ECM (8). Collagen contains a relatively high proportion of the amino 
acids arginine, proline and glycine and the availability of these amino acids is the limiting 
factor in the synthesis of collagen (9). This phenomenon permits to target amino acid 
metabolism to reduce fibrogenesis. 
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The metabolism of the non-essential amino acid arginine is closely related to the 
metabolism of proline. L-arginine is the exclusive substrate of the enzymes nitric oxide 
synthase (NOS) and arginase (9).NOS has three isoforms: neuronal NOS (nNOS), 
inducible NOS (iNOS) and endothelial NOS (eNOS) which are encoded by NOS1, NOS2 
and NOS3, respectively. Arginase has two isoforms: Arg1 and Arg2. Arg1 is predominantly 
expressed in the cytoplasm of liver cells, whereas Arg2 is localized in mitochondria of 
kidney cells(10). NOS converts arginine into nitric oxide (NO) and citrulline. NO is an 
important gasotransmitter and activates soluble guanylate cyclase (sGC). Some studies 
suggest that activation of sGC attenuates fibrosis (11). In addition, NO can serve as a 
reductant to scavenge ROS and to inhibit the proliferation of aHSCs (12). Arginase 
catalyzes the reaction arginine + H2O → ornithine + urea. Ornithine can be converted by 
ornithine aminotransferase (OAT) into proline and by ornithine decarboxylase (ODC) into 
polyamines. Proline is essential for collagen synthesis. Polyamines are necessary for 
progression through the cell cycle and proliferation (10). It has been demonstrated that 
arginine promotes the synthesis of proline and collagen in vascular smooth muscle cells, a 
cell type which could be considered the myofibroblast in vascular tissue (13). Since the 
catabolism of arginine by NOS and arginase are likely to induce opposite effects in HSCs, 
the metabolic fate of arginine is hypothesized to be associated with the transdifferentiation 
of HSCs. However, there is currently little evidence to support the hypothesis that 
(increased) arginase promotes fibrosis and (increased) NOS is attenuates fibrosis. 
The differential expression of iNOS and Arg1 is associated with M1 and M2 
polarization in macrophages, respectively (10). It has not been elucidated whether 
activation of HSCs is associated with a similar metabolic shift of arginine catabolism. Our 
hypothesis in this study is that the activation of HSC is accompanied by a metabolic shift 
in arginine catabolism. Primary rat HSCs are an established in vitro model to study the 
activation of hepatic stellate cells and were used in this study to test the hypothesis.  
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Materials and methods 
Hepatic stellate cell isolation and culture 
Primary rat hepatic stellate cells were isolated as previously described (14). Following 
isolation, HSCs were cultured in Iscove’s Modified Dulbecco’s Medium supplemented with 
Glutamax (Thermo Fisher Scientific, Waltham, MA, USA), 20% heat inactivated fetal calf 
serum (Thermo Fisher Scientific), 1% MEM Non Essential Amino Acids (Thermo Fisher 
Scientific), 1% Sodium Pyruvate (Thermo Fisher Scientific) and antibiotics: 50 µg/mL 
gentamycin (Thermo Fisher Scientific), 100 U/mL Penicillin (Lonza, Verviers, Belgium), 10 
µg/mL streptomycin (Lonza) and 250 ng/mL Fungizone (Lonza) in an incubator containing 
5% CO2 at 37°C. HSCs were culture-activated for seven days on tissue culture plastic. 
Quantitative Real-Time Polymerase Chain Reaction 
Total RNA was isolated by Tri-reagent (Sigma Aldrich) according to manufacturer’s 
protocol and then used for preparation of cDNA. cDNA was diluted in RNAse-free water 
and used for real-time polymerase chain reaction on the QuantStudioTM 3 system 
(Thermo Fisher Scientific). All samples were analyzed in duplicate using 36b4 as 
housekeeping gene. The genes were quantified by TaqMan probes and primers. Relative 
gene expression was calculated via the 2-𝚫𝚫Ct or 2-ΔCt method. The primers and probes are 




















Acta GCCAGTCGCCATCAGGAAC CACACCAGAGCTGTGC CTTCACACATAGCTGGAGCA
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Cell proliferation assays 
Cell proliferation was determined by BrdU incorporation assay (Roche Diagnostic 
Almere, the Netherlands) and Real-Time xCelligence assay (RTCA DP; ACEA 
Biosciences, Inc., CA, USA). Cells were seeded in 96-well plates and treated as described. 
Incorporation of BrdU was detected by chemiluminescence using Synergy-4 (Bio-Tek).  
Western blot analysis 
Cells were seeded and treated as described. Protein lysates were prepared by 
scraping in cell lysis buffer (HEPES 25 mmol/L, KAc 150 mmol/L, EDTA pH 8.0 2 mmol/L, 
NP-40 0.1%, NaF 10 mmol/L, PMSF 50 mmol/L, aprotinin 1 µg/µL, pepstatin 1 µg/µL, 
leupeptin 1 µg/µL, DTT 1 mmol/L). 10-20 µg protein was loaded on SDS-PAGE gels and 
transferred to nitrocellulose transfer membranes using Trans-Blot Turbo Blotting System 
for tank blotting. Proteins were detected using the primary antibodies listed in table 2. 
Protein band intensities were determined and detected using the Chemidoc MR (Bio-Rad) 
system.  
Table2. 
Protein Species Dilution Company 
β-Actin Polyclonal rabbit 1:1000 4970, Cell Signaling 
Collagen type 1 Polyclonal goat 1:2000 1310-01, Southern Biotech 
αSMA Monoclonal mouse 1:5000 A5228, Sigma Aldrich 
iNOS Monoclonal mouse 1:2000 610432, BD Bioscience 
Arg1 Monoclonal rabbit 1:2000 ab233548, Abcam 
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Data are presented as mean ± standard deviation (mean ± SD) or mean ± standard 
error of mean (mean ± sem) of at least three independent experiments. Statistical 
significance was analyzed by Mann-Whitney test between the two groups. P<0.05 was 
considered statistically significant. Analysis was performed using GraphPad Prism 7 
(GraphPad Software, San Diego, CA, USA).  
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Differential transcription of inducible nitric oxide synthase (iNOS) and 
arginase-1 (Arg1) during activation of hepatic stellate cells 
 
Figure 1. mRNA expression of iNOS, Arg1 and Acta2 during activation of primary rat HSCs.  
Panel A: mRNA expression of Arg1. Panel B: mRNA expression of iNOS. Panel C: Ratio of mRNA 
expression of Arg1 to iNOS. Panel D: mRNA expression of Acta2. Data are shown as mean ± sem. n = 3, 
*p < 0.05. 
mRNA level of Arg1 was increased up to 5 fold in aHSCs compared to qHSCs (Figure 
1A). In contrast, mRNA level of iNOS was strongly diminished in activated HSCs (Fig. 1B) 
B. To illustrate the differential expression of Arg1 and iNOS, the ratio of Arg1 to iNOS was 
calculated. The ratio of Arg1 to iNOS was sharply increased during activation. These 
results demonstrate that arginine catabolizing enzymes exhibit differential transcription 
profiles in qHSCs and aHSCs. Activation of stellate cells at day 7 was confirmed by 
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measuring mRNA level of Acta2, an established marker of HSC activation (Fig. 1D).  
Protein expression of arginine catabolizing enzymes 
 
Figure 2. Panel A: Protein levels of the arginine catabolizing enzymes iNOS and Arginase 1 (Arg1) 
and the stellate cell activation makers α-smooth muscle actin (αSMA) and collagen  
type 1. β-actin was used as loading control. n=3. Panel B: Protein expression of collagen type 1 and Arg1 
in activated hepatic stellate cells treated with or without 5 ng/ml TGF-β. Panel C: Relative protein 
expression of iNOS, Arg1 and aSMA. Intensity of protein signals from repeated Western blotting was 
quantified and analyzed. Data are shown as mean ± sem, n =3. 
In line with the mRNA levels, the protein level of iNOS was increased at day1 but 
strongly reduced at day 7 (Fig. 2A, C). Protein expression of Arg1 was increased at day 3 
and appeared to be even more increased at day 7 (Fig. 2A, C). As expected, the protein 
levels of the activation markers collagen type 1 and αSMA were strongly induced in 
activated HSCs. In addition, in aHSCs (D7) treated with the pro-fibrogenic cytokine TGF-β 
demonstrated increased expression of Arg1 (Fig. 2B). 
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Inhibition of Arginase 1 reduces collagen production in activated hepatic 
stellate cells without affecting proliferation 
 
Figure 3. Effect of the Arg1 inhibitor Nor-NOHA on aHSCs.  
Panel A: Western blot for collagen type 1 and αSMA in aHSCs treated with Nor-NOHA for 72h. Panel B. 
BrdU incorporation into aHSCs treated with Nor-NOHA for 72h. n=2. 
Nor-NOHA is a reversible and specific inhibitor of arginase. Nor-NOHA was used to 
demonstrate the necessity of Arg1 for collagen production and proliferation of aHSCs. 
Nor-NOHA at 50 μmol/L significantly inhibited collagen type 1 protein level, but had no 
effect on αSMA protein expression (Fig. 3A). BrdU proliferation assay was performed to 
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verify the effect of Nor-NOHA on aHSCs. As shown in Fig. 3B Nor-NOHA at 2 μmol/L to 50 
μmol/L did not affect HSC proliferation. These data demonstrate that arginase specifically 
affects collagen protein synthesis in HSCs.  
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Arginase inhibition reduces arginine-stimulated proliferation of hepatic 
stellate cells 
Figure 4. Cell proliferation of hepatic stellate cells treated with arginine and/or Nor-NOHA. 
Panel A: Cell index of HSCs treated with different concentrations of arginine. Arginine (Arg) was added 
24h after cell seeding. Panel B: HSCs cultured in arginine-deficient medium for 20h followed by culture in 
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low serum (1% FCS) medium with different concentrations of arginine. Panel C: Cell index of HSCs 
treated with arginine and/or Nor-NOHA. The concentrations of arginine and Nor-NOHA were 1 mmol/L 
and 100 μmol/L, respectively. 
Polyamine synthesis is dependent on arginase catalyzing the conversion of arginine 
into ornithine. Therefore, addition of exogenous arginine may increase the synthesis of 
polyamines and promote cell proliferation. To verify this hypothesis, cell proliferation was 
analyzed in real-time in HSCs treated with 0.2-5 mmol/L L-arginine (Fig. 4A). Only 1 
mmol/L arginine increased proliferation of HSCs. Since serum-containing culture medium 
contains significant amounts of arginine, we performed experiments using arginine 
starvationfollowed by low-serum containing culture medium (Fig. 4B). After arginine 
starvation, aHSCs appeared to be more sensitive to exogenous arginine with 0.5 mmol/L 
exogenous arginine maximally increased proliferation. Next, we investigated the effect of 
the arginase inhibitor nor-NOHA on the proliferation of HSCs (Fig. 4C). HSCs were treated 
with 1 mmol/L arginine with or without 100 μmol/L Nor-NOHA and the cell proliferation 
was analyzed. The arginase inhibitor only decreased proliferation of HSCs treated with 
arginine. The results indicate that exogenous arginine promotes cell proliferation of HSCs 
in an arginase-dependent manner. 
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Activation of HSCs is a key pathogenetic mechanism in liver fibrosis. It has been 
demonstrated that clearance and/or inactivation of aHSCs is a therapeutic mechanism to 
alleviate or resolve liver fibrosis(4, 15). The activation of HSCs is driven by endogenous 
and exogenous factors. Extracellular mitogens, including TGF-β, PDGF, and FGF,activate 
qHSCs(4, 16). Upon activation, HSCs acquire the ability to secrete pro-fibrogenic 
mitogens and cytokines, causing a positive feedback loop in fibrogenesis (17). 
Endogenous factors that affect HSC activation include dysregulated intracellular 
processes like mitochondrial function, signal transduction pathways, autophagy etc. 
(18-20). Spontaneous activation of isolated primary HSCs on tissue culture plastic is well 
known model for HSC activation (21). Even though the exact mechanism of spontaneous 
activation is not fully elucidated yet, primary aHSCs share a highly similar phenotype with 
pathogenetic aHSCs (22). Increased expression of ACTA2 and COL1A1 and reduced 
expression of the quiescence-associated transcription factor PPARG and LRAT are 
characteristic for the transcription profile of aHSCs and is identical in culture activated 
HSCs and in situ activated HSCs (3, 22).  
ECM deposition by aHSCs is the key mechanism of liver scar tissue formation. 
Arginine is a non-essential amino acid but it is conditionally essential during wound 
healing (23). Arginine is the exclusive substrate of NOS and arginase. NOS consists of 
three isoforms including iNOS, eNOS and nNOS. iNOS is an inducible NOS widely 
expressed in many cell types while eNOS and nNOS are specifically expressed in 
endothelium and neurons, respectively. Arginase has two isoforms Arg1 and Arg2. Arg1 is 
dominantly expressed in liver while Arg2 is dominantly expressed in kidney (10). NOS and 
arginase play opposite roles in the polarization of macrophages, with NOS promoting the 
M1 phenotype and Arginase the M2 phenotype (10). NO has been demonstrated to inhibit 
the proliferation of aHSCs and alleviate liver fibrosis (24). Activation of sGC, the 
downstream target of NO, has been demonstrated to suppress activation of HSCs as well 
(25). Ornithine, which is synthesized from arginine by arginase, is subsequently converted 
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by ODC and OAT into putrescine and proline, respectively. Putrescine is the main 
substrate for polyamine biosynthesis and is essential for cell cycle progression (26). 
Proline is the most abundant amino acid of collagen. The opposite roles of NOS and 
arginase on macrophage polarization is well-known. However, a shift in arginine 
catabolism between NOS and Arginase in the activation of HSCs has not been 
demonstrated. In this study, we have demonstrated that during activation of primary HSCs, 
the dominant catabolic enzyme of arginine shifts from iNOS to Arg1. The differential 
expression of iNOS and Arg1 was demonstrated both at the transcriptional (mRNA) and 
translational (protein) level. The differential expression of iNOS and Arg1 in HSC 
activation is in accordance with the function of proline in collagen production and 
polyamines in proliferation of aHSCs. Inhibition of NOS has been demonstrated to 
promote activation of fibroblasts and to prevent resolution of liver fibrosis (27, 28). In a rat 
model of wound healing induced by experimental surgical trauma, oral administration of 
arginine increased the systemic concentration of hydroxyproline, a marker of collagen 
production (29). Likewise, inhibition of Arg1 or OAT decreased the concentration of 
intracellular proline and reduces collagen synthesis in vascular smooth muscle cells and 
colonic epithelial cell (13, 30). Based on these studies, we hypothesized that the 
downregulation or inhibition of iNOS and the upregulation of Arg1 induces a switch in 
arginine catabolism that promotes activation of HSCs. 
Since arginase activity determines proline and collagen synthesis and cell 
proliferation, inhibition of Arg1 could be a therapeutic method to alleviate hepatic fibrosis. 
N(omega)-hydroxy-nor-L-arginine (nor-NOHA) is a specific arginase inhibitor without 
inhibitory effects on NOS (31). Our results demonstrated that inhibition of Arg1 by 
Nor-NOHA reduced collagen production but did not affect cell proliferation at the same 
concentration. However, supplementation of arginine did increase proliferation of HSCs. 
Ornithine is an amino acid that is not present in proteins. It is synthesized from arginine by 
arginase. It has been observed that polyamine synthesis remains intact even when 
ornithine concentrations are reduced by the arginase inhibitor Nor-NOHA (32). Since ODC 
is the key enzyme in polyamine synthesis, we assumed that the ODC activity of aHSCs 
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was not as sensitive as OAT when intracellular concentration of ornithine is decreased by 
Nor-NOHA.  
In conclusion, the activation of HSC is accompanied by a switch in arginine 
catabolism resulting from downregulation of iNOS and upregulation of Arg1. Inhibition of 
Arg1 can be an anti-fibrotic target for the treatment of liver fibrosis. 
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Decompensating cirrhosis is the final outcome of progressive liver fibrosis. As the 
most advanced stage of chronic liver disease, decompensated cirrhosis causes more than 
1 million deaths per year globally. Liver fibrosis is the intermediate stage of chronic liver 
disease. Liver fibrosis is still reversible, but can also progress to cirrhosis, deteriorating 
the prognosis of patients. To minimize the incidence of cirrhosis, liver fibrosis is targeted 
as the last interventional phase due to the reversibility of this stage (1). Liver resident cells, 
including hepatocytes, macrophages, sinusoidal endothelial cells, hepatic stellate cells 
(HSC) and infiltrating inflammatory cells all contribute to the pathogenesis of fibrogenesis. 
Uncontrolled fibrogenesis caused by activated HSC disrupts the normal architecture of the 
liver and exacerbates liver dysfunction, thus constituting a vicious cycle advancing to the 
final stages of chronic liver diseases (2).  
The characteristic histology of liver fibrosis is fibrous expansion ranging from 
perisinusoidal fibrosis to bridging fibrosis (3). HSCs are the most important cells that 
produce ECM in the fibrotic liver. Upon chronic injury, quiescent HSCs (qHSCs) 
transdifferentiate into myofibroblasts, a process termed activation (2). Compared to 
qHSCs, activated HSC (aHSC) proliferate and synthesize large amounts of ECM 
components, notably collagens. (4). Recent preclinical evidence has demonstrated that 
targeting HSC to reduce the number of aHSCs or decrease HSC activation is a way to 
attenuate liver fibrosis (5, 6). In addition, liver fibrosis can be spontaneously reversed 
when the injurious stimuli are removed (7). Activated HSCs that are “inactivated” to a 
quiescence-like phenotype have a transcriptomic profile that is different from qHSCs and 
aHSCs (8). This type of HSCs is termed inactivated HSCs (iHSCs). 
Various mechanisms are involved in the activation and inactivation of HSC. In this 
dissertation, a few promising mechanisms and therapeutic targets were investigated and 
elucidated. In chapter 2, biomarkers, mechanisms and consequences of cellular 
senescence were reviewed and the concept of therapy-induced senescence was 
introduced as a promising strategy to alleviate fibrogenesis. In chapter 3, the bioactive 
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compound esculetin was shown to decrease the activation of HSC by inducing 
senescence via a mechanism that involves the PI3K-Akt-GSK3β pathway. In chapter 4, 
the bioenergetic effect of H2S was demonstrated to promote the activation of HSC. In 
chapter 5, we demonstrated that inhibition of H2S induces HSC senescence and 
decreases HSC activation and fibrogenesis. In chapter 6, the broad-spectrum anti-fibrotic 
drug pirfenidone was shown to inhibit proliferation and collagen production in primary 
intestinal fibroblasts via the TGF-β/mTOR axis. In chapter 7, differential expression of the 
arginine-metabolizing enzymes inducible Nitric Oxide Synthase (iNOS) and Arginase1 
(ARG1) in activating HSC was investigated and it was shown that the increased 
expression of Arg1 was associated with HSC activation and inhibition of Arg1 decreased 
collagen synthesis. Details of the results and their implications for future research and 
therapy are discussed in the next paragraphs. 
Cellular Senescence of Hepatic Stellate Cells in Liver Fibrosis: A Review 
of Characteristics, Mechanisms and Consequences 
Cellular senescence is defined as a state of permanent cell cycle arrest (9). 
Senescent cells have been identified in fibrotic livers (10). Senescent cells cultured in vitro 
have a different morphology: cells become flattened and nuclei are enlarged. In addition, 
senescent cells exhibit increased senescence-associated beta-galactosidase (SA-β-Gal) 
activity, shortened or dysfunctional telomeres, elevated expression levels of P21CIP1 and 
P16INK4A and hypophosphorylated Retinoblastoma protein (RB), senescence-associated 
heterochromatin foci (SAHF) and a senescence-associated secretory phenotype (SASP) 
(9). These characteristic biomarkers are commonly used to identify senescent cells, but it 
should be noted that not all the biomarkers are simultaneously detectable in all senescent 
cells.  
Several mechanisms are involved in cellular senescence. The DNA damage 
response can trigger the initiation of cellular senescence (11). NF-κB activation is 
essential for senescence progression and SASP secretion (12, 13). Persistent PI3K-Akt 
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activation, associated with GSK3β and mTOR kinases, regulates the negative cell cycle 
regulators P21CIP1 and SASP (14-16). Furthermore, mTOR complexes, including 
mTORC1 and mTORC2, autophagy, oxidative stress, gasotransmitters like hydrogen 
sulfide, the STAT3 signaling pathway, all impact on senescence as discussed in detail in 
chapter 2. 
HSCs are the main source of senescent cells in experimental models of fibrosis (17). 
Senescent HSC are characterized by a defective ability to proliferate and reduced 
fibrogenic properties, as well as enhanced chemotaxis to natural killer cells (17). It has 
been shown that the ability of HSCs to enter senescence is essential to slow down the 
progression of liver fibrosis (17, 18). In addition to HSCs, hepatocytes can also undergo 
cellular senescence in chronic liver diseases (10). In general, senescence is a 
tumor-suppressing mechanism. However, senescent hepatocytes can escape the 
senescent state and re-enter the cell cycle, becoming pre-malignant and promote 
tumorigenesis (19).  
Therapy-induced senescence has been described in the response of tumor cells to 
CDK4/6 inhibitors (20). Recently, it has been demonstrated that bioactive compounds and 
cytokines, including curcumin and interleukin-22, can trigger HSC senescence to alleviate 
liver fibrosis (18, 21). Inducing transient senescence of HSC to treat liver fibrosis could be 
an attractive therapeutic strategy, but more studies are needed to completely elucidate the 
role of senescence in the pathogenesis of liver fibrosis. Important remaining issues are 
detrimental effects of inducing senescence on other liver cell types, notably hepatocytes, 
and the clearance of senescent HSCs by immune cells, notably NK cells. 
The heterogeneous phenotype of senescent cells and the limited availability of 
specific biomarkers is a barrier to translate in vitro results to the in vivo situation (9). SA-β
-Galactosidase staining is the most common method to detect senescent cells in vivo. 
However, the constitutive expression of β-Galactosidase in macrophages may be a 
confounder and lead to an overestimation of senescent cells on histological screening (22, 
23). Senescent cells may contribute to the maintenance of the function of injured tissue 
and (acute) elimination of senescent cells might disrupt this delicate balance (24). The 
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dynamics of elimination of senescent cells and regeneration of non-senescent cells may 
therefore be an important factor in the outcome of integrative therapy. A thorough study of 
the timing of administration of inducers of senescence and senolytics is therefore very 
important.  
Bioactive coumarin-derivative esculetin decreases HSC activation via 
induction of cellular senescence via the PI3K-Akt-GSK3β pathway 
 Esculetin is a bioactive compound, which has been shown to attenuate high fat 
diet-induced hepatic steatosis and inflammation (25) and to arrest cell proliferation of 
tumor cells (26). In chapter 2, therapy-induced senescence was proposed as a possible 
therapeutic strategy to treat liver fibrosis. In chapter 3, esculetin was investigated as a 
candidate to induce HSC senescence. Esculetin increased markers of senescence in both 
qHSCsand aHSCs: the number of SA-β-Gal positive cells and mRNA transcription of 
Cdkn1a and Il6 were both increased by esculetin treatment. SA-β-Gal staining is a 
well-established marker of senescent cells in vitro and in vivo. Cdkn1a encodes the cell 
cycle negative regulator P21Cip1, which is a downstream target of P53. IL-6 is one of the 
SASP molecules. Esculetin-treated HSCs also showed reduced expression of activation 
and fibrogenic markers, including αSMA and Collagen type 1. Interestingly, 
esculetin-induced senescence was not accompanied by restoration of the expression of 
the quiescence marker Lrat, demonstrating that senescent HSCs are not identical to 
qHSCs.  
Serum contains growth factors that induce cell cycle progression and cell division. 
Senescent cells have lost the ability to respond to growth factors. Non-proliferating 
esculetin-treated aHSCs remain unresponsive to serum-derived growth factors as shown 
by the wash-out studies in chapter 3. We used PCNA, a scaffold protein that allows DNA 
polymerase to bind to DNA and initiates DNA replication, as a marker of an intact cell 
cycle. (27). Esculetin treatment dramatically reduced PCNA expression in the subsequent 
wash-out incubation, demonstrating that the arrested cell proliferation of aHSCs was 
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irreversible. In line with this, SA-β-Gal staining and transcription of Cdkn1a, Il6 and Mmp9, 
all indicators of HSC senescence, were also not reversed after esculetin wash-out, 
indicating the long-lasting effect of esculetin in decreasing the activation of HSCs. It has 
been demonstrated that co-culture of senescent cells and non-senescent cells will induce 
senescence in the non-senescent cells(28). This phenomenon in which progression of 
cellular senescence is independent of its inducer has been termed cell-non-autonomous 
senescence. It is driven by the paracrine action of released SASP molecules. The 
phenomenon might favor a stable and long-lasting effect on the inhibition of HSC 
activation and fibrogenesis. 
PI3K-Akt activity has been demonstrated to be involved in cellular senescence. 
Phosphorylation of Ser9 on GSK3β, a well-established downstream target of Akt, is 
positively correlated with cellular senescence (15, 29). Inhibition of Akt and GSK3β exerts 
an inhibitory effect on the induction of cellular senescence. In line with this, we 
demonstrated that esculetin-induced senescence is dependent on an intact 
PI3K-Akt-GSK3β axis. As expected, non-selective inhibition of PI3K restored the ability of 
collagen synthesis and cell proliferation. These results demonstrate the causal 
association between induction of HSC senescence and deficient fibrogenesis. Hence, 
therapy-induced senescence may be a promising strategy in the treatment of liver fibrosis. 
As a coumarin derivative, esculetin may have effects on Vitamin K-dependent 
enzymes. This has been well-described for the coumarin-derivative warfarin. Vitamin K is 
involved in various essential physiological process. Vitamin K serves as a co-factor in the 
posttranslational modification executed by γ -glutamyl carboxylase (GGCX) in which 
specific glutamic acid residues (Glu) are converted into γ-carboxyglutamate (Gla).(30). 
Warfarin is widely used as anti-coagulation medication in cardiovascular diseases 
because of its powerful inhibitory effect on the hepatic synthesis of coagulation factors II, 
VII, IX, X and the anticoagulant proteins C and S (31). In addition, Vitamin K has 
anti-inflammatory and anti-oxidant properties independent of GGCX, which implies that 
Vitamin K may have effects on aging and senescence (30). A subclinical deficiency of 
Vitamin K has been demonstrated in patients with cystic fibrosis (32). However, the role of 
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Vitamin K in liver fibrosis is not clear. Furthermore, excessive exposure to the Vitamin K 
analog menadione induces oxidative stress in hepatocytes (33). Therefor it is important to 
elucidate the effect of esculetin on Vitamin K metabolism and to consider potential side 
effects. Esculetin can be converted into scopoletin and isoscopoletin by 
Catechol-O-methyltransferase (COMT) (34). Some studies demonstrated that scopoletin 
can attenuate hepatic steatosis, but its effect on fibrosis is not clear (35, 36). Unpublished 
data from our laboratory demonstrated that scopoletin has no anti-proliferative or 
anti-fibrogenic effects on rat HSCs in vitro. COMT degrades catecholamines, such as 
dopamine and epinephrine. Inhibitors of COMT are used in the treatment of Parkinson’s 
disease (37). Considering the relation between COMT and esculetin, (genetic) variations 
in the expression of COMT may influence the pharmacokinetic half-life of esculetin and its 
anti-fibrotic effects. However, the pattern of expression and activity of COMT in the natural 
history of liver fibrosis has not been elucidated yet. High-fat diet decreases protein 
expression of COMT in the liver and COMT inhibitors enhance hepatic steatosis, which 
suggests a role for COMT in this metabolic disorder (38). Therefore, various experimental 
models of chronic liver disease may be needed to identify indications for the clinical use of 
esculetin. The potential effect of esculetin on catecholamine metabolism also needs to be 
investigated. 
Hydrogen sulfide stimulates activation of hepatic stellate cells through 
increased cellular bio-energetics 
Hydrogen sulfide is an essential gasotransmitter involved in various 
(patho)physiological processes. E.g. H2S mediated S-sulfhydration of Kelch-like 
ECH-associated protein (KEAP1) facilitates dissociation of Nuclear erythroid 2-related 
factor 2 (Nrf2) from KEAP1(39). In chapter 4, the association between hydrogen 
sulfide-stimulated mitochondrial bioenergetics and HSC activation was investigated. 
During the activation of HSC, the expression of the hydrogen sulfide-synthesizing 
enzymes Cystathionine gamma-lyase (Cth) and Mercaptopyruvate sulfurtransferase 
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(Mpst) were increased, while expression of Cbs was reduced. Despite the reduced 
expression of Cbs, the net result was increased endogenous hydrogen sulfide production. 
Hydrogen sulfide donors release H2S with different kinetics. Fast-releasing donors are 
represented by NaHS and slow-releasing donors by GYY4137. Proliferation of HSC was 
increased by H2S donors and decreased by H2S inhibitors. Inhibition of endogenous 
production of H2S decreased collagen synthesis. However, hydrogen sulfide donors did 
not affect transcription and translation of collagen type 1. These results indicate that local 
production of H2S in HSCs promotes fibrogenesis, probably by stimulating mitochondrial 
bioenergetics. 
In general, H2S is regarded as a redox regulator that activates the Nrf2-dependent 
anti-oxidant pathway (40, 41). Oxidative stress (ROS) causes hepatocyte damage and 
death and contributes to fibrosis. Therefore, it was expected that H2S was anti-fibrogenic. 
However, our results revealed a HSC-specific profibrogenic effect of H2S. We speculate 
that the decreased H2S production of hepatocytes during fibrogenesis outweighs the 
increased H2S production of HSCs. To support this hypothesis, mRNA expression of 
H2S-producing enzymes was measured and the results supported our hypothesis: mRNA 
expression of Cth, Cbs and Mpst was decreased in fibrotic liver tissue. TGF-β is a 
well-known cytokine known to promote liver fibrosis. Interestingly, TGF-β decreased the 
expression of all H2S-producing enzymes in hepatocytes, but it increased Cth expression 
in aHSCs. The opposite response to TGF-β between HSCs and hepatocytes could be due 
to cell-specific metabolic effects of H2S. Since H2S has a pro-fibrogenic effect on HSCs, 
specific inhibition of H2S production in HSCs may be a therapeutic strategy to alleviate 
liver fibrosis. 
Inhibition of endogenous hydrogen sulfide reduces hepatic stellate cells 
activation via induction of cellular senescence 
Induction of HSC senescence decreased the activation of HSC as reported in 
chapter 3. In chapter 4, we demonstrated that H2S promotes HSC proliferation via 
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improving mitochondrial bioenergetics. In addition, inhibitors of H2S production exhibited 
anti-proliferative effects on aHSCs. Therefore, we hypothesized that inhibition of H2S 
production could induce HSC senescence. TGF-β is the well-established pro-fibrotic 
cytokine that activates HSC. In chapter 4, we demonstrated that Cth expression 
wasincreased by TGF-β. The CTH inhibitor DL-PAG was used to inhibit the activity of CTH 
and block the production of H2S. Interestingly, DL-PAG also inhibited the expression of 
CTH. DL-PAG reduced both mRNA transcription and protein production of collagen type 1 
in aHSCs. Senescence markers were increased in aHSCs treated with DL-PAG. In 
addition, DL-PAG permanently arrested proliferation of aHSCs. GYY4137, the 
slow-releasing H2S donor, restored the proliferation ability of aHSCs and decreased 
markers of cellular senescence. Moreover, we demonstrated that DL-PAG-induced HSC 
senescence was dependent on an intact PI3K-Akt pathway, in accordance with the 
mechanism of esculetin-induced senescence, described in chapter 3.  
Knockout of the Cth gene in mouse embryonic myofibroblasts leads to lack of H2S 
generation and initiates cellular senescence (41). In line with this, DL-PAG, the inhibitor of 
Cth, decreases CTH expression and H2S production of aHSCs and leads to senescence. 
The anti-senescence effect of H2S has been demonstrated in senescent endothelial cells 
to be the result of mitochondrial dysfunction (42). H2S is capable to increase NAD+ levels 
to improve mitochondrial activity (43). In chapter 4, we also demonstrated that H2S 
improved the bioenergetics of HSC mitochondria. H2S has been demonstrated to increase 
Akt activity in cell lines and to modulate cell proliferation. In our results, the effect of H2S 
was also shown to be mediated by the PI3K-Akt pathway. These results indicate the 
association between PI3K-Akt signaling and mitochondrial activity in cellular senescence. 
The causal association between HSC senescence and decreased fibrogenesis supports 
the idea that the H2S-synthesizing enzyme CTH can be a HSC-specific target for drug 
development to alleviate liver fibrosis. 
Hepatocytes contain much higher levels of H2S producing enzymes than HSCs and 
are therefore also the major cell type responsible for hepatic H2S production. On the other 
hand, CTH is the key enzyme accounting for H2S production in aHSCs, but HSCs are not 
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the major H2S producing cell type in the liver (44). DL-PAG is an amino acid analog of 
glycine which irreversibly inhibits the enzyme CTH. CTH knock-out mice as well as 
DL-PAG-treated wildtype mice have a delayed onset of diabetes (45). Likewise, CTH 
deletion protects mice against inflammation and acute liver injury and maintains the 
fenestration of liver sinusoidal endothelial cells (46). In addition, our results demonstrate 
that CTH inhibition induces HSC senescence but this cannot be completely reversed by 
supplementation of H2S. Therefore, CTH may have effects that are independent of H2S. 
The evidence indicates that the products of CTH, including α-ketobutyrate, cysteine and 
H2S, may have different targets and effects. α-Ketobutyrate administration has been 
shown to increase autophagy and attenuate aging-induced hair loss in mice (47). 
Interestingly, α-ketobutyrate maintains cell proliferation when mitochondrial respiration is 
inhibited (48). However, the role of α-ketobutyrate in chronic liver diseases remains to be 
elucidated. It can be hypothesized that endogenous α-ketobutyrate, in conjunction with 
H2S, maintains mitochondrial respiration. These data suggest that CTH may also be an 
interesting therapeutic target in the treatment of chronic liver diseases. 
Pirfenidone Inhibits Cell Proliferation and Collagen I Production of 
Primary Human Intestinal Fibroblasts 
Pirfenidone is a broad-spectrum anti-fibrotic drug, which has been demonstrated to 
reduce fibrogenesis in lung, liver and kidney. It has been approved for the treatment of 
idiopathic pulmonary fibrosis (49). Both in experimental models of liver fibrosis and in 
clinical practice, pirfenidone is sufficient to reduce fibrogenesis and attenuate 
inflammation (50, 51). Intestinal fibrosis is correlated with the deterioration of inflammatory 
bowel disease (IBD). Anti-fibrotic treatments have been shown to alleviate IBD in 
preclinical models (52). In line with this, pirfenidone has been suggested to be a potential 
therapeutic candidate in the treatment of IBD. 
Pirfenidone decreases fibrogenesis via inhibition of the TGF-β signaling pathway (53). 
TGF-β is known to induce fibrogenesis in various organs and to regulate the inflammatory 
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response in chronic diseases. TGF-β has been shown to activate SMAD3 to promote 
collagen synthesis in various models of fibrosis. In addition, TGF-β has been shown to 
modulate additional signaling pathways, including P38/MAPK, ERK/JNK and mTOR (54).  
To fully understand the anti-fibrotic mechanism of pirfenidone in intestinal fibrosis, 
primary human intestinal fibroblasts were used as an in vitro model. We show that 
pirfenidone dose-dependently inhibited proliferation and collagen synthesis of intestinal 
fibroblasts. The effect of pirfenidone is not associated with cellular senescence since 
pirfenidone did not induce irreversible cell cycle arrest in intestinal fibroblasts. Pirfenidone 
did reduce mTOR/P70S6K signaling, which was activated by TGF-β. Similarly, rapamycin, 
an established mTOR inhibitor, decreased TGF-β-increased collagen production. We 
concluded that the effect of pirfenidone was associated with inhibiting the 
TGF-β/mTOR/P70S6K axis. 
Increased arginase-1 expression during hepatic stellate cell activation 
promotes fibrogenesis 
Arginine is a non-essential amino acid in adults, but conditionally essential in infants. 
It is the exclusive substrate of two enzymes: Nitric Oxide Synthase (NOS) and arginase. 
NOS converts arginine into citrulline and nitric oxide (NO), whereas arginase converts 
arginine into ornithine. In turn, ornithine is the substrate for both Ornithine Decarboxylase 
(ODC), which leads to the production of polyamines and Ornithine Aminotransferase 
(OAT) ,which leads to the production of proline (55). NO is a well-known gasotransmitter 
that activates soluble guanylate cyclase (sGC). It has been demonstrated that activation 
of the NO-sGC pathway decreases the activation of HSCs and prevents liver fibrosis (56). 
Polyamines are necessary for cell cycle progression. Proline is the most abundant amino 
acid in collagen and therefore essential for collagen biosynthesis. The concentration of 
proline is tightly controlled by arginase activity. Intracellular synthesis of proline is 
dependent on arginase activity (57, 58). Dietary supplementation of L-arginine increases 
plasma concentration of proline (59). In contrast, deficient Arg1 activity decreases plasma 
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concentration of proline (60). Differential expression of iNOS and Arg1 is a well-known 
characteristic of macrophage polarization with high iNOS expression being associated 
with the pro-inflammatory M1 phenotype and high Arg1 expression with the pro-fibrogenic 
M2 phenotype. (61). In view of the opposite effect of their metabolites, the arginine 
catabolizing enzymes are likely to modulate transdifferentiation of HSCs. Our results show 
that during transdifferentiation/activation, HSCs increase mRNA and protein expression of 
Arg1 and gradually decrease the expression of iNOS, resulting in a strong increase in the 
ratio of Arg1 to iNOS in fully activated HSCs. This increased Arg1/iNOS ratio correlated 
with increased expression of the activation markers αSMA and Collagen type 1 in aHSCs. 
The change of arginine catabolism promotes proliferation and collagen synthesis of HSCs. 
To verify whether arginase activity is necessary for cell proliferation and collagen 
synthesis in HSCs, the arginase inhibitor, Nor-NOHA, was used to block the arginase 
activity. As expected, the arginase inhibitor decreased collagen synthesis. However, the 
arginase inhibitor only decreased cell proliferation in conditions of extra arginine 
supplementation. These results indicate different sensitivities of OAT and ODC in 
response to decreased ornithine concentrations. Collectively, the results demonstrate that 
the arginine metabolic pathway is a promising therapeutic target to treat liver fibrosis. 
Conclusions 
Hepatic stellate cells are the main effector cells in the formation of fibrous tissue in 
liver injury caused by various etiologies. Induction of HSC senescence, e.g. by esculetin, 
could be a therapeutic strategy to attenuate progression of liver fibrosis. Intact Akt activity 
is essential to induce senescence. H2S is an important gasotrasmitter that promotes 
bioenergetics of HSCs and decreases cellular senescence. Conversely, inhibition of 
H2S-producing enzymes induces HSC senescence in an Akt-dependent manner. The 
TGF-β/mTOR signaling pathway is the target of pirfenidone in the inhibition of proliferation 
and collagen synthesis in intestinal fibroblasts. During HSC activation, the arginine 
metabolism is profoundly altered by a change in the ratio of the arginine metabolizing 
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enzymes iNOS and Arg1 in aHSCs. Inhibition of arginase decreases collagen synthesis 
and arginine-dependent cell proliferation in HSCs.   
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aHSC Activated HSC  
aHSCs Activated HSCs  
αSMA  Alpha-smooth muscle actin 
ARG1  Arginase-1  
ARG2  Arginase-2  
ACTA2  Alpha actin 2  
ATM  Ataxia-Telangiectasia Mutated 
ATR ATM- and Rad3-related 
ALD Alcoholic liver disease  
BDL Bile duct ligation 
Bio-Rad  Bio-Rad protein assay  
COL1A1 Collagen type 1 alpha-1  
CTGF  Connective tissue growth factor  
CSE Cystathionine γ-lyase 
CBS Cystathionine β-synthase 
CMA  Chaperone-mediated autophagy 
CBS Cystathionine β-synthase  
CTH/CSE Cystathionine -lyase  
CCl4 Carbon tetrachloride  
CBS Cystathionine β-synthase 
CTH Cystathionine γ-lyase 
CO  Carbon monoxide 
COMT Catechol-O-methyltransferase 
CDKs Cyclin dependent kinases 
cGMP Cyclic guanosine monophosphate  
DDR DNA-damage response 
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DL-PAG  DL-propargylglycine 
DATS  Diallyl trisulfide 
eNOS  Endothelial NOS 
ECM  Extracellular matrix 
ECAR Extra-Cellular Acidification Rate 
ECM  Excessive extracellular matrix  
GFAP  Glial fibrillary acidic protein 
GSK3  Glycogen Synthase Kinase 3 
G-CSF  Granulocyte colony-stimulating factor  
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
GGCX  γ -glutamyl carboxylase  
Glu  Glutamic acid residues  
Gla γ-carboxyglutamate 
HSCs Hepatic stellate cells  
HMGA  High-mobility group A 
H3K4me3 Histone 3 lysine 4 trimethylation 
H2S  Hydrogen sulfide 
iHSCs  Inactivated HSCs 
IBD  Inflammatory bowel diseases 
IPF  Idiopathic pulmonary fibrosis 
iNOS Inducible nitric oxide synthase  
IBD Inflammatory bowel disease 
IKK IKB kinase 
KEAP1 Kelch-like ECH-associated protein  
LRAT Lecithin retinol acyltransferase  
LADs Lamin-associated domains 
LAMP2a  Lysosomeassociated membrane protein type 2a  
mTOR Mammalian target of rapamycin  
MSCs Mesenchymal stromal cells  
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mean± SD  Mean ± standard deviation  
mean± sem  Mean ± standard error of means  
MPST 3-mercaptopyruvate sulfur transferase 
mTOR  The mammalian target of rapamycin 
Mpst  Mercaptopyruvate sulfurtransferase  
MAFLD Metabolic Associated Fatty Liver Disease  
MRN Mre11-Rad50-Nbs1 
NAFLD Non-alcoholic fatty liver disease 
NAS CRN  Non-alcoholic Steatohepatitis Clinical Research Network  
NASH CRN NASH Clinical Research Network  
NAD+ Nicotinamide adenine dinucleotide  
NAFLD  Non-alcoholic fatty liver disease  
NO Nitric oxide 
NOS  Nitric Oxide Synthases 
Nrf2  Nuclear factor E2-related factor 2 
NF-κB Nuclear factor kappa B 
Nrf2 Nuclear erythroid 2-related factor 2 
nor-NOHA  N(omega)- hydroxy-nor-L-arginine 
nNOS Neuronal NOS  
ODC  Ornithine decarboxylase  
OPTN Optineurin 
OCR  Oxygen Consumption Rate 
ODC  Ornithine Decarboxylase  
OAT Ornithine Aminotransferase 
PDGF Platelet-derived growth factor 
PI3K Phosphoinositide 3-kinases 
PKC  Protein kinase C 
PFs  Portal fibroblasts  
PDGFRβ  Platelet-derived growth factor receptor-β 
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PPARG Peroxisome proliferator-activated receptor gamma 
PARP  Poly (ADP)ribose polymerase 
PI3K Phosphatidylinositol-3-kinase 
pS473  Phospho-Ser473 
pT308 Phospho Thr308 
PIKK PI3K-related kinase 
PLP- pyridoxal-5’-phosphate- 
PCNA Proliferating cell nuclear antigen 
PDGF-BB Platelet-derived growth factor BB 
PDGF  Growth factors 
p-hIFs Primary human intestinal fibroblasts 
qHSCs Quiescent hepatic stellate cells 
RB  Retinoblastoma protein 
RCTA  Real-Time Cell Analysis  
ROS Reactive oxygen species 
RT-qPCR Reverse transcription PCR 
ROS Oxidative stress 
STAT Signal Transducers and Activators of Transcription 
SA-β-Gal  Senescence Associated β-Galactosidase  
SASP Senescence-Associated Secretory Phenotype  
SAHF Senescence-Associated heterochromatin foci 
SGC  Soluble guanylate cyclase 
SOX  SRY-related HMG-box 
SOCS3  Suppressor of cytokine signaling 3 
SREBP  Sterol responsive element binding protein 
TGF-β  Transforming growth factor beta  
TGFβ Transforming growth factor 
3-MST 3-mercaptopyruvate sulfurtransferase 
UPR  Unfolded protein response 
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WST-1  Water Soluble Tetrazolium Salt-1 
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In chapter 1, the essential role of hepatic stellate cell activation in the pathogenesis of 
live fibrosis was introduce. The activated hepatic stellate cells are the main precursor of 
myofibroblasts. Targeting hepatic stellate cells can be the way to prevent or reverse liver 
fibrosis. 
In chapter 2, senescence of hepatic stellate cells was interpreted as a protective 
mechanism against liver fibrosis progression. The biomarkers, signaling pathways and 
probable effects of hepatic stellate cells senescence was elucidated. Among various 
biomarkers, we proposed that P21 (cell-cycle arrest), Senescence-associated β 
Galactosidase (lysosomal mass), Interleukin-6 (senescence-associated secretory 
phenotype) could be used as biomarkers to identify senescent hepatic stellate cells. The 
pathogenic role of hepatic stellate cell senescence was not fully elucidated. 
Therapy-induced senescence of hepatic stellate cells followed by senolytics may be an 
optimized strategy to attenuate liver fibrosis.  
In chapter 3, a coumarin derivative, esculetin was demonstrated to induce 
senescence in hepatic stellate cells. With increased senescent hepatic stellate cells, 
collagen production and cell proliferation were inhibited. Senescent hepatic stellate cells 
acquired resistance to be reverted to active proliferation. The effect of esculetin was 
dependent on PI3K-Akt-GSK3β signaling pathway.  
In chapter 4, differential expression of H2S producing enzymes were determined 
during the activation of hepatic stellate cells and determined in bile duct ligation rats. The 
cystathionine γ-lyase (CTH) was increased accompanied by activation of hepatic stellate 
cells, while the other enzymes cystathionine β-synthase (CBS) and 3-mercaptopyruvate 
sulfur transferase (MPST) were decreased in vitro and in vivo. However, the endogenous 
H2S was demonstrated to be increased in activated hepatic stellate cells. The H2S 
inhibitor was shown to decrease cell proliferation and collagen synthesis whereas H2S 
donor was shown to increase cell proliferation. The mechanism of H2S promoting hepatic 
stellate cell activation was associated with improvement of mitochondrial bioenergetics.  
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In chapter 5, The hypothesis of inducing senescence via inhibiting H2S to decrease 
fibrogenic potential of hepatic stellate cells was investigated. CTH inhibitor DL 
-Propargylglycine (PAG) was demonstrated to decrease cell proliferation and collagen 
synthesis of hepatic stellate cells via inducing senescence. The senescent phenotype of 
hepatic stellate cells can be partially decreased via exogenos H2S and PI3K inhibitor. 
In chapter 6, the broad-spectrum anti-fibrotic drug pirfenidone was investigated the 
anti-fibrotic effect on primary human intestinal fibroblasts. Pirfenidone was demonstrated 
to reversibly decrease cell proliferation and collagen production of intestinal fibroblasts. 
The mechanism of pirfenidone was not associated with induction of cellular senescence 
or apoptosis. The mechanism of pirfenidone was demonstrated to be associated with 
TGF-β1/mTOR/p70S6K signaling pathway.  
In chapter 7, differential expression of arginine metabolizing enzymes iNOS 
(inducible Nitric Oxide Synthase) and ARG1 (Arginase-1) were determined during 
activation of hepatic stellate cells. iNOS was decreased and ARG1 was increased during 
the activation of hepatic stellate cells. ARG1 inhibitor Nor-NOHA was shown to decrease 
collagen production and cell proliferation in arginine-dependent manner.  
In chapter 8, the results and further steps of research were discussed. 
Therapy-induced senescence of hepatic stellate cells may be a promising strategy to 
alleviate liver fibrosis. But senolytics should be considered as combination therapy to 
avoid potential pro-inflammatory effect of senescent hepatic stellate cells. To further 
investigate the effect of esculetin in vivo, Vitamin K-dependent coagulation factors should 
be investigated to determine the potential side effect and Catechol-O-methyltransferase 
(COMT) dependent metabolism may dampen effect of esculetin via influencing its 
pharmacokinetics. Among H2S producing enzymes, CTH may be a promising target for 
the treatment of liver fibrosis. And the byproduct of CTH α-ketobutyrate needs to be 
further investigated. Pirfenidone has been verified to alleviate intestinal fibrosis in vitro. 
But various model of liver fibrosis should be considered to testify the effect of pirfenidone 
before clinical application. Arginine metabolizing change was demonstrated in the 
activation of hepatic stellate cells. Increased expression of ARG1 can be a promising 
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therapy target for the treatment of liver fibros
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Hoofdstuk 1 introduceert de cruciale rol van de activatie van stellaatcellen in de lever 
bij het ontstaan van leverfibrose. Geactiveerde lever-stellaatcellen zijn de belangrijkste 
precursors van myofibroblasten. Therapie gericht op lever-stellaatcellen kan leverfibrose 
voorkomen of omkeren. 
In hoofdstuk 2 wordt de veroudering van lever-stellaatcellen geïnterpreteerd als een 
mechanisme dat beschermt tegen de progressie van leverfibrose. De biomarkers, 
signaalroutes en waarschijnlijke effecten van de veroudering van lever-stellaatcellen 
worden toegelicht. We stellen voor dat de biomarkers P21 (stilstand van de celcyclus), 
senescentie-geassocieerd β-galactosidase (lysosomale inhoud), en interleukine-6 
(senescentie-geassocieerd secretoir fenotype) gebruikt kunnen worden omverouderde 
lever-stellaatcellen te identificeren. Ondanks dat de veroudering van lever-stellaatcellen 
nog niet volledig is opgehelderd, kan therapie-geïnduceerde veroudering van 
lever-stellaatcellen, gevolgd door senolytica, een optimale strategie zijn voor het 
tegengaan van leverfibrose. 
In hoofdstuk 3 wordt aangetoond dat esculetine, een cumarine-derivaat, de 
veroudering van lever-stellaatcellen veroorzaakt en blijkt dat bij verouderde 
lever-stellaatcellen, de collageenproductie en celproliferatie zijn verminderd. Verouderde 
lever-stellaatcellen ontwikkelen bovendien resistentie tegen een terugkeer naar actieve 
proliferatie. Het effect van esculetine blijkt afhankelijk van de 
PI3K/AKT/GSK3β-signaalroute. 
In hoofdstuk 4 is de differentiële expressie van H2S-producerende enzymen bepaald 
tijdens de activatie van lever-stellaatcellen in ratten die aan ligatie van de galgang zijn 
onderworpen. Tijdens dit proces nam de expressie van cystathionine γ-lyase (CTH) toe, 
en ging gepaard met de activatie van lever-stellaatcellen; de expressie van de enzymen 
cystathionine β-synthase (CBS) en 3-mercaptopyruvaat zwaveltransferase (MPST) nam 
juist af, zowel in vitro als in vivo. In geactiveerde lever-stellaatcellen bleek echter een 
endogene H2S-toename. Daarnaast bleek dat de H2S-remmer celproliferatie en 
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collageensynthese verminderde, terwijl de H2S-donor celproliferatie verhoogde. Het 
mechanisme dat de activatie van lever-stellaatcellen door H2S bevordert, kan leiden tot 
een verbeterde mitochondriale bio-energetica. 
In hoofdstuk 5 wordt de hypothese onderzocht dat veroudering van 
lever-stellaatcellen door middel van H2S-remming hun fibrogene potentie kan 
verminderen. Zo blijkt dat de CTH-remmer DL-propargylglycine (PAG), door veroudering 
te induceren, de celproliferatie van en collageensynthese door lever-stellaatcellen 
verminderde. Het verouderd fenotype van lever-stellaatcellen kan gedeeltelijk verminderd 
worden door exogeen H2S en een PI3K-remmer. 
In hoofdstuk 6 wordt het effect van het breedspectrum antifibrotischgeneesmiddel 
pirfenidon op primaire humane darmfibroblasten bestudeerd. Zo blijkt dat pirfenidon de 
celproliferatie van en de collageenproductie door darmfibroblasten reversibel vermindert. 
De werking van pirfenidon blijkt niet samen te hangen met de inductie van cellulaire 
veroudering of apoptose, maar wel met de TGF-β1/mTOR/p70S6K signaal-route. 
In hoofdstuk 7 wordt de differentiële expressie van de arginine-metaboliserende 
enzymen iNOS (induceerbaar stikstofmonoxide synthase) en ARG1 (arginase-1) tijdens 
de activatie van lever-stellaatcellen bepaald. Hieruit blijkt dat de expressie van iNOS was 
verlaagd en die van ARG1 verhoogd. Daarnaast blijkt dat de ARG1-remmer nor-NOHA de 
collageenproductie en celproliferatie op een arginine-afhankelijke wijze verlaagt. 
In hoofdstuk 8 worden de resultaten besproken evenals stappen om het onderzoek 
voort te zetten. Therapie-geïnduceerde veroudering van lever-stellaatcellen kan een 
veelbelovende strategie zijn om leverfibrose te verlichten. Daarbij moeten senolytica 
overwogen worden als combinatietherapie om potentiële pro-ontstekingseffecten van 
verouderde lever-stellaatcellen te voorkomen. Om het effect van esculetine in vivo nader 
te bestuderen, moeten vitamine K-afhankelijke stollingsfactoren onderzocht worden om 
zo mogelijke bijwerkingen vast te stellen. Tegelijkertijd moet er rekening mee worden 
gehouden dat metabolisme afhankelijk van catechol-O-methyltransferase (COMT) het 
effect van esculetine kan verzwakken omdat dit de farmacokinetiek hiervan beïnvloedt. 
Van de H2S-producerende enzymen is CTH een veelbelovend target voor de behandeling 
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van leverfibrose. Het bijproduct van CTH, α-ketobutyraat, moet echter nog nader 
onderzocht worden. Het is in ieder geval aangetoond dat pirfenidon darmfibrose in vitro 
verbetert. Er moeten echter meerdere leverfibrosemodellen overwogen worden om het 
effect van pirfenidon te bevestigen voordat er sprake kan zijn van klinische toepassing. Dit 
onderzoek toont ook een arginine-metaboliserende verandering tijdens de activatie van 
lever-stellaatcellen aan. Een verhoogde expressie van ARG1 kan eveneens een 
veelbelovend target zijn voor de behandeling van leverfibrose. 
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